Following The Patents: Covid-19 & Medical Tyranny

 

Over the past two decades, a company named M·CAM has been monitoring possible violations of the 1925 Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare (the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of Bacteriological and Toxin Weapons and Their Destruction (the BTWC). In their 2003-2004 Global Technology Assessment: Vector Weaponization, M·CAM highlighted China’s growing involvement in Polymerase Chain Reaction (PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Since that time, on a weekly basis, they have monitored the development of research and commercial efforts in this field, including, but not limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC), the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC), Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, and many other research institutions, and their commercial affiliations.

 

The National Institute of Health’s grant AI23946-08, issued to Dr. Ralph Baric at the University of North Carolina at Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit. (Source: U.S. Provisional Application No. 60/206,537, filed May 21, 2000) In one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full-length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.

 

“Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones.” (Source: https://www.pnas.org/content/100/22/12995)

 

On April 19, 2002, the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first public record of the claims, they sought to patent a means of producing, “an infectious, replication defective, coronavirus.” This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 before SARS was ever detected in humans!

 

Against this backdrop, they noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003 SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Work associated with this virus by their select collaborators included considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment (both vaccine and therapeutic intervention), and weaponization inquiries.

 

In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852 patent (Claim 1), no research in the United States could be conducted without permission or infringement.

 

It was noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research grants from several federal agencies but also sat on the World Health Organization’s International Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for determining “novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the form of new research funding authorizations and associated patenting and commercial collaboration. Together with CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of interests constituted what we would suggest are “interlocking directorates” under U.S. anti-trust laws.

 

These entities also were affiliated with the WHO’s Global Preparedness Monitoring Board (GPMB) whose members were instrumental in the Open Philanthropy-funded global coronavirus pandemic “desk-top” exercise EVENT 201 in October 2019. This event, funded by the principal investor in Sherlock Biosciences and linking interlocking funding partner, the Bill and Melinda Gates Foundation into the GPMB mandate for a respiratory disease global preparedness exercise to be completed by September 2020 alerted us to anticipate an “epidemic” scenario. We expected to see such a scenario emerge from Wuhan or Guangdong China, northern Italy, Seattle, New York or a combination thereof, as Dr. Zhengli Shi and Dr. Baric’s work on zoonotic transmission of coronavirus identified overlapping mutations in coronavirus in bat populations located in these areas.

35 U.S.C. § 101

 

Section 101 of the Patent Act:   "Whoever invents or discovers any new and useful ... composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title." 35 U.S.C. § 101.

 

We have "long held that this provision contains an important implicit exception[:] Laws of nature, natural phenomena, and abstract ideas are not patentable." Mayo, 566 U.S., at    , 132 S.Ct., at 1293 (internal quotation marks and brackets omitted). Rather, "`they are the basic tools of scientific and technological work'" that lie beyond the domain of patent protection. Id., at    , 132 S.Ct., at 1293. As the Court has explained, without this exception, there would be considerable danger that the grant of patents would "tie up" the use of such tools and thereby "inhibit future innovation premised upon them." Id., at     _, 132 S.Ct., at 1301. This would be at odds with the very point of patents, which exist to promote creation. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980) (Products of nature are not created, and "`manifestations... of nature [are] free to all men and reserved exclusively to none'").(Source: Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013))

 

In their majority opinion in 2013, the U.S. Supreme Court made it abundantly clear that the Court had “long held” that nature was not patentable. Merely isolating DNA does not constitute patentable subject matter. In their patent, the CDC made false and misleading claims to the United States Patent & Trademark Office by stating that, “A newly isolated human coronavirus has been identified as the causative agent of SARS, and is termed SARS-CoV.” (Source: U.S. Patent 7,220,852) No “causal” data was provided for this statement.

 

When they filed their patent application on April 25, 2003, their first claim (and the only one that survived to ultimate issuance over the objection of the patent examiner in 2006 and 2007) was the genome for SARS CoV.

 

While this patent is clearly illegal under 35 U.S.C. §101, not only did the CDC insist on its granting over non-final and final rejections, but they also continued to pay maintenance fees on the patent after the 2013 Supreme Court decision confirmed that it was illegal.

 

In addition, the CDC patented the detection of SARS CoV using a number of methods including reverse transcription polymerase chain reaction (RT-PCR). With this patent, they precluded anyone outside of their licensed or conspiring interest from legally engaging in independent verification of their claim that they had isolated a virus, that it was a causative agent for SARS, or that any therapy could be effective against the reported pathogen.

 

It is important to note that the CDC’s patent applications were also rejected in non-final and final rejections for ineligibility under 35 U.S.C. § 102 for being publicly disclosed prior to their own filing. In the first non-final rejection, the USPTO stated that the CDC’s genome was published in four Genbank accession entries on April 14, 18, and 21, 2003 with identity ranging from 96.8% to 99.9% identical sequences. (Source: USPTO Non-Final Rejection File #10822904, September 7, 2006, page 4.) Dr. Fauci knew, and failed to disclose evidence that the CDC patent was illegal, based on work he had funded in the years leading up to the SARS outbreak.

 

After seeking an illegal patent, petitioning to override the decision of an examiner to reject it, and ultimately prevailing with the patent’s grant, the CDC lied to the public by stating they were controlling the patent so that it would be “publicly available”. (Source: https://apnews.com/article/145b4e8d156cddc93e996ae52dc24ec0) Tragically, this public statement is falsified by the simple fact that their own publication in Genbank had, in fact, made it public domain and thereby unpatentable. This fact, confirmed by patent examiners, was overridden by CDC in a paid solicitation to override the law.

 

While not covered under 35 U.S.C. §101, Dr. Fauci’s abuse of the patent law is detailed below. Of note, however, is his willful and deceptive use of the term “vaccine” in patents and public pronouncements to pervert the meaning of the term for the manipulation of the public.

 

In the 1905 Jacobson v. Mass case, the court was clear that a PUBLIC BENEFIT was required for a vaccine to be mandated. Neither Pfizer nor Moderna have proved a disruption of transmission. In Jacobson v. Massachusetts, 197 U.S. 11 (1905), the court held that the context for their opinion rested on the following principle:

 

“This court has more than once recognized it as a fundamental principle that 'persons and property are subjected to all kinds of restraints and burdens in order to secure the general comfort, health, and prosperity of the state…”

 

The Moderna and Pfizer “alleged vaccine” trials have explicitly acknowledged that their gene therapy technology has no impact on viral infection or transmission whatsoever and merely conveys to the recipient the capacity to produce an S1 spike protein endogenously by the introduction of a synthetic mRNA sequence. Therefore, the basis for the Massachusetts statute and the Supreme Court’s determination is moot in this case.

Further, the USPTO, in its REJECTION of Anthony Fauci's HIV vaccine made the following statement supporting their rejection of his bogus "invention"

 

 

18 U.S.C. §2339 C et seq. – Funding and Conspiring to Commit Acts of Terror

Indirectly, unlawfully, and willfully provides or collects funds with the intention that such funds be used, or with the knowledge that such funds are to be used, in full or in part, in order to carry out—

1. an act which constitutes an offense within the scope of a treaty specified in subsection (e)(7), as implemented by the United States, or
2. any other act intended to cause death or serious bodily injury to a civilian, or to any other person not taking an active part in the hostilities in a situation of armed conflict, when the purpose of such act, by its nature or context, is to intimidate a population, or to compel a government or an international organization to do or to abstain from doing any act….

 

By no later than April 11, 2005, Dr. Anthony Fauci was publicly acknowledging the association of SARS with bioterror potential. Leveraging the fear of the anthrax bioterrorism of 2001, he publicly celebrated the economic boon that domestic terror had directed towards his budget. He specifically stated that NIAID was actively funding research on a “SARS Chip” DNA microarray to rapidly detect SARS (something that was not made available during the current “pandemic”) and two candidate vaccines focused on the SARS CoV spike protein. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/ ) Led by three Chinese researchers under his employment – Zhi-yong Yang, Wing-pui Kong, and Yue Huang – Fauci had at least one DNA vaccine in animal trials by 2004. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/ ) This team, part of the Vaccine Research Center at NIAID, was primarily focused on HIV vaccine development but was tasked to identify SARS vaccine candidates as well. Working in collaboration with Sanofi, Scripps Institute, Harvard, MIT and NIH, Dr. Fauci’s decision to unilaterally promote vaccines as a primary intervention for several designated “infectious diseases” precluded proven therapies from being applied to the sick and dying.(Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/)

 

The CDC and NIAID led by Anthony Fauci entered into trade among States (including, but not limited to working with EcoHealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent rights. This research was known to involve surface proteins in coronavirus that had the capacity to directly infect human respiratory systems. In flagrant violation of the NIH moratorium on gain of function research, NIAID and Ralph Baric persisted in working with chimeric coronavirus components specifically to amplify the pathogenicity of the biologic material.

 

By October 2013, the Wuhan Institute of Virology 1 coronavirus S1 spike protein was described in NIAID’s funded work in China. This work involved NIAID, USAID, and Peter Daszak, the head of EcoHealth Alliance. This work, funded under R01AI079231, was pivotal in isolating and manipulating viral fragments selected from sites across China which contained high risk for severe human response. (Source: Ge, XY., Li, JL., Yang, XL. et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535–538 (2013).)

 

By March 2015, both the virulence of the S1 spike protein and the ACE II receptor was known to present a considerable risk to human health. NIAID, EcoHealth Alliance and numerous researchers lamented the fact that the public was not sufficiently concerned about coronavirus to adequately fund their desired research.(Source: Forum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington (DC): National Academies Press (US); 2016 Feb 12. 6, Developing MCMs for Coronaviruses. Available from: https://www.ncbi.nlm.nih.gov/books/NBK349040/)

 

Dr. Peter Daszak of EcoHealth Alliance offered the following assessment:

  

“Daszak reiterated that, until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the need for MCMs such as a pan-influenza or pan-coronavirus vaccine. A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of process, Daszak stated.”

 

Economics will follow the hype.

 

The CDC and NIAID entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016. These projects took place during a time when the work being performed was prohibited by the United States National Institutes of Health.

 

The public was clearly advised of the dangers being presented by NIAID-funded research by 2015 and 2016 when the Wuhan Institute of Virology material was being manipulated at UNC in Ralph Baric’s lab.

 

“The only impact of this work is the creation, in a lab, of a new, non-natural risk,” agrees Richard Ebright, a molecular biologist and biodefence expert at Rutgers University in Piscataway, New Jersey. Both Ebright and Wain-Hobson are long-standing critics of gain-of-function research.

 

In their paper, the study authors also concede that funders may think twice about allowing such experiments in the future. "Scientific review panels may deem similar studies building chimeric viruses based on circulating strains too risky to pursue," they write, adding that discussion is needed as to "whether these types of chimeric virus studies warrant further investigation versus the inherent risks involved”.

 

But Baric and others say the research did have benefits. The study findings “move this virus from a candidate emerging pathogen to a clear and present danger”, says Peter Daszak, who co-authored the 2013 paper. Daszak is president of the EcoHealth Alliance, an international network of scientists, headquartered in New York City, that samples viruses from animals and people in emerging-diseases hotspots across the globe.

 

Studies testing hybrid viruses in human cell culture and animal models are limited in what they can say about the threat posed by a wild virus, Daszak agrees. But he argues that they can help indicate which pathogens should be prioritized for further research attention.”(Source: https://www.nature.com/news/engineered-bat-virus-stirs-debate-over-risky-research-%201.18787 )

 

Knowing that the U.S. Department of Health and Human Services (through CDC, NIH, NIAID, and their funded laboratories and commercial partners) had patents on each proposed element of medical counter measures and their funding, Dr. Fauci, Dr. Gao (China CDC), and Dr. Elias (Bill and Melinda Gates Foundation) conspired to commit acts of terror on the global population – including the citizens of the United States – when, in September 2019, they published the following mandate:

 

“Countries, donors and multilateral institutions must be prepared for the worst. A rapidly spreading pandemic due to a lethal respiratory pathogen (whether naturally emergent or accidentally or deliberately released) poses additional preparedness requirements. Donors and multilateral institutions must ensure adequate investment in developing innovative vaccines and therapeutics, surge manufacturing capacity, broad-spectrum antivirals and appropriate non-pharmaceutical interventions. All countries must develop a system for immediately sharing genome sequences of any new pathogen for public health purposes along with the means to share limited medical countermeasures across countries.

 

Progress indicator(s) by September 2020

 

A.     Donors and countries commit and identify timelines for: financing and development of a universal influenza vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its Member States develop options for standard procedures and timelines for sharing of sequence data, specimens, and medical countermeasures for pathogens other than influenza.

 

B.      Donors, countries and multilateral institutions develop a multi-year plan and approach for strengthening R&D research capacity, in advance of and during an epidemic.

 

C.      WHO, the United Nations Children’s Fund, the International Federation of Red Cross and Red Crescent Societies, academic and other partners identify strategies for increasing capacity and integration of social science approaches and researchers across the entire preparedness/response continuum.”(Source: https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf (page 8) )

 

As if to confirm the utility of the September 2019 demand for “financing and development of” vaccine and the fortuitous SARS CoV-2 alleged outbreak in December of 2019, Dr. Fauci began gloating that his fortunes for additional funding were likely changing for the better. In a February 2020 interview in STAT, he was quoted as follows:

 

““The emergence of the new virus is going to change that figure, likely considerably, Fauci said. “I don’t know how much it’s going to be. But I think it’s going to generate more sustained interest in coronaviruses because it’s very clear that coronaviruses can do really interesting things.””(Source: https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-interest-hurt-coronavirus-research/)

 

 

18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting in death of American Citizens

Section 802 of the USA PATRIOT Act (Pub. L. No. 107-52) expanded the definition of terrorism to cover "domestic," as opposed to international, terrorism. A person engages in domestic terrorism if they do an act "dangerous to human life" that is a violation of the criminal laws of a state or the United States, if the act appears to be intended to: (i) intimidate or coerce a civilian population; (ii) influence the policy of a government by intimidation or coercion;

 

Dr. Anthony Fauci has intimidated and coerced a civilian population and sought to influence the policy of a government by intimidation and coercion.

 

With no corroboration, Dr. Anthony Fauci promoted (Source: https://www.cato.org/blog/did-mitigation-save-two-million-lives ) Professor Neil Ferguson’s computer simulation derived claims that,

 

“The world is facing the most serious public health crisis in generations. Here we provide concrete estimates of the scale of the threat countries now face.

 

“We use the latest estimates of severity to show that policy strategies which aim to mitigate the epidemic might halve deaths and reduce peak healthcare demand by two-thirds, but that this will not be enough to prevent health systems being overwhelmed. More intensive, and socially disruptive interventions will therefore be required to suppress transmission to low levels. It is likely such measures – most notably, large scale social distancing – will need to be in place for many months, perhaps until a vaccine becomes available.” (Source: https://www.imperial.ac.uk/news/196234/covid-19-imperial-researchers-model-likely-impact/)

 

Reporting to the President that as many as 2.2 million deaths may result from a pathogen that had not yet been isolated and could not be measured with any accuracy, Dr. Fauci intimidated and coerced the population and the government into reckless, untested, and harmful acts creating irreparable harm to lives and livelihoods. (Source: https://www.npr.org/2020/03/31/823916343/coronavirus-task-force-set-to-detail-the-data-that-led-to-extension-of-guideline) Neither the Imperial College nor the “independent” Institute for Health Metrics and Evaluation (principally funded by the Bill and Melinda Gates Foundation) (Source: https://www.gatesfoundation.org/Media-Center/Press-Releases/2017/01/IHME-Announcement) had any evidence of success in estimating previous burdens from coronavirus but, without consultation or peer-review, Dr. Fauci adopted their terrifying estimates as the basis for interventions that are explicitly against medical advice.

 

a.      The imposition of social distancing was based on computer simulation and environmental models with NO disease transmission evidence whatsoever.

 

b.      The imposition of face mask wearing was directly against controlled clinical trial evidence and against the written policy in the Journal of the American Medical Association.

 

“Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people from becoming ill.”(Source: https://jamanetwork.com/journals/jama/fullarticle/2762694?fbclid=IwAR2RE-c4V-fhUodui0JQRbiHRcgEJuDKG_21N4oL5zAfciQfWCyHAsetJmo)

c.      In both the Imperial College and the IHME simulations, quarantines were modeled for the sick, not the healthy.

 

  

Insisting on vaccines while blockading the emergency use of proven pharmaceutical interventions may have contributed to the death of many patients and otherwise healthy individuals.(Source: https://www.reuters.com/investigates/special-report/health-coronavirus-usa-cost/)

Using the power of NIAID during the alleged pandemic, Dr. Anthony Fauci actively suppressed proven medical countermeasures used by, and validated in scientific proceedings, that offered alternatives to the products funded by his conspiring entities for which he had provided direct funding and for whom he would receive tangible and intangible benefit.

 

 

18 U.S.C. § 1001 – Lying to Congress

Except as otherwise provided in this section, whoever, in any matter within the jurisdiction of the executive, legislative, or judicial branch of the Government of the United States, knowingly and willfully—

1. falsifies, conceals, or covers up by any trick, scheme, or device a material fact;
2. makes any materially false, fictitious, or fraudulent statement or representation; or
3. makes or uses any false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry;

shall be fined under this title, imprisoned not more than 5 years or, if the offense involves international or domestic terrorism (as defined in section 2331), imprisoned not more than 8 years, or both. If the matter relates to an offense under chapter 109A, 109B, 110, or 117, or section 1591, then the term of imprisonment imposed under this section shall be not more than 8 years.

 

On October 22, 2020, the United States Government Accountability Office (GAO) published a report entitled: BIOMEDICAL RESEARCH: NIH Should Publicly Report More Information about the Licensing of Its Intellectual Property. In this document, the authors reported that the National Institutes of Health (NIH) received, “up to $2 billion in royalties from its contributions to 34 drugs sold from 1991-2019.”(Source: https://www.gao.gov/products/GAO-21-52)

 

A casual review of the NIH Office of Technology Transfer report of active licenses (Source: https://www.ott.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics) appears to conflict with the GAO report on several important facts. Conspicuously absent from the GAO report are over 30 patents associated with active compounds generating billions of dollars in revenue. Why would it be that the GAO and the NIH couldn’t agree on something as simple as drugs generating income for NIH?

 

Since the passage of the Bayh Dole Act (Pub. L. 96-517, December 12, 1980), federally funded research has been an economic bonanza for U.S. universities, federal agencies, and their selected patronage. For the first decade following Bayh Dole, NIH funding doubled from $3.4 billion to $7.1 billion. A decade later, it doubled again to $15.6 billion. In the wake of September 2001, the National Institute for Allergy and Infectious Diseases (NIAID) saw its direct budget increase over 300%, without accounting for DARPA, funds of as much as $1.7 billion annually from 2005 forward. In 2020, NIH’s budget was over $41 billion.

 

What has become of the $763 billion of taxpayer funds allocated to making America healthier since inventors have been commercially incentivized? Who has been enriched?

 

The answer, regrettably, is that no accountability exists to answer these questions. The NIH is the named owner of at least 138 patents since 1980.

The United States Department of Health and Human Services is the named owner of at least 2,600 patents.

 

NIAID grants or collaboration have resulted in 2,655 patents and patent applications of which only 95 include an assignment to the Department of Health and Human Services as an owner. Most of these patents are assigned to universities thereby making the ultimate commercial beneficiaries entirely opaque. One of the largest holders is SIGA Technologies (NASDAQ: SIGA) who, while publicly reporting close affiliation with NIAID, is not referenced in the NIH GAO report. SIGA’s CEO, Dr. Phillip L. Gomez spent 9 years at NIAID developing its vaccine program for HIV, SARS, Ebola, West Nile Virus, and Influenza before exiting to commercial ventures. While their technology is clearly derived from NIAID science, the company reports revenue from NIAID but no royalty or commercial payments to NIH or any of its programs.

  

NIAID’s Director, Dr. Anthony Fauci, is listed as an inventor on 8 granted U.S. patents. None of them are reported in NIAID, NIH, or GAO reports of active licensing despite the fact that Dr. Fauci reportedly was compelled to get paid for his interleukin-2 “invention” – payments he reportedly donated to an unnamed charity. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545012/)

 

Of the 21 patents listed in the U.S. Food and Drug Administration’s (FDA) Orange book, itemized in the GAO report, none of Dr. Anthony Fauci’s patents are listed. Furthermore, none of the NIAID patents are listed despite clear evidence that Gilead Sciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) have generated over $2 billion annually from sales that were the direct result of NIAID funded science. Missing from the GAO report are 2 patents for Velclade® which has been generating sales in excess of $2.18 billion annually for several years. None of the patents for Yescarta® are listed in the GAO report. None of the Lumoxiti® patents are listed in the GAO report. None of the Kepivance® patents are listed in the GAO report. In violation of 37 USC §410.10 and 35 USC §202(a), over 13 of the 21 patents in the GAO report fail to disclose government interest despite being the direct result of NIH funding.

 

Dr. Anthony Fauci’s Own Patent Track Record:

 

US Patent 6,190,656 and 6,548,055 - Immunologic enhancement with intermittent interleukin-2 therapy:

 

A method for activating a mammalian immune system entails a series of IL-2 administrations that are affected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T-cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is affected by delivering a genetically engineered retroviral vector directly to the patient.

 

This application is a continuation of U.S. patent application Ser. No. 08/487,075, filed Jun. 7, 1995, now abandoned, which is a continuation in part of U.S. patent application Ser. No. 08/063,315, filed May 19, 1993, now issued as U.S. Pat. No. 5,419,900, and U.S. patent application Ser. No. 08/452,440, filed May 26, 1995, now issued as U.S. Pat. No. 5,696,079, which is the National Stage filed under 35 USC 371 of PCT/US94/05397, filed May 19, 1994, the contents of which are incorporated herein by reference.

 

Filed May 19, 1993

 

Issued a Final Rejection January 20, 1998. Rejected after abandonment August 14, 1998 and April 12, 1999. Reduced and modified claims granted May 8, 2000.

 

This family of patents was the basis of Fauci’s lie to the British Medical Journal in which he falsely stated:

 

“Dr Anthony Fauci told the BMJ that as a government employee he was required by law to put his name on the patent for the development of interleukin 2 and was also required by law to receive part of the payment the government received for use of the patent. He said that he felt it was inappropriate to receive payment and donated the entire amount to charity.”

 

            US Patent 6,911,527 - HIV related peptides:

 

This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.

 

Filed May 6, 1999

 

Rejected as unpatentable January 22, 2003. Issued with a final rejection on July 15, 2004 after submitting reconsideration requests. Modified and restricted claims allowed September 29, 2004.

 

US Patent 7,368,114 - Fusion protein including of CD4:

 

Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.

 

Filed October 24, 2002

 

Rejected as unpatentable August 18, 2006. Paid appeal to overturn examiner’s findings February 15, 2007. Rejected again May 11, 2007. On October 10, 2007 applicants further narrowed the construction of what was clearly not a patent and the USPTO granted less than half the claims that had been sought in the original filing.

 

 

US Patent 9,896,509, 9,193,790 and 9,441,041 - Use of antagonists of the interaction between HIV GP120 and .alpha.4.beta.7 integrin:

 

Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist, thereby treating the HIV infection. In several examples, the .alpha.4 integrin antagonist is a monoclonal antibody that specifically binds to a .alpha.4, .beta.1 or .beta.7 integrin subunit, or a cyclic hexapeptide, with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

 

Rejected May 22, 2017 as Double Patenting. In their response, the applicants acknowledge the illegal act and seek only those components of their application that extend beyond the life of the issued patents. On October 11, 2017, the limited claims were issued.

 

A sample of the convoluted flow of funds that evades public disclosure.

 

U.S. Patent 8,999,351 was issued to Tekmira Pharmaceuticals Corporation in Burnaby, British Columbia. In their patent, they disclose that their research was supported by a grant from the National Institute of Allergy and Infectious Disease (Grant HHSN266200600012C). Ironically, this $23 million grant was awarded in 2006 to Alnylam Pharmaceuticals, Inc., not to Tekmira.(Source: Alnylam Awarded $23 Million U.S. Government Contract to Develop RNAi Therapeutics | Technology Networks)

 

 

In 2012, Alnylam agreed to pay Tekmira $65 million to settle legal disputes including a $1 billion damages claim for “relentless and egregious” misappropriation of Tekmira’s trade secrets. From the patent filing’s earliest priority of November 10, 2008, there is no public record stating Tekmira as the beneficiary of this NIAID grant. Notwithstanding, the lipid nanoparticle technology developed from this grant is the technology now used in the Moderna COVID-19 intervention. In their 10-Q filing, Alnylam reports to have a license to technology from Arbutus – formerly Tekmira – which has accused Acuitas of misappropriating trade secrets and licensing them to Moderna and Pfizer’s collaboration with BioNTech.

 

Additional references can be found at:

 

https://www.ott.nih.gov/nih-and-its-role-technology-transfer https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206288Orig1s000TAltr.pdf https://www.gao.gov/assets/720/710287.pdf https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%22

 

 

15 U.S.C. §1-3 – Conspiring to Criminal Commercial Activity

 

Every contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce among the several States, or with foreign nations, is declared to be illegal. Every person who shall make any contract or engage in any combination or conspiracy hereby declared to be illegal shall be deemed guilty of a felony, and, on conviction thereof, shall be punished by fine not exceeding $100,000,000 if a corporation, or, if any

other person, $1,000,000, or by imprisonment not exceeding 10 years, or by both said punishments, in the discretion of the court.

 

The National Institute of Health’s grant AI23946-08 issued to Dr. Ralph Baric at the University of North Carolina at Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci’s NIAID by at least 2003) began the work on synthetically altering the Coronaviridae (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.(Source: U.S. Provisional Application No. 60/206,537, filed May 21, 2000) In one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.

 

“Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones.”(Source: https://www.pnas.org/content/100/22/12995)

 

On April 19, 2002, the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first public record of the claims, they sought to patent a means of producing, “an infectious, replication defective, coronavirus.” This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 before SARS was ever detected in humans.

 

Against this backdrop, we noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003 SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Work associated with this virus by their select collaborators included considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment (both vaccine and therapeutic intervention), and weaponization inquiries.

 

In short, with Baric’s U.S. Patent 6,593,111 (Claims 1 and 5) and CDC’s ‘852 patent (Claim 1), no research in the United States could be conducted without permission or infringement.

 

We noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research grants from several federal agencies but also sat on the World Health Organization’s International Committee on Taxonomy of Viruses (ICTV) and the Coronaviridae Study Group (CSG). In this capacity, he was both responsible for determining “novelty” of clades of virus species but directly benefitted from determining declarations of novelty in the form of new research funding authorizations and associated patenting and commercial collaboration. Together with CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of interests constituted what we would suggest are “interlocking directorates” under U.S. anti-trust laws.

 

 

 

·        1986-1990    NIAID Grant AI 23946 leading to patent U.S. 7,279,327 “Methods for Producing Recombinant Coronavirus” Filed 2002 and issued 2007 https://patents.google.com/patent/US7279327B2/ru

The paper first published from the NIAID grant is https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf

 

·        1990    Pfizer files U.S. Patent 6,372,224 on a vaccine for the S-protein on coronavirus November 14, 2000 which was abandoned April 2010 making it public domain.

 

·        1990s    Work focused on CoV association with cardiomyopathy (see above)

Early reference to the “emergence” of CoV as a respiratory pathogen in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf

 

·        2000    Ralph Baric AI23946 and GM63228 from the National Institutes of Health actively working recombinant CoV

 

·        2001    National Institute of Health, Allergy and Infectious diseases. “Reverse Genetics with a Coronavirus Infectious cDNA Construct.” 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI

 

·        2002    Asia CoV SARS outbreak

 

·        2003    April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus.

Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation’s Global Grand Challenges Scientific Advisory Board (served through 2010).

 

·        April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163 https://www.sbir.gov/node/305319

 

·        July 21, 2003 Ralph Baric’s team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https://patents.google.com/patent/US7618802B2

Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS CoV. This research is supported by several NIH grants including National Institutes of Health Grants A128785, A148436, and A1053822.

 

·        2004    January 6, 2004 – SARS and Bioterrorism linked at Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators. https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706

At this conference, the term “The New Normal” was introduced by Merck

 

FAUCI AND BARIC start making money!!! National Institutes of Health, Allergy and Infectious Diseases. SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic mouse model for SARS-CoV infection.

 

National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million

 

·        November 22, 2004    University of Hong Kong patents SARS associated spike protein on CoV and pursues patent US 7,491,489

 

·        2005    DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling Technologies, June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker

 

Review timeline from https://www.youtube.com/watch?v=rO_EeYB0i0U and https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf

 

·        2008    Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC Chapel Hill https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104

 

·        2009    Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant from NIAID)

 

·        2010    Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID)

Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued patents.

 

·        August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164 which attracted the investment of (and “inventorship” for) venture capitalists at Flagship Ventures. This patent grew out of the work of Dr. Jason P. Schrum of Harvard Medical School supported by National Science Foundation Grant #0434507. While the application claims priority to August 2010, the application didn’t get finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final rejection on this original patent rejecting all claims.

https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with reference to the grant funding in https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf

 

 

·        2011    Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all of its SARS technology.

 

Biodefense Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill (non-competitive grant from NIAID)

 

·        2012    MERS isolated in Egypt

 

Biodefense Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive grant from NIAID)

 

·        2013    Biodefense Grant U54 AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant from NIAID)

 

·        2014    April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435

 

·        2015    Moderna signs a vaccine development agreement with NIAID and executes it with the lead on the mRNA-1273 lead developer and inventor Guiseppe Ciaramella. https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html

 

·        2016    NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use” disclosing mRNA technology that overlaps (and is used in tandem with) Moderna’s technology. https://patents.google.com/patent/WO2018081318A1/en Lead Inventor Barney Scott Graham was well known to Moderna as he’s the person at NIH that Moderna “e-mailed” to get the sequence for SARS

CoV-2 according to Moderna’s report here (“In January 2020, once it was discovered that the infection in Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic sequence for the virus.”) https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html

In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the Chinese government filed in Australia in 2013 https://patents.google.com/patent/AU2014231357A1/en?inventor=Jason+MCLELLAN.

 

·        2017    August – Sanofi buys Protein Science Corp with considerable SARS patent holdings

·        2018    June – Sanofi buys Ablynx with considerable SARS patent holdings

·        2019    March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create- affordable-molecular-diagnostics/ funded by Open Philanthropy – the same organization that would be the financial sponsor of the Event 201 “table-top” exercise that laid out the entire “pandemic” plan in October 2019.

 

 

 

 

15 U.S.C. §8 – Market Manipulation and Allocation

Every combination, conspiracy, trust, agreement, or contract is declared to be contrary to public policy, illegal, and void when the same is made by or between two or more persons or corporations, either of whom, as agent or principal, is engaged in importing any article from any foreign country into the United States, and when such combination, conspiracy, trust, agreement, or contract is intended to operate in restraint of lawful trade, or free competition in lawful trade or commerce, or to increase the market price in any part of the United States of any article or articles imported or intended to be imported into the United States, or of any manufacture into which such imported article enters or is intended to enter. Every person who shall be engaged in the importation of goods or any commodity from any foreign country in violation of this section, or who shall combine or conspire with another to violate the same, is guilty of a misdemeanor, and on conviction thereof in any court of the

United States such person shall be fined in a sum not less than $100 and not exceeding $5,000, and shall be further punished by imprisonment, in the discretion of the court, for a term not less than three months nor exceeding twelve months.

 

Through non-competitive grant awards to UNC Chapel Hill’s Ralph Baric, to selection of the Bio-Safety Level 4 laboratory locations, to the setting of prices for Remdesivir and mRNA therapies from Moderna and Pfizer, NIAID, CDC, and the U.S. Department of Health and Human Services have been involved in allocating Federal funds to conspiring parties without independent review.

 

Around March 12, 2020, in an effort to enrich their own economic interests by way of securing additional funding from both Federal and Foundation actors, the CDC and NIAID’s Dr Fauci elected to suspend testing and classify COVID-19 by capricious symptom presentation alone. Forcing the public to rely on The COVID Tracking Project – funded by the Bloomberg, Zuckerberg and Gates Foundation and presented by a media outlet (The Atlantic) – not a public health agency – Dr. Fauci used fraudulent testing technology (RT-PCR) to conflate “COVID cases” with positive PCR tests in the living while insisting that COVID deaths be counted by symptoms alone. This perpetuated a market demand for his desired vaccine agenda which was recited by him and his conspiring parties around the world until the present. Not surprisingly, this was necessitated by the apparent fall in cases that constituted Dr. Fauci’s and others’ criteria for depriving citizens of their 1st Amendment rights.

 

 

15 U.S.C. § 19 – Interlocking Directorates

No person shall, at the same time, serve as a director or officer in any two corporations (other than banks, banking associations, and trust companies) that are—

1. engaged in whole or in part in commerce; and
2. by virtue of their business and location of operation, competitors, so that the elimination of competition by agreement between them would constitute a violation of any of the antitrust laws; if each of the corporations has capital, surplus, and undivided profits aggregating more than $10,000,000 as adjusted pursuant to paragraph (5) of this subsection.

 

 

Dr. Fauci is on the Leadership Council of the Bill and Malinda Gates Global Vaccine Action Plan

 

Dr. Fauci while controlling the economic dispensation of Federal research funding, Dr. Fauci has been, and continues to be, on the World Health Organization’s Global Preparedness Monitoring Board. He is joined on this board by the conflicted donor from the Bill and Melinda Gates Foundation’s Dr. Chris Elias and the State Council of China’s Dr. George

F. Gao of the Chinese CDC. This GPMB stipulated that all member states must take part in a global simulation of the release of a respiratory pathogen.

 

Dr. Baric is one of the primary beneficiaries of U.S. Federal funds, runs a BSL-4 facility and sits on the International Committee on Taxonomy of Virus Coronaviridae Working Group tasked to confirm the presence of absence of the pathogen for which he is directly compensated.

 

As referenced in the section covering violations of 18 U.S.C. § 1001 above, numerous undisclosed commercial relationships exist between funded researchers, their funding agencies, and commercial interests in which disclosed and undisclosed commercial terms exist. A complete list of all potential implicated parties is listed in the section below entitled “The Commercial Actors”.

 

It appears that during the period of patent enforcement and after the Supreme Court ruling confirming that patents on genetic material were illegal, the CDC and National Institute of Allergy and Infectious Diseases led by Anthony Fauci (hereinafter “NIAID” and "Dr Fauci", respectively) entered into trade among States (including, but not limited to working with Ecohealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent rights.

 

It further appears that during the period of patent enforcement and after the Supreme Court ruling confirming that patents on genetic material was illegal, the CDC and National Institute of Allergy and Infectious Diseases (hereinafter “NIAID”) entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016.

 

It further appears that during the period of patent enforcement and after the Supreme Court ruling confirming that patents on generic material was illegal, the CDC and NIAID entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations to conduct chimeric construction of novel coronavirus material with specific virulence properties prior to, during, and following the determination made by the National Institutes for Health in October 17, 2014 that this work was not sufficiently understood for its biosecurity and safety standards.

 

In this inquiry, it is presumed that the CDC and its associates were: a) fully aware of the work being performed using their patented technology; b) entered into explicit or implicit agreements including licensing, or other consideration; and, c) willfully engaged one or more foreign interests to carry forward the exploitation of their proprietary technology when the U.S. Supreme Court confirmed that such patents were illegal and when the National Institutes of Health issued a moratorium on such research.

 

Reportedly, in January 2018, the U.S. Embassy in China sent investigators to Wuhan Institute of Virology and found that, “During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory.” The Washington Post reported that this information was contained in a cable dated 19 January 2018. Over a year later, in June 2019, the CDC conducted an inspection of Fort Detrick’s U.S. Army Medical Research Institute of Infectious Diseases (hereinafter “USAMRIID”) and ordered it closed after alleging that their inspection found biosafety hazards. A report in the journal Nature in 2003 (423(6936): 103) reported cooperation between CDC and USAMRIID on coronavirus research followed by considerable subsequent collaboration. The CDC, for what appear to be the same type of concern identified in Wuhan, elected to continue work with the Chinese government while closing the U.S. Army facility.

 

The CDC reported the first case of SARS-CoV like illness in the United States in January 2020 with the CDC’s Epidemic Intelligence Service reporting 650 clinical cases and 210 tests. Given that the suspected pathogen was first implicated in official reports on December 31, 2019, one can only conclude that CDC: a) had the mechanism and wherewithal to conduct tests to confirm the existence of a “novel coronavirus”; or, b) did not have said mechanism and falsely reported the information in January. It tests credulity to suggest that the WHO or the CDC could manufacture and distribute tests for a “novel” pathogen when their own subsequent record on development and deployment of tests has been shown to be without reliability.

 

35 U.S.C. §200 - 206 – Disclosure of Government Interest

35 U.S.C. §202 (c)(6)

 

An obligation on the part of the contractor, in the event a United States patent application is filed by or on its behalf or by any assignee of the contractor, to include within the specification of such application and any patent issuing thereon, a statement specifying that the invention was made with Government support and that the Government has certain rights in the invention.

 

Over 5000 patents and patent applications have included reference to SARS Coronavirus dating back to priority dates of 1998. They are summarized below.

 

 

On July 23, 2020, the Patent Trial and Appeal Board of the United States Patent and Trademark Office rejected Moderna’s efforts to invalidate U.S. Patent 8,058,069. This patent, owned by Arbutus Biopharma Corp (principally owned by Roivant Science Ltd), covers the lipid nanoparticle (LNP) required to deliver an mRNA vaccine. Some of the core technology was based on work originally done at the University of British Columbia and was first licensed in 1998.

 

mRNA-1273 – the experimental vaccine developed by Moderna for COVID-19 – uses the LNP technology that Moderna thought it had licensed from Acuitas Therapeutics Inc., a firm developed by a former principal of Arbutus’ prior company Tekmira. That license did not authorize Moderna to use the technology for the COVID-19 vaccine.

 

M·CAM and Knowledge Ecology International have independently confirmed that Moderna has violated U.S. law in failing to disclose the U.S. government’s funding interest in their patents and patent applications. While this negligence impacts all of Moderna’s over 130 granted U.S. patents, it is particularly problematic for U.S. Patent 10,702,600 (‘600) which is the patent relating to, “a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle.” The specific claims addressing the pivot to the SARS Coronavirus were patented on March 28, 2019 – 9 months before the SARS CoV-2 outbreak! Both the patent and the DARPA funding for the technology were disclosed in scientific publication (New England Journal of Medicine) but the government funds were not acknowledged in the patent.

 

In 2013, the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program awarded grant funding to Moderna Therapeutics for the development of a new type of vaccine based on messenger RNA. The initial DARPA grant was W911NF-13-1-0417. The company used that technology to develop its COVID-19 vaccine, currently undergoing clinical trials in conjunction with NIH.(Source: https://crsreports.congress.gov/product/pdf/IN/IN11446)

 

Under the Federal Acquisition Regulation (FAR) rules, contractor to the Federal Government must provide information regarding intellectual property infringement issues as part of their contract. Under FAR §27.201-1(c) and (d), the Government both requires a notice of infringement or potential infringement as well as retention of economic liability for patent infringements. Specifically, in FAR §52.227.3 (a), the “Contractor shall indemnify the Government and its officers, agents, and employees against liability, including costs for infringement of any United States Patent…”. In addition to the patents cited by the USPTO in their examination of ‘600, M·CAM has identified fourteen other issued patents preceding the ‘600 patent which were used by patent examiners to limit patents arising from the same funded research including patents sought by CureVac.

 

In short, while Moderna enjoys hundreds of millions of dollars of funding, allegiance, and advocacy from Anthony Fauci and his NIAID, since its inception, it has been engaged in illegal patent activity and demonstrated contempt for U.S. Patent law. To make matters worse, the U.S. Government has given it financial backing in the face of undisclosed infringement risks potentially contributing to the very infringement for which they are indemnified.

 

 

21 C.F.R. § 50.24 et seq., Illegal Clinical Trial

 

It is unlawful to conduct medical research (even in the case of emergency) without a series of steps taken to:

1. Establish the research with a duly authorized and independent institutional review board;
2. Secure informed consent of all participants including a statement of risks and benefits; and,
3. Engage in consultation with the community in which the study is to be conducted.

 

Dr. Anthony Fauci has forced upon the healthy population of the United States an unlawful clinical trial in which the U.S. Department of Health and Human Services are extrapolating epidemiologic data. No informed consent has been sought or secured for any of the “medical countermeasures” forced upon the population and no independent review board – as defined by the statute – has been empaneled.

 

Through April 2020, the official recommendation by the Journal of the American Medical Association was unambiguous.

 

“Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people from becoming ill.”(Source: Medical Masks | Infectious Diseases | JAMA | JAMA Network)

 

Part of that lack of evidence in fact showed that cloth facemasks actually increased influenza-linked illness. (Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420971/)

 

In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a “belief” that face masks limit the spread of SARS CoV-2. To date, not a single study has confirmed that a mask prevented the transmission of, or the infection by SARS CoV-2.

 

All parties mandating the use of facemasks are not only willfully ignoring established science but are engaging in what amounts to a whole population clinical trial. This conclusion is reached by the fact that facemask use and COVID-19 incidence are being reported in scientific opinion pieces promoted by the United States Centers for Disease Control and Prevention and others.(Source: https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html)

 

Social distancing of up to 6 feet has been promoted as a means of preventing person-to-person transmission of influenza-like viruses. While one study hypothesized that infection could happen in a 6 foot range, the study explicitly states that person-to-person transfer was not tested and viability of the virus at 6 feet was not even a subject of the investigation.(Source: Werner E. Bischoff, Katrina Swett, Iris Leng, Timothy R. Peters, Exposure to Influenza Virus Aerosols During Routine Patient Care, The Journal of Infectious Diseases, Volume 207, Issue 7, 1 April 2013, Pages 1037–1046, https://doi.org/10.1093/infdis/jis773) That did not stop the misrepresentation of the study to be used as the basis for an unverified medical counter measure of social distancing. To date, no study has established the efficacy of social distancing to modify the transmission of SARS CoV-2. Public health officials have referenced:

 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907354/#CR43

 

In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a “belief” that social distancing of a healthy population limits the spread of SARS CoV-2. To date, not a single study has confirmed that social distancing of any population prevented the transmission of, or the infection by SARS CoV-2.

It is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product or service can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well- controlled human clinical studies, substantiating that the claims are true at the time they are made. As a result, every party promoting the use of face masks is violating the FTC Act.

 

 

 

The Commercial Actors

SARS coronavirus is a new topic for many individuals. Since 1999, the ability to manipulate and exploit coronavirus for a variety of purposes has attracted the attention of individuals, institutions and commercial organizations in public, private, and not-for-profit sectors.

The following is a list of over 4,000 patents and patent applications filed for the express purpose of controlling some aspect of the SARS coronavirus.

PATENT	Title	Owner	Priority	File Date	Issue Date
US9995706	Amperometric gas sensor	Steris Corporation	25- Jun- 12	30- Sep -14	12- Jun- 18
US9995705	Amperometric gas sensor	Steris Corporation	25- Jun- 12	30- Sep -14	12- Jun- 18
US9994558	Multicyclic compounds and methods of using same	Karyopharm Therapeutics Inc.	20- Sep- 13	19- Sep -14	12- Jun- 18
US9994550	Heterocyclic modulators of lipid synthesis for use against cancer and viral infections	3-V Biosciences, Inc.	7- Jan- 14	7- Jan -15	12- Jun- 18
US9993543	Immunogenic compositions comprising silicified virus and methods of use	Portland State University	31- Jan- 13	31- Jan -14	12- Jun- 18
US9982257	Chiral control	WAVE LIFE SCIENCES LTD.	13- Jul-12	12- Jul- 13	29- May -18
US9982241	Recombinant HCMV and RHCMV vectors and uses thereof	Oregon Health & Science University	14- May- 10	1- Oct -15	29- May -18
US9982025	Monomeric griffithsin tandemers	The United States of America, as represented by the Secretary, Department of Health and Human Services	5- Jun- 13	5- Jun -14	29- May -18
US9981036	Compositions, comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	12- Dec- 11	26- Feb -16	29- May -18
US9975885	Broad-spectrum non-covalent coronavirus protease inhibitors	PURDUE RESEARCH FOUNDATION	28- Apr- 16	28- Apr -17	22- May -18
US9974850	Immunogenic compositions and uses thereof	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	25- Mar- 15	25- Mar -16	22- May -18
US9974848	Tetanus toxoid and CCL3 improve DC vaccines	Duke University	14- Nov- 13	14- Nov -14	22- May -18
US9974845	Combination of vaccination and inhibition of the PD-1 pathway	CureVac AG	22- Feb- 13	21- Feb -14	22- May -18
US9970061	Bioagent detection oligonucleotides	IBIS BIOSCIENCES, INC.	27- Dec- 11	27- Dec -12	15- May -18
US9969793	Compositions and methods for the treatment of immunodeficiency	ADMA Biologics, Inc.	28- Oct- 14	13- Nov -17	15- May -18
US9963718	LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus- producing cells for the therapy of tumors	VIRATHERAPEUTICS GMBH	8- Oct- 08	7- Apr -17	8- May -18
US9963611	Composition for use in decreasing the transmission of human pathogens	Innonix Technologies, Incorporated	29- May- 09	21- May -10	8- May -18
US9963427	Dithiol mucolytic agents	PARION SCIENCES, INC.	23- Aug- 13	11- Mar -16	8- May -18
US9962439	Injectable vaccine composition	NITTO DENKO CORPORATION	3- Oct- 13	2- Oct -14	8- May -18
US9957302	Treating cancer with viral nucleic acid	Mayo Foundation for Medical Education and Research	20- Feb- 07	6- Jul- 15	1- May -18
US9957300	Virus-like particles, methods of preparation, and immunogenic compositions	Emory University	17- May- 02	4- May -15	1- May -18
US9957238	Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds	Parion Sciences, Inc.	13- Dec- 13	1- Mar -17	1- May -18
US9951317	Highly efficient influenza matrix (M1) proteins	NOVAVAX, INC.	11- Jul-03	6- Oct -16	24- Apr- 18
US9951124	Antibody producing non-human mammals	MERUS N.V.	27- Jun- 08	25- Jan -13	24- Apr- 18
US9951122	Antibodies against influenza virus and methods of use thereof	BURNHAM INSTITUTE FOR MEDICAL RESEARCH	6- Dec- 07	12- Aug -13	24- Apr- 18
US9950062	Compounds and compositions as TLR activity modulators	GLAXOSMITHKLINE BIOLOGICALS SA	2- Sep- 09	1- Sep -10	24- Apr- 18
US9945856	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics	AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V.	18- Aug- 03	13- Aug -14	17- Apr- 18
US9945780	Use of a fluorescent material to detect failure or deteriorated performance of a fluorometer	GEN-PROBE INCORPORATED	14- Jun- 12	7- Jun -13	17- Apr- 18
US9944928	Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositions	York Yuan Yuan Zhu	23- Jul-07	2- Jul- 15	17- Apr- 18
US9944695	Antibody producing non-human mammals	Merus N.V.	27- Jun- 08	30- Apr -14	17- Apr- 18
US9944686	Treatment of tumors with recombinant interferon alpha	SUPERLAB FAR EAST LIMITED	28- Feb- 01	5- Sep -13	17- Apr- 18
US9944649	Compounds and compositions as toll-like receptor 7 agonists	Novartis Ag	1- May- 14	29- Apr -15	17- Apr- 18
US9943614	Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods	BRIGHAM YOUNG UNIVERSITY	17- Jun- 08	16- Jun -09	17- Apr- 18
US9938300	Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors	Forma Therapeutics, Inc.	5- Feb- 15	4- Feb -16	10- Apr- 18
US9938275	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	18- Jun- 04	23- Jan -17	10- Apr- 18
US9938258	Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof	Karyopharm Therapeutics Inc.	29- Nov- 12	27- Nov -13	10- Apr- 18
US9932351	Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors	Forma Therapeutics, Inc.	5- Feb- 15	4- Feb -16	3- Apr- 18
US9932323	Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones	Rutgers, The State University of New Jersey	11- Sep- 12	13- Jan -17	3- Apr- 18
US9931316	Antiviral activity from medicinal mushrooms and their active constituents	Not Available	31- Mar- 15	14- Sep -15	3- Apr- 18
US9926340	NAD analogs and methods of using said NAD analogs in determining ribosylation of proteins with PARP mutants	Biolog Life Science Institute Forshungslabor und Biochemica-Vertrieb GmbH	8- Apr- 15	1- Apr -16	27- Mar -18
US9925215	Anionically modified polyallylamine derivative, use of anionically modified polyallylamine derivative as medicine, particularly for propylaxis and treatment of infections of respiratory tract caused by human metapneumovirus (hMPV), human rhinoviruses (HRV), and infection by influenza virus type A (IAV) and pharmaceutical composition comprising the anionically modified polyallylamine derivative	UNIWERSYTET JAGIELLONSKI	29- Jul-14	25- Oct -17	27- Mar -18
US9920314	Compositions for and methods of identifying antigens	President and Fellows of Harvard College	21- Feb- 06	6- May -15	20- Mar -18
US9920128	Synthetic antiserum for rapid-turnaround therapies	The Johns Hopkins University	28- Jan- 15	20- Jan -16	20- Mar -18
US9919034	Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V	TAMIR BIOTECHNOLOGY, INC.	28- Mar- 14	10- Jun -15	20- Mar -18
US9915613	Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector	GEN-PROBE INCORPORATED	24- Feb- 11	21- Mar -14	13- Mar -18
US9914976	Methods and compositions for prostate cancer metastasis	FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FA	25- Mar- 11	27- May -16	13- Mar -18
US9913801	Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione	YOUR ENERGY SYSTEMS, LLC	15- Feb- 13	15- Mar -13	13- Mar -18
US9909176	Efficient deep sequencing and rapid genomic speciation of RNA viruses (vRNAseq)	The Johns Hopkins University	8- Sep- 14	1- Sep -15	6- Mar -18
US9908946	Generation of binding molecules	Merus N.V.	26- Sep- 11	16- Sep -15	6- Mar -18
US9908675	Powdered pouch and method of making same	MONOSOL, LLC	16- Apr- 12	19- Jul- 16	6- Mar -18

US9907796	Methods of treating tumoral diseases, or bacterial or viral infections	INHIBIKASE THERAPEUTICS, INC.	4- Oct- 12	15- Sep -16	6- Mar -18
US9895692	Sample-to-answer microfluidic cartridge	Micronics, Inc.	29- Jan- 10	5- Aug -15	20- Feb -18
US9895411	Analogs of C5a and methods of using same	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	29- Jun- 10	29- Jun -11	20- Feb -18
US9895341	Inflammation and immunity treatments	Ocean Spray Cranberries, Inc.	1- Apr- 11	30- Mar -12	20- Feb -18
US9894888	Transgenic immunodeficient mouse expressing human SIRP-alpha	INSTITUT PASTEUR	26- Mar- 12	26- Mar -13	20- Feb -18
US9890419	Nanoreporters and methods of manufacturing and use thereof	NanoString Technologies, Inc.	23- Dec- 05	20- May -16	13- Feb -18
US9890408	Multiple displacement amplification	IBIS BIOSCIENCES, INC.	15- Oct- 09	15- Oct -10	13- Feb -18
US9890362	Compositions, methods and uses for inducing viral growth	Takeda Vaccines, Inc.	5- Dec- 08	19- Sep -14	13- Feb -18
US9890361	Methods for increasing the infectivity of viruses utilizing alkyne- modified fatty acids	LIFE TECHNOLOGIES CORPORATION	26- Jan- 12	25- Jan -13	13- Feb -18
US9890206	H1N1 flu virus neutralizing antibodies	Medigen Biotechnology Corporation	20- Aug- 15	20- Aug -15	13- Feb -18
US9890169	Triazolinone compounds as HNE inhibitors	CHIESI FARMACEUTICI S.P.A.	14- Dec- 15	12- Dec -16	13- Feb -18
US9890124	Benzazepine sulfonamide compounds	Hoffmann-La Roche Inc.	15- Dec- 15	14- Jun -17	13- Feb -18
US9889194	Immunogenic composition for MERS coronavirus infection	New York Blood Center, Inc.	1- Mar- 13	28- Feb -14	13- Feb -18
US9885092	Materials and methods for detection of HPV nucleic acids	QIAGEN GAITHERSBURG INC.	24- Feb- 11	23- Feb -12	6- Feb -18
US9885082	Embodiments of a probe and method for targeting nucleic acids	University of Idaho	19- Jul-11	19- Jul- 12	6- Feb -18
US9885037	Chiral control	WAVE LIFE SCIENCES LTD.	13- Jul-12	12- Jul- 13	6- Feb -18
US9884895	Methods and compositions for chimeric coronavirus spike proteins	The University of North Carolina at Chapel Hill	20- Mar- 14	20- Mar -15	6- Feb -18
US9884876	Anti-viral compounds, pharmaceutical compositions, and methods of use thereof	Kineta, Inc.	9- May- 14	8- May -15	6- Feb -18
US9884129	Release of agents from cells	The Brigham and Women's Hospital, Inc.	15- Oct- 09	5- Jan -15	6- Feb -18
US9884032	Esters of short chains fatty acids for use in the treatment of immunogenic disorders	PROPONENT BIOTECH GMBH	3- Oct- 12	3- Mar -16	6- Feb -18
US9884026	Modular particles for immunotherapy	YALE UNIVERSITY	1- Nov- 13	31- Oct -14	6- Feb -18
US9880151	Method of determining, identifying or isolating cell-penetrating peptides	Phylogica Limited	23- May- 11	23- May -12	30- Jan- 18
US9879026	Substituted spirocycles	Boehringer Ingelheim International GmbH	12- Sep- 14	29- Nov -16	30- Jan- 18
US9879003	Host targeted inhibitors of dengue virus and other viruses	Dana-Farber Cancer Institute, Inc.	11- Apr- 12	15- Mar -13	30- Jan- 18
US9878988	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases	PARION SCIENCES, INC.	29- May- 12	5- Jan -16	30- Jan- 18
US9873678	Chemical compounds	AstraZeneca AB	18- Mar- 14	17- Mar -15	23- Jan- 18
US9873674	C-Rel inhibitors and uses thereof	CORNELL UNIVERSITY	21- Sep- 12	19- Sep -13	23- Jan- 18
US9872900	Nucleic acid vaccines	ModernaTX, Inc.	23- Apr- 14	5- Apr -16	23- Jan- 18
US9872898	Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome	Ohio State Innovation Founation	24- Apr- 12	3- Oct -16	23- Jan- 18
US9872895	TLR5 ligands, therapeutic methods, and compositions related thereto	Emory University	24- Sep- 10	20- Sep -11	23- Jan- 18
US9868952	Compositions and methods for “resistance-proof†SiRNA therapeutics for influenza	Sirnaomics, Inc.	8-Jul- 12	7- Jul- 13	16- Jan- 18
US9868740	Pyrimidinone compounds which are HNE inhibitors	CHIESI FARMACEUTICI S.p.A.	12- Jun- 14	12- Jun -14	16- Jan- 18
US9868736	Deubiquitinase inhibitors and methods for use of the same	THE REGENTS OF THE UNIVERSITY OF MICHIGAN	10- Oct- 13	10- Oct -14	16- Jan- 18
US9867882	Carbohydrate conjugates as delivery agents for oligonucleotides	Alnylam Pharmaceuticals, Inc.	4- Dec- 07	25- Aug -15	16- Jan- 18
US9867877	Methods for preparing squalene	NOVARTIS AG	12- May- 10	22- Nov -16	16- Jan- 18
US9862706	Compounds	CHIESI FARMACEUTICI S.p.A.	31- May- 16	26- May -17	9- Jan- 18
US9861614	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	9- May- 12	23- Jun -15	9- Jan- 18
US9856254	Alkoxy substituted imidazoquinolines	3M Innovative Properties Company	3- Oct- 03	13- Jun -16	2- Jan- 18
US9856241	Substituted benzofuranyl and benzoxazolyl compounds and uses thereof	Karyopharm Therapeutics Inc.	3-Jul- 13	3- Jul- 14	2- Jan- 18
US9856228	Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors	PROZYMEX A/S	9- Sep- 13	8- Sep -14	2- Jan- 18
US9856224	Stable sodium channel blockers	PARION SCIENCES, INC.	30- Jun- 14	30- Jan -17	2- Jan- 18
US9855287	Anti-viral azide containing compounds	LIFE TECHNOLOGIES CORPORATION	28- Jul-10	20- Aug -15	2- Jan- 18
US9855284	Pharmaceutical compositions and methods	Pop Test Oncology LLC	3- Aug- 15	6- Dec -16	2- Jan- 18
US9849143	Broad spectrum antiviral and methods of use	The Burlington HC Research Group, Inc.	17- Apr- 06	16- Feb -17	26- Dec -17
US9845342	Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria	Spogen Biotech Inc.	17- Sep- 14	17- Sep -15	19- Dec -17
US9840731	Preservation of biological materials in non-aqueous fluid media	Gentegra, LLC	14- Mar- 13	14- Mar -14	12- Dec -17
US9840719	Variant AAV and compositions, methods and uses for gene transfer to cells, organs and tissues	The Children's Hospital of Philadelphia	22- Jul-13	22- Jul- 14	12- Dec -17
US9840491	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5- Feb- 15	4- Feb -16	12- Dec -17
US9839687	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule	SUZHOU M-CONJ BIOTECH CO., LTD.	15- Jul-15	15- Jul- 15	12- Dec -17
US9834812	Probe kit for detecting a single strand target nucleotide sequence	Fondazione Istituto Italiano Di Tecnologia	27- Dec- 12	27- Dec -13	5- Dec -17
US9834791	CRISPR-related methods and compositions with governing gRNAS	Editas Medicine, Inc.	7- Nov- 13	7- Nov -14	5- Dec -17
US9834757	Hand, foot, and mouth vaccines and methods of manufacture and use thereof	Takeda Vaccines, Inc.	7- Nov- 14	6- Nov -15	5- Dec -17
US9834595	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases	Ablynx N.V.	5- Jun- 08	29- Oct -15	5- Dec -17
US9833504	Virus-like particles and process for preparing same	Folia Biotech Inc.	13- May- 11	1- May -12	5- Dec -17
US9833492	Combinations of a caspase inhibitor and an antiviral agent	Centre National de la Recherche Scientifique	2- Nov- 07	15- May -15	5- Dec -17
US9832998	Antiviral compositions	Long Island University	30- May- 07	19- Mar -15	5- Dec -17
US9828382	Pyrimidinone compounds as human neutrophil elastase inhibitors	Chiesi Farmaceutici S.p.A.	18- Dec- 12	10- May -16	28- Nov -17
US9828379	Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof	ABIDE THERAPEUTICS, INC.	3-Jul- 13	1- Jul- 14	28- Nov -17
US9828370	Compositions and methods for inhibiting kinases	INHIBIKASE THERAPEUTICS, INC.	23- Apr- 15	22- Apr -16	28- Nov -17
US9828346	N-myristoyl transferase inhibitors	University of Dundee	2- Sep- 08	31- Aug -15	28- Nov -17
US9828342	Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof	CITY OF HOPE	24- Feb- 12	25- Feb -13	28- Nov -17
US9827190	Intradermal delivery of immunological compositions comprising toll- like receptor 7 agonists	GLAXOSMITHKLINE BIOLOGICALS SA	1- Feb- 13	30- Jan -14	28- Nov -17
US9822339	Means and methods for influencing the stability of antibody producing cells	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM	9- Dec- 05	26- Aug -15	21- Nov -17
US9822173	Heterodimeric immunoglobulins	AMGEN INC.	21- Nov- 12	21- Nov -13	21- Nov -17
US9822165	Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external region	DANA-FARBER CANCER INSTITUTE, INC.	18- Jun- 09	18- Jun -10	21- Nov -17
US9822155	Method of preventively treating a subject at the risk of developing infections of a respiratory virus	Xiangxue Group (Hong Kong) Company Limited	9- May- 13	23- Aug -16	21- Nov -17
US9822127	GAK modulators as antivirals	The Board of Trustees of the Leland Stanford Junior University	23- Jul-14	23- Jul- 15	21- Nov -17
US9822065	Benzazepine dicarboxamide compounds	Hoffmann-La Roche Inc.	6- Mar- 15	14- Feb -17	21- Nov -17
US9821052	Reverse genetics systems	Seqirus UK Limited	31- Jul-09	30- Jul- 10	21- Nov -17
US9821051	Reducing hospitalization in elderly influenza vaccine recipients	Seqirus UK Limited	28- Oct- 10	21- Oct -11	21- Nov -17
US9816078	Compositions for increasing polypeptide stability and activity, and related methods	SOLIS BIODYNE OÜ	19- Nov- 09	11- Mar -16	14- Nov -17
US9815886	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC.	28- Oct- 14	8- Jan -15	14- Nov -17
US9815805	Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as dipeptidyl peptidase 1 inhibitors	ASTRAZENECA AB	24- Jan- 14	8- Nov -16	14- Nov -17
US9814777	Targeting lipids	Arbutus Biopharma Corporation	4- Dec- 07	22- Oct -13	14- Nov -17
US9810683	Use of live cell inteferometry with reflective floor of observation chamber to determine changes in mass of mammalian cells	The Regents of the University of California	6- May- 09	25- Nov -13	7- Nov -17
US9809845	Methods and reagents for amplifying nucleic acids	The United States of America, as represented by the Secretary, Department of Health and Human Services	6- Aug- 12	6- Aug -12	7- Nov -17
US9809796	Animal protein-free media for cultivation of cells	Baxalta GmbH	29- Oct- 04	18- May -17	7- Nov -17
US9809632	Universal protein tag for double stranded nucleic acid delivery	University of Washington Through its Center for Commercialization	23- Oct- 13	22- Oct -14	7- Nov -17
US9809591	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc.	8- Mar- 11	5- Oct -15	7- Nov -17
US9808490	Induced hepatocytes and uses thereof	ACCELERATED BIOSCIENCES CORP.	26- Nov- 14	25- Nov -15	7- Nov -17
US9803236	Microarray-based assay integrated with particles for analyzing molecular interactions	CapitalBio Corporation	6- Aug- 10	6- Aug -10	31- Oct- 17
US9803197	Particle-nucleic acid conjugates and therapeutic uses related thereto	Emory University	25- Jun- 12	27- Feb -13	31- Oct- 17
US9802937	Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors	ORIGENIS GMBH	21- Apr- 11	23- Apr -12	31- Oct- 17
US9802919	Compounds	CHIESI FARMACEUTICI S.p.A.	31- May- 16	26- May -17	31- Oct- 17
US9801948	Antimicrobial compositions and methods of use thereof	Yale University	21- Sep- 11	21- Sep -12	31- Oct- 17
US9801947	Methods and compositions for enhancing immune response	3M INNOVATIVE PROPERTIES COMPANY	10- Apr- 03	6- Oct -14	31- Oct- 17
US9801935	Soluble needle arrays for delivery of influenza vaccines	SEQIRUS UK LIMITED	20- Aug- 10	11- Oct -16	31- Oct- 17
US9801897	Delivery of RNA to trigger multiple immune pathways	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul- 10	6- Jul- 11	31- Oct- 17
US9797000	Non-target amplification method for detection of RNA splice-forms in a sample	QIAGEN GAITHERSBURG INC.	1- May- 09	30- Apr -10	24- Oct- 17
US9796979	Oligonucleotide modulators of the toll-like receptor pathway	Quark Pharmaceuticals Inc.	3- Mar- 11	28- Jul- 16	24- Oct- 17
US9796735	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	20- Jun- 07	7- Nov -14	24- Oct- 17
US9795669	Lipidated immune response modifier compound compositions, formulations, and methods	3M INNOVATIVE PROPERTIES COMPANY	17- Aug- 10	15- Dec -15	24- Oct- 17
US9795668	Delivery of self-replicating RNA using biodegradable polymer particles	GlaxoSmithKline Biologicals S.A.	6-Jul- 10	23- Nov -15	24- Oct- 17
US9795666	High-yield transgenic mammalian expression system for generating virus-like particles	Academia Sinica	5- Sep- 06	11- Feb -15	24- Oct- 17
US9791437	Multianalyte assay	Nexus Dx, Inc.	30- Apr- 07	15- Jun -15	17- Oct- 17
US9789180	D-amino acid derivative-modified peptidoglycan and methods of use thereof	The Regents of the University of California	30- Nov- 12	31- Mar -16	17- Oct- 17
US9786050	Stain-free histopathology by chemical imaging	The Board of Trustees of the University of Illinois	15- Mar- 13	14- Mar -14	10- Oct- 17
US9783595	Neutralizing GP41 antibodies and their use	The United States of America, as represented by the Secretary, Department of Health and Human Services	7- Nov- 11	2- Aug -16	10- Oct- 17
US9782470	Method of obtaining thermostable dried vaccine formulations	Merck Sharp & Dohme Corp.	16- Oct- 13	13- Oct -14	10- Oct- 17
US9782434	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution	Sonoma Pharmaceuticals, Inc.	20- Jan- 06	7- Jul- 15	10- Oct- 17
US9770504	Generating peptoid vaccines	The Board of Regents of the University of Texas System	3- May- 13	2- May -14	26- Sep -17
US9770463	Delivery of RNA to different cell types	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul- 10	7- Jun -11	26- Sep -17
US9765395	System and method for DNA sequencing and blood chemistry analysis	Nanomedical Diagnostics, Inc.	28- Apr- 14	10- Apr -15	19- Sep -17
US9765133	Antibody producing non-human mammals	Merus N.V.	27- Jun- 08	29- Apr -14	19- Sep -17
US9765071	Substituted imidazo ring systems and methods	3M INNOVATIVE PROPERTIES COMPANY	25- Nov- 03	14- Mar -16	19- Sep -17
US9764027	Outer membrane vesicles	GLAXOSMITHKLINE BIOLOGICALS SA	18- Sep- 12	18- Sep -13	19- Sep -17
US9759723	B-cell antigen presenting cell assay	University of Pittsburgh—Of the Commonwealth System of Higher Education	8- Apr- 10	21- Mar -16	12- Sep -17
US9758840	Parasite detection via endosymbiont detection	IBIS BIOSCIENCES, INC.	14- Mar- 10	11- Mar -11	12- Sep -17
US9758820	Organism identification panel	BioFire Diagnostics, LLC	2- Apr- 07	1- Apr -08	12- Sep -17
US9758775	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10- Dec- 09	14- Apr -14	12- Sep -17
US9758568	Oligopeptide-free cell culture media	Baxalta GmbH	4- Jan- 06	16- Nov -15	12- Sep -17
US9758553	Yeast strain for the production of proteins with terminal alpha-1,3- linked galactose	MERCK SHARP & DOHME CORP.	30- May- 08	2- Jul- 14	12- Sep -17
US9757478	Mutant protease biosensors with enhanced detection characteristics	Promega Corporation	11- May- 10	7- Jan -16	12- Sep -17
US9757470	Peptides for assisting delivery across the blood brain barrier	Children's Medical Center Corporation	22- May- 06	30- Apr -14	12- Sep -17
US9757446	Influenza virus vectors and uses therefor	FLUGEN, INC.	17- Mar- 14	13- Mar -15	12- Sep -17
US9757407	Treatment of viral infections by modulation of host cell metabolic pathways	The Trustees of Princeton University	1- Jun- 07	21- Dec -15	12- Sep -17
US9751945	Sortase-modified VHH domains and uses thereof	Whitehead Institute for Biomedical Research	13- Apr- 12	15- Apr -13	5- Sep -17
US9750798	Bunyaviruses with segmented glycoprotein precursor genes and methods for generating these viruses	STICHTING WAGENINGEN RESEARCH	21- May- 13	21- May -14	5- Sep -17
US9750797	Sustained release vaccine composition	VIRBAC CORPORATION	16- Jun- 04	16- Jun -05	5- Sep -17
US9750690	Circulation of components during microfluidization and/or homogenization of emulsions	NOVARTIS AG	3- Dec- 09	5- Sep -14	5- Sep -17
US9746985	System and method for detecting, collecting, analyzing, and communicating event-related information	Georgetown University	25- Feb- 08	20- Apr -11	29- Aug -17
US9746459	Antigen presenting cell assay	University of Pittsburgh—Of the Commonwealth System of Higher Education	8- Apr- 10	11- Oct -13	29- Aug -17
US9745306	2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4- D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin- 4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitors	Respivert Limited	15- Mar- 13	14- Mar -14	29- Aug -17
US9744231	Quality control methods for oil-in-water emulsions containing squalene	NOVARTIS AG	8- Nov- 06	27- Aug -13	29- Aug -17
US9744229	Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	4- Apr- 08	28- Apr -14	29- Aug -17
US9744183	Nucleic acid prodrugs and methods of use thereof	WAVE LIFE SCIENCES LTD.	6-Jul- 09	6- Jul- 10	29- Aug -17
US9738894	Short interfering RNA (siRNA) analogues	Roche Innovation Center Copenhagen A/S	21- Mar- 03	28- Mar -16	22- Aug -17
US9738624	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	21- Jun- 13	20- Jun -14	22- Aug -17
US9737618	Adeno-associated virus (AAV) glades, sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	30- Sep- 03	20- Jul- 15	22- Aug -17
US9737593	Carbon nanotube compositions and methods of use thereof	Yale University	19- Mar- 08	15- Mar -13	22- Aug -17
US9730997	Alphavirus vectors for respiratory pathogen vaccines	Novartis Vaccines and Diagnostics, Inc.	21- May- 04	20- Aug -14	15- Aug -17
US9730912	Pharmaceutical compounds	ASTEX THERAPEUTICS LIMITED	12- Oct- 06	12- Oct -07	15- Aug -17
US9727810	Spatially addressable molecular barcoding	Cellular Research, Inc.	27- Feb- 15	26- Feb -16	8- Aug -17
US9726607	Systems and methods for detecting multiple optical signals	GEN-PROBE INCORPORATED	10- Mar- 05	3- Mar -14	8- Aug -17
US9725770	Methods and compositions for identification of source of microbial contamination in a sample	The Regents of the University of California	6- Mar- 12	6- Mar -13	8- Aug -17
US9725487	Compositions and methods for measles virus inhibition	Autoimmune Technologies, LLC	4- Nov- 03	13- May -15	8- Aug -17
US9719106	Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof	The Trustees of the University of Pennsylvania	29- Apr- 13	29- Apr -14	1- Aug -17
US9719083	Bioagent detection methods	IBIS BIOSCIENCES, INC.	8- Mar- 09	8- Mar -10	1- Aug -17
US9718774	Indole carboxamide derivatives as P2X7 receptor antagonist	IDORSIA PHARMACEUTICALS LTD	12- Dec- 12	11- Dec -13	1- Aug -17
US9717755	Method of treating inflammation	Cytosorbents Corporation	1- Apr- 10	1- Apr -11	1- Aug -17
US9717749	Production of stable non-polyadenylated RNAs	Massachusetts Institute of Technology	16- Oct- 12	16- Oct -13	1- Aug -17
US9717732	Drug combination	VERONA PHARMA PLC	15- Mar- 13	17- Mar -14	1- Aug -17
US9714411	Animal protein-free media for cultivation of cells	Baxalta GmbH	29- Oct- 04	30- Nov -15	25- Jul- 17
US9714283	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC.	28- Oct- 14	2- Jul- 15	25- Jul- 17
US9714226	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29- Jul-11	13- Nov -15	25- Jul- 17
US9713641	Anti-TIGIT antigen-binding proteins and methods of use thereof	Potenza Therapeutics, Inc.	13- Feb- 17	13- Feb -17	25- Jul- 17
US9713606	Methods for treating pulmonary emphysema using substituted 2- Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	14- Mar- 13	1- Dec -15	25- Jul- 17
US9708375	Inhibitory polypeptides specific to WNT inhibitors	Amgen Inc.	15- Mar- 13	14- Mar -14	18- Jul- 17
US9707278	Methods of modulating immune responses by modifying Akt3 bioactivity	Augusta University Research Institute, Inc.	17- Apr- 14	17- Apr -15	18- Jul- 17
US9701736	Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection	New York Blood Center, Inc.	20- Oct- 10	9- Oct -14	11- Jul- 17
US9701638	Therapeutic hydroxyquinolones	Rutgers, The State University of New Jersey	9- Nov- 12	8- Nov -13	11- Jul- 17
US9700616	Arranging interaction and back pressure chambers for microfluidization	NOVARTIS AG	3- Dec- 09	22- Mar -16	11- Jul- 17
US9700614	Intranasal vaccination dosage regimen	Eurocine Vaccines AB	17- Dec- 12	17- Dec -13	11- Jul- 17
US9700558	Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist	VERONA PHARMA PLC	15- Mar- 13	17- Mar -14	11- Jul- 17
US9696247	Sample fixation and stabilisation	RNASSIST LTD.	1- Mar- 13	28- Feb -14	4- Jul- 17
US9695445	Method for production of reprogrammed cell using chromosomally unintegrated virus vector	ID Pharma Co., Ltd.	16- Jul-08	29- Jul- 15	4- Jul- 17
US9695135	Therapeutic catechols	Rutgers, The State University of New Jersey	12- May- 14	11- May -15	4- Jul- 17
US9695134	3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine- 2-carboxamide compounds	Parion Sciences, Inc.	17- Dec- 12	8- Jan -15	4- Jul- 17
US9689018	Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses	Diagnostic Hybrids, Inc.	24- Apr- 98	4- Aug -14	27- Jun- 17
US9688982	Methods and compositions for the treatment of cancer or other diseases	CITY OF HOPE	26- Jan- 07	11- Oct -13	27- Jun- 17
US9687536	Methods and compositions for intranasal delivery	SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.	15- Apr- 10	15- Apr -11	27- Jun- 17
US9683256	Biological specimen collection and transport system	Longhorn Vaccines and Diagnostics, LLC	1- Oct- 07	15- Dec -15	20- Jun- 17
US9683017	Inhibitory peptides of viral infection	UNIVERSITY TENNESSEE RESEARCH FOUNDATION	17- Jul-14	16- Jul- 15	20- Jun- 17
US9682133	Disrupted adenovirus-based vaccine against drugs of abuse	CORNELL UNIVERSITY	17- Mar- 10	17- Mar -11	20- Jun- 17
US9677089	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17- Dec- 01	30- Mar -16	13- Jun- 17
US9676867	Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibody	Dana-Farber Cancer Institute Inc.	2- Dec- 05	8- May -13	13- Jun- 17
US9676857	Soluble engineered monomeric Fc	The United States of America, as represented by the Secretary, Department of Health and Human Services	16- Mar- 12	14- Mar -13	13- Jun- 17
US9676727	Myxovirus therapeutics, compounds, and uses related thereto	Children's Healthcare of Atlanta, Inc.	24- Oct- 11	7- Jul- 16	13- Jun- 17
US9675550	Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	26- Jul-10	25- Jan -13	13- Jun- 17
US9670507	Directed evolution and in vivo panning of virus vectors	The University of North Carolina at Chapel Hill	30- Apr- 08	28- Jun -16	6- Jun- 17
US9670166	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	6- Feb- 13	5- Aug -16	6- Jun- 17
US9669092	Antagonism of the VIP signaling pathway	Emory University	2- Feb- 11	31- Jan -12	6- Jun- 17
US9669089	Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen	CureVac AG	15- Feb- 12	15- Feb -13	6- Jun- 17
US9669088	Vaccination with multiple clades of H5 influenza A virus	Seqirus UK Limited	26- Nov- 07	25- Nov -08	6- Jun- 17
US9661856	Synergy of plant antimicrobials with silver	The Arizona Board of Regents on Behalf of The University of Arizona	24- Aug- 12	26- Aug -13	30- May -17
US9657278	Methods to produce bunyavirus replicon particles	Stichting Dienst Landbouwkundig Onderzoek	20- Sep- 10	10- Jul- 15	23- May -17
US9657076	GM-CSF and IL-4 conjugates, compositions, and methods related thereto	Children's Healthcare of Atlanta, Inc.	23- Oct- 12	23- Oct -13	23- May -17
US9657048	Enantiomers of the 1′,6′-isomer of neplanocin A	Auburn University	4- Aug- 14	4- Aug -15	23- May -17

US9657015	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31- Jul-14	27- Jul- 15	23- May -17
US9655896	Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity	PARION SCIENCES, INC.	27- Jun- 11	12- Jan -15	23- May -17
US9655845	Oil-in-water emulsions that contain nucleic acids	GlaxoSmithKline Biologicals, S.A.	6-Jul- 11	6- Jul- 12	23- May -17
US9655367	Disinfecting composition and wipes with reduced contact time	LONZA, INC.	6- Nov- 13	4- Nov -14	23- May -17
US9651543	Malaria antigen screening method	The United States of America as Represented by the Secretary of the Navy	31- Aug- 05	19- Apr -13	16- May -17
US9650685	Selective detection of human rhinovirus	The United States of America, as represented by the Secretary, Department of Health and Human Services	5- Dec- 08	15- Dec -14	16- May -17
US9650649	LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus- producing cells for the therapy of tumors	VIRATHERAPEUTICS GMBH	8- Oct- 08	8- Oct -09	16- May -17
US9649324	Use of tylvalosin as antiviral agent	CAMBRIDGE UNIVERSITY TECHNICAL SERVICES	13- Jul-06	8- Jun -15	16- May -17
US9649309	Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity	The University of North Carolina at Chapel Hill	11- Apr- 14	3- Apr -15	16- May -17
US9644180	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18- Nov- 13	12- Jun -15	9- May -17
US9642876	Method of preventing or treating sinusitis with oxidative reductive potential water solution	SONOMA PHARMACEUTICALS, INC.	30- Dec- 03	27- Oct -15	9- May -17
US9642873	Combinations of TGFβ and COX-2 inhibitors and methods for their therapeutic application	Sirnaomics, Inc.	4- May- 10	4- May -11	9- May -17
US9637524	Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector	The Regents of the University of California	27- Feb- 09	5- Nov -14	2- May -17
US9637491	Pyrazolo[4,3-D]pyrimidines as kinase inhibitors	ORIGENIS GMBH	19- Oct- 12	18- Oct -13	2- May -17
US9636410	Cationic oil-in-water emulsions	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul- 11	6- Jul- 12	2- May -17
US9636397	Adjuvant compositions and related methods	Vaxliant, LLC	24- Mar- 15	24- Mar -16	2- May -17
US9636370	AAV vectors targeted to oligodendrocytes	The University of North Carolina at Chapel Hill	28- Sep- 12	27- Sep -13	2- May -17
US9629907	Compositions for and methods of inducing mucosal immune responses	The Trustees of the University of Pennsylvania	19- Nov- 04	28- Oct -11	25- Apr- 17
US9624173	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc.	8- Mar- 11	19- Mar -15	18- Apr- 17
US9623040	Immunomodulation by controlling expression levels of microRNAs in dendritic cells	The Board of Trustees of the Leland Stanford Junior University	14- Jul-14	10- Jul- 15	18- Apr- 17
US9618508	Flow cytometry analysis of materials adsorbed to metal salts	GlaxoSmithKline Biologicals SA	14- Dec- 10	14- Dec -11	11- Apr- 17
US9618476	System and method for electronic biological sample analysis	NANOMEDICAL DIAGNOSTICS, INC.	28- Apr- 14	28- Apr -14	11- Apr- 17
US9618429	Polymer stabilization of chromogen solutions	Ventana Medical Systems, Inc.	23- Jan- 12	18- Jan -13	11- Apr- 17
US9611481	Chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof	UNIVERSITE DE MONTPELLIER	24- Sep- 09	23- Sep -10	4- Apr- 17
US9611474	Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof	QUARK PHARMACEUTICALS, INC.	12- Sep- 12	12- Sep -13	4- Apr- 17
US9605276	Replication defective adenovirus vector in vaccination	Etubics Corporation	24- Aug- 12	15- Mar -13	28- Mar -17
US9603864	Substituted nucleosides, nucleotides and analogs thereof	Alios BioPharma, Inc.	24- Jun- 14	22- Jun -15	28- Mar -17
US9603850	MerTK-specific pyrazolopyrimidine compounds	The University of North Carolina at Chapel Hill	11- Apr- 14	3- Apr -15	28- Mar -17
US9599606	ADP-ribose detection reagents	The Board of Regents of the University of Texas System	10- Jun- 14	9- Jun -15	21- Mar -17
US9598459	Pharmaceutical compositions and methods	Pop Test Oncology LLC	3- Aug- 15	28- Jul- 16	21- Mar -17
US9597333	Benzazepine dicarboxamide compounds	Hoffmann-La Roche Inc.	6- Mar- 15	28- Sep -16	21- Mar -17
US9593334	Use of the chromosome 19 microRNA cluster (C19MC) for treating viral disease and promoting authophagy	University of Pittsburgh—Of the Commonwealth System of Higher Education	7- Mar- 12	6- Mar -13	14- Mar -17
US9593331	Double-stranded nucleic acid molecule for gene expression control	Osaka City University	2- Nov- 11	1- Nov -12	14- Mar -17
US9593084	Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity	Parion Sciences, Inc.	17- Dec- 12	13- Dec -13	14- Mar -17
US9592284	Immunization regimen with E4-deleted adenovirus prime and E1- deleted adenovirus boost	The Trustees of the University of Pennsylvania	28- Apr- 04	27- Apr -05	14- Mar -17
US9592277	Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases	Avirid, Inc.	14- Apr- 04	14- Apr -05	14- Mar -17
US9588069	Methods for performing thermal melt analysis	GEN-PROBE INCORPORATED	31- Jul-12	31- Jul- 13	7- Mar -17
US9587250	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	Trustees of the University of Pennsylvania	17- Dec- 01	16- Jan -15	7- Mar -17
US9586998	Methods of propagating monkey adenoviral vectors	GenVec, Inc.	9- Nov- 09	4- Aug -15	7- Mar -17
US9586911	Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel blocking compounds	Parion Sciences, Inc.	13- Dec- 13	19- Dec -14	7- Mar -17
US9586910	3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6- pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra zine-2-carboxamide	Parion Sciences, Inc.	27- Jun- 11	18- Dec -13	7- Mar -17
US9585968	Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom	3M Innovative Properties Company	3- Jun- 11	14- Aug -15	7- Mar -17
US9585953	Immunogenic compositions in particulate form and methods for producing the same	MUCOSIS B.V.	22- Mar- 11	22- Mar -12	7- Mar -17
US9585874	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	9- May- 12	6- Jan -16	7- Mar -17
US9585849	Broad spectrum antiviral and methods of use	The Burlington HC Research Group, Inc.	17- Apr- 06	17- Apr -07	7- Mar -17
US9580474	Polyionic papilloma virus-like particle (VLP) vaccines	THE JOHNS HOPKINS UNIVERSITY	8- Sep- 10	8- Sep -11	28- Feb -17
US9580468	Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells	CENTRE DE INVESTIGACION BIOMEDICA EN RED BIOINGENIERA BIOMATERIALS Y NANOMEDICINA (CIBER BBN)	13- Jan- 11	13- Jan -12	28- Feb -17
US9580429	Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy	AstraZeneca AB	6- Dec- 04	15- Sep -14	28- Feb -17
US9574189	Enzymatic encoding methods for efficient synthesis of large libraries	Nuevolution A/S	1- Dec- 05	1- Dec -06	21- Feb -17
US9574181	Influenza virus reassortment method	Seqirus UK Limited	21- May- 10	24- Oct -14	21- Feb -17
US9573955	Compounds	Chiese Farmaceutici S.p.A.	16- Dec- 13	16- Dec -14	21- Feb -17
US9573938	Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones	Rutgers, The State University of New Jersey	11- Sep- 12	11- Sep -13	21- Feb -17
US9572899	Compositions for enhancing transport of molecules into cells	AVI BIOPHARMA, INC.	29- Apr- 03	5- Nov -08	21- Feb -17
US9572864	Compositions and uses of lectins	Emory University	12- Feb- 10	11- Dec -15	21- Feb -17
US9572823	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	5- Apr -16	21- Feb -17
US9567336	Conjugated TLR7 and/or TLR8 and TLR2 agonists	INVIVOGEN	19- Nov- 12	15- Mar -13	14- Feb -17
US9566326	Adjuvanted influenza vaccines for pediatric use	Seqirus UK Limited	22- Feb- 08	21- Jun -13	14- Feb -17
US9566291	Nutritional composition comprising indigestible oligosaccharides	N.V. Nutricia	24- Aug- 04	24- Aug -05	14- Feb -17
US9566290	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	20- Apr -16	14- Feb -17
US9566289	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	17- Feb -16	14- Feb -17
US9565857	Antimicrobial solutions	Board of Regents, The University of Texas System	10- Sep- 10	9- Sep -11	14- Feb -17
US9562110	Bispecific antibody	Wuhan YZY Biopharma Co., Ltd.	21- Nov- 12	21- Nov -12	7- Feb -17
US9561263	Treatment of inflammatory illnesses with ACE2	Apeiron Biologics AG	18- Dec- 07	18- Dec -08	7- Feb -17
US9556237	Antiviral rift valley fever virus peptides and methods of use	The United States of America, as represented by the Secretary of the Army, on behalf of the U.S. Army Medical Research Institute of Infectious Diseases	6- Dec- 12	4- Jun -15	31- Jan- 17
US9556229	Modification of peptides using a bis(thioether)arylbridge approach	The Regents of the University of California	18- May- 12	17- May -13	31- Jan- 17
US9556184	Phosphoinositide 3-kinase inhibitors	Respivert, Ltd.	15- Mar- 13	4- Dec -15	31- Jan- 17
US9556117	Indole carboxamide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	18- Dec- 12	17- Dec -13	31- Jan- 17
US9555031	Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity	The University of North Carolina at Chapel Hill	11- Apr- 14	3- Apr -15	31- Jan- 17
US9555030	Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity	The University of North Carolina at Chapel Hill	11- Apr- 14	3- Apr -15	31- Jan- 17
US9550773	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	18- Jun- 04	13- Apr -15	24- Jan- 17
US9550757	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	5- Mar- 10	28- Jun -13	24- Jan- 17
US9549949	Antiviral agent	NBC MESHTEC, INC.	3- Sep- 08	31- Aug -09	24- Jan- 17
US9549938	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	11- Mar -16	24- Jan- 17
US9546371	Chimeric polynucleotides and polypeptides enabling secretion of a polypeptide of interest in association with exosomes and use thereof for the production of immunogenic compositions	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	18- Mar- 08	18- Mar -09	17- Jan- 17
US9546184	Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines	3M INNOVATIVE PROPERTIES COMPANY	13- Aug- 08	8- Jun -15	17- Jan- 17
US9546150	Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7	HYBRIGENICS SA	2- Sep- 11	29- Aug -12	17- Jan- 17
US9545440	Methods for preparing squalene	NOVARTIS AG	12- May- 10	23- Oct -15	17- Jan- 17
US9540373	Substituted spirocycles	Boehringer Ingelheim International GmbH	12- Sep- 14	10- Sep -15	10- Jan- 17
US9539321	HMGB1-derived peptides enhance immune response to antigens	The Regents of the University of California	27- Jul-10	9- Mar -15	10- Jan- 17
US9539217	Nanoparticle compositions	Allertein Therapeutics, LLC	3- Apr- 13	3- Apr -14	10- Jan- 17
US9533978	Pyrimidine derivatives and their use in the treatment of cancer and further diseases	Sumitomo Dainippon Pharma Co., Ltd	21- May- 09	26- Aug -14	3- Jan- 17
US9533037	Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes	Declion Holdings LLC	16- Oct- 07	16- Oct -08	3- Jan- 17
US9529974	System and method for detecting, collecting, analyzing, and communicating event-related information	Georgetown University	25- Feb- 08	27- Jul- 11	27- Dec -16
US9527903	Engineered antibody constant domain molecules	The United States of America, as represent by the Secretary, Department of Health and Human Services	31- Jan- 08	1- Oct -13	27- Dec -16
US9526803	Diagnostic chewing gum for pathogens	Julius-Maximilians-Universitaet Wuerzburg	8- Mar- 12	8- Mar -13	27- Dec -16
US9526700	Composition for inactivating an enveloped virus	VIROBLOCK SA	19- May- 06	17- Nov -14	27- Dec -16
US9522962	Peptides, conjugates and method for increasing immunogenicity of a vaccine	Academisch Ziekenhuis Leiden h.o.d.n. LUMC	15- Mar- 10	15- Mar -11	20- Dec -16
US9522894	Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as dipeptidyl peptidase 1 inhibitors	AstraZeneca AB	24- Jan- 14	21- Jan -15	20- Dec -16
US9522171	EV576 for use in the treatment of viral infections of the respiratory tract	Volution Immuno Pharmaceuticals SA	8- Jan- 10	2- Jan -15	20- Dec -16
US9518093	Topical formulation of arginine-rich cyclic antimicrobial peptides	NOVABIOTICS LIMITED	24- Feb- 06	9- Nov -15	13- Dec -16
US9518083	Gadd45beta targeting agents	Imperial Innovations Limited	22- Oct- 09	10- Feb -15	13- Dec -16
US9517263	Benzonaphthyridine-containing vaccines	GlaxoSmithKline Biologicals SA	10- Jun- 09	10- Jun -10	13- Dec -16
US9517205	Soluble needle arrays for delivery of influenza vaccines	Seqirus UK Limited	20- Aug- 10	19- Aug -11	13- Dec -16
US9512471	Methods and kits for detecting human papillomavirus	DIACARTA Inc	30- Jun- 10	30- Jun -10	6- Dec -16
US9512443	Recombinant expression of multiprotein complexes using polygenes	ETH ZURICH	8- Nov- 05	6- Nov -06	6- Dec -16
US9512181	Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses therefor	Tetragenetics, Inc.	27- May- 11	29- May -12	6- Dec -16
US9511070	Heterocyclyl carboxamides for treating viral diseases	NovaDrug, LLC	31- Aug- 12	30- Aug -13	6- Dec -16
US9506063	SiRNA compositions and methods for treatment of HPV and other infections	Sirnaomics, Inc.	29- Jul-10	29- Jan -13	29- Nov -16
US9504747	Lipids and lipid compositions for the delivery of active agents	Novartis AG	8- Mar- 13	7- Mar -14	29- Nov -16
US9504673	Agent for the prophylaxis and treatment of highly pathogenic infectious diseases	LTD “Valenta-Intellektâ€	21- May- 09	10- May -10	29- Nov -16
US9504255	Physical antimicrobial method	NMS TECHNOLOGIES CO., LTD.	1- Aug- 12	16- Jul- 13	29- Nov -16
US9499799	Cells and methodology to generate non-segmented negative-strand RNA viruses	Centre National De La Recherche Scientifique	22- Dec- 06	15- Oct -13	22- Nov -16
US9499535	Kinase inhibitors	ORIGENIS GMBH	21- Apr- 11	23- Apr -12	22- Nov -16
US9499489	Myxovirus therapeutics, compounds, and uses related thereto	Children's Healthcare of Atlanta, Inc.	24- Oct- 11	24- Oct -12	22- Nov -16
US9498548	Method of using oxidative reductive potential water solution in dental applications	Oculus Innovative Sciences, Inc.	2- May- 05	2- May -06	22- Nov -16
US9498544	Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents	Tissue Regeneration Therapeutics Inc.	21- Apr- 08	13- Mar -15	22- Nov -16
US9498527	Vaccine composition	NITTO DENKO CORPORATION	4- Apr- 12	3- Apr -13	22- Nov -16
US9494571	Methods of testing for intracellular pathogens	Novartis AG	8- Mar- 10	7- Mar -11	15- Nov -16
US9493788	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17- Dec- 01	16- Jan -15	15- Nov -16
US9493572	GITR antibodies and methods of inducing or enhancing an immune response	GITR, Inc.	25- Mar- 05	23- Mar -15	15- Nov -16
US9493518	Compositions and methods for treating clostridium difficile- associated diseases	National Health Research Institutes	14- Mar- 13	13- Mar -14	15- Nov -16
US9492528	Influenza virus-like particles (VLPS) comprising hemagglutinin	MEDICAGO INC.	13- Jul-07	2- Jul- 09	15- Nov -16
US9492413	Use of salt of an acetylsalicylic acid for the treatment of viral infections	Ventaleon GMBH	14- Jan- 08	14- Jan -09	15- Nov -16
US9489495	System and method for detecting, collecting, analyzing, and communicating event-related information	GEORGETOWN UNIVERSITY	25- Feb- 08	28- Aug -08	8- Nov -16
US9487838	Oligonucleotide probe for the detection of adenovirus	QIAGEN HAMBURG GMBH	28- Dec- 10	28- Dec -10	8- Nov -16
US9487837	Exosome-mediated diagnosis of hepatitis virus infections and diseases	MOREHOUSE SCHOOL OF MEDICINE	6- Oct- 08	21- Jan -14	8- Nov -16
US9487778	Oligonucleotide modulators of the toll-like receptor pathway	QUARK PHARMACEUTICALS, INC.	3- Mar- 11	1- Mar -12	8- Nov -16
US9487749	Use of methylsulfonylmethane (MSM) to modulate microbial activity	Biogenic Innovations, LLC	30- Oct- 09	12- Aug -14	8- Nov -16
US9487528	Compounds	Chiesi Farmaceutici S.p.A.	9- Jun- 14	5- Jun -15	8- Nov -16
US9486479	Antimicrobial solutions containing dichloride monoxide and methods of making and using the same	Oculus Innovative Sciences, Inc.	13- Mar- 07	21- Jul- 14	8- Nov -16
US9481912	Compositions and methods for detecting and identifying nucleic acid sequences in biological samples	Longhorn Vaccines and Diagnostics, LLC	12- Sep- 06	8- Oct -13	1- Nov -16
US9481724	hDC-sign binding peptides	Sloan-Kettering Institute for Cancer Research	19- Dec- 11	10- Dec -12	1- Nov -16
US9481630	Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing same	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY	19- Oct- 11	28- Sep -12	1- Nov -16
US9476090	Signal propagation biomolecules, devices and methods	STC.UNM	21- May- 13	21- May -14	25- Oct- 16
US9476032	Attenuated viruses useful for vaccines	The Research Foundation for The State University of New York	30- Mar- 07	31- Mar -08	25- Oct- 16
US9475872	Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F	ImmunoQure AG	28- Dec- 11	2- Jan -13	25- Oct- 16
US9475862	Neutralizing GP41 antibodies and their use	The United States of America, as represented by the Secretary, Department of Health and Human Services	7- Nov- 11	7- Nov -12	25- Oct- 16
US9475832	Phosphonates with reduced toxicity for treatment of viral infections	The Regents of the University of California	14- Apr- 10	29- Sep -14	25- Oct- 16
US9475804	Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom	3M Innovative Properties Company	3- Jun- 11	1- Jun -12	25- Oct- 16
US9475779	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31- Jul-14	27- Jul- 15	25- Oct- 16
US9475775	Benzazepine dicarboxamide compounds	Hoffmann-La Roche Inc.	6- Mar- 15	4- Mar -16	25- Oct- 16
US9474844	Methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto	Hemalux LLC	22- Oct- 14	29- Dec -15	25- Oct- 16
US9474759	Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses	Kansas State University Research Foundation	27- Sep- 11	27- Sep -12	25- Oct- 16
US9469876	Circulating biomarkers for metastatic prostate cancer	Caris Life Sciences Switzerland Holdings GmbH	6- Apr- 10	6- Apr -11	18- Oct- 16
US9464276	Highly efficient influenza matrix (M1) proteins	Novavax, Inc.	11- Jul-03	23- Feb -15	11- Oct- 16
US9464123	Peptides having activity of inhibiting infections of respiratory viruses and use of the same	XIANGXUE GROUP (HONG KONG) COMPANY LIMITED	9- May- 13	21- Feb -14	11- Oct- 16
US9463240	Arranging interaction and back pressure chambers for microfluidization	NOVARTIS AG	3- Dec- 09	11- Jul- 14	11- Oct- 16
US9459247	Quantitative measurement of nano/micro particle endocytosis with cell mass spectrometry	Academia Sinica	29- Mar- 10	29- Mar -11	4- Oct- 16
US9459233	Amperometric gas sensor	Steris Corporation	25- Jun- 12	26- Feb -13	4- Oct- 16
US9458492	Methods and cells for identifying RIG-I pathway regulators	Kineta, Inc.	25- Feb- 11	23- Feb -12	4- Oct- 16
US9458470	Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin	MEDICAGO INC.	21- Jan- 08	23- Jan -13	4- Oct- 16
US9458184	Compositions of TLR7 and/or TLR8 agonists conjugated to lipids	INVIVOGEN	15- Jun- 12	15- Mar -13	4- Oct- 16
US9458113	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31- Jul-14	27- Jul- 15	4- Oct- 16
US9457074	Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome	Ohio State Innovation Foundation	24- Apr- 12	23- Feb -15	4- Oct- 16
US9453043	Nucleic acid chemical modifications	ALNYLAM PHARMACEUTICALS, INC.	2- Mar- 09	22- Jan -15	27- Sep -16
US9452973	Modulators of the relaxin receptor 1	THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES	4- May- 12	15- Mar -13	27- Sep -16
US9452210	Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant	MEDICAGO INC.	13- Jul-07	4- Jan -13	27- Sep -16
US9447462	Methods for concurrent identification and quantification of an unknown bioagent	IBIS BIOSCIENCES, INC.	18- Feb- 04	27- Jan -14	20- Sep -16
US9447132	Highly active nucleoside derivative for the treatment of HCV	Achillion Pharmaceuticals, Inc.	12- Apr- 13	14- Apr -14	20- Sep -16
US9447097	4-amino-imidazoquinoline compounds	Hoffmann-La Roche Inc.	22- Apr- 14	7- Apr -16	20- Sep -16
US9446062	Methods of treating ischemia-reperfusion injury with siRNAs	Quark Pharmaceuticals, Inc.	25- Oct- 06	8- Jan -15	20- Sep -16
US9442107	Antibody-nanoparticle conjugates and methods for making and using such conjugates	Ventana Medical Systems, Inc.	27- Apr- 10	21- Apr -15	13- Sep -16
US9441247	TC-83-derived alphavirus vectors, particles and methods	ALPHAVAX, INC.	18- May- 04	6- Jul- 15	13- Sep -16
US9440960	Substituted oxetanes and their use as inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	1- Aug- 14	31- Jul- 15	13- Sep -16
US9440930	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31- Jul-14	27- Jul- 15	13- Sep -16
US9435795	Enhanced deposition of chromogens utilizing pyrimidine analogs	Ventana Medical Systems, Inc.	30- Dec- 10	6- Oct -14	6- Sep -16
US9435000	Primate T-lymphotropic viruses	Johns Hopkins University	21- Feb- 05	20- Sep -13	6- Sep -16
US9434997	Methods, compounds and systems for detecting a microorganism in a sample	Lawrence Livermore National Security, LLC	24- Aug- 07	21- Aug -08	6- Sep -16
US9434769	Peptide compositions and methods for inhibiting herpesvirus infection	The Administrators of the Tulane Educational Fund	30- Oct- 09	9- Jul- 14	6- Sep -16
US9433672	Compositions and methods for activating innate and allergic immunity	ID Biomedical Corporation of Quebec	26- Apr- 12	28- Apr -14	6- Sep -16
US9430610	Re-sequencing pathogen microarray	The United States of America, as represented by the Secretary of the Navy	2-Jul- 04	10- Apr -08	30- Aug -16
US9428739	Norovirus and Sapovirus antigens	NOVARTIS VACCINES AND DIAGNOSTICS, INC.	24- Mar- 01	27- Nov -12	30- Aug -16
US9428574	Polypeptides and uses thereof for treatment of autoimmune disorders and infection	COMPUGEN LTD.	30- Jun- 11	1- Jul- 12	30- Aug -16
US9428571	Antibodies and processes for preparing the same	TAIGA BIOTECHNOLOGIES, INC.	16- May- 08	18- Mar -15	30- Aug -16
US9428490	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29- Jul-11	26- Jul- 12	30- Aug -16
US9428439	Hydrobenzamide derivatives as inhibitors of Hsp90	ASTEX THERAPEUTICS LTD.	12- Oct- 06	7- Jan -14	30- Aug -16
US9426989	Organic peroxide compounds for microorganism inactivation	NOVARTIS AG	6- May- 10	6- May -11	30- Aug -16
US9422367	Antigenic GM-CSF peptides and antibodies to GM-CSF	Morphotek, Inc.	7- Feb- 06	26- Nov -13	23- Aug -16
US9421254	Immunostimulatory combinations of TLR ligands and methods of use	The United States of America, as represented by the Secretary, Department of Health and Human Services	24- Sep- 07	24- Sep -08	23- Aug -16
US9416416	Biological specimen collection/transport compositions and methods	Longhorn Vaccines and Diagnostics, LLC	1- Oct- 07	16- Dec -11	16- Aug -16
US9416409	Capture primers and capture sequence linked solid supports for molecular diagnostic tests	IBIS BIOSCIENCES, INC.	31- Jul-09	30- Jul- 10	16- Aug -16
US9416396	Covalently linked thermostable kinase for decontamination process validation	The Secretary of State for Health	20- Feb- 08	18- Feb -09	16- Aug -16
US9415392	Slip chip device and methods	The University of Chicago	24- Mar- 09	23- Mar -10	16- Aug -16
US9415087	Compositions and methods for treating coronavirus infection	Ludwig-Maximilians-Universitaet Muenchen	11- Mar- 14	8- May -15	16- Aug -16
US9415033	Esters of short chains fatty acids for use in the treatment of immunogenic disorders	PROPONENT BIOTECH GMBH	3- Oct- 12	3- Oct -13	16- Aug -16
US9409987	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer	COMPUGEN LTD	15- Apr- 11	16- Apr -12	9- Aug -16
US9409917	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	20- Jan- 12	18- Jan -13	9- Aug -16
US9409870	Compounds	CHIESI FARMACEUTICI S.p.A.	15- Dec- 14	27- Nov -15	9- Aug -16
US9408908	Combination adjuvant formulation	Not Available	16- Oct- 08	15- Feb -13	9- Aug -16
US9408907	Homogenous suspension of immunopotentiating compounds and uses thereof	GlaxoSmithKline Biologicals SA	15- Dec- 09	15- Dec -10	9- Aug -16
US9404160	Methods for the detection of microorganisms	Becton, Dickinson and Company	22- Dec- 09	21- Dec -10	2- Aug -16
US9403868	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20- Mar- 09	5- Mar -15	2- Aug -16
US9402921	Directed evolution and in vitro panning of virus vectors	The University of North Carolina at Chapel Hill	30- Apr- 08	22- Oct -14	2- Aug -16
US9402878	Depsipeptide and uses thereof	NovoBiotic Pharmaceuticals, LLC	3- Dec- 12	1- Jul- 15	2- Aug -16
US9402812	Methods for the preparation of liposomes	Indu Javeri	23- Sep- 09	23- Sep -10	2- Aug -16
US9394092	Powdered pouch and method of making same	MONOSOL, LLC	16- Apr- 12	14- Mar -13	19- Jul- 16
US9393564	Bioagent detection systems, devices, and methods	IBIS BIOSCIENCES, INC.	30- Mar- 09	30- Mar -10	19- Jul- 16
US9393295	Nanoparticles for use in pharmaceutical compositions	Novartis AG	28- Apr- 08	28- Apr -09	19- Jul- 16
US9393215	Nanoparticles for use in immunogenic compositions	Novartis AG	2- Dec- 05	1- Dec -06	19- Jul- 16
US9388429	Method for propagating adenoviral vectors encoding inhibitory gene products	GenVec, Inc.	10- Nov- 05	28- May -14	12- Jul- 16
US9388234	Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds	Not Available	6- Jun- 03	19- Jun -13	12- Jul- 16
US9388198	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	21- Jan- 14	21- Jan -14	12- Jul- 16
US9388197	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	22- Jan- 13	21- Jan -14	12- Jul- 16
US9387242	Chimeric viruses presenting non-native surface proteins and uses thereof	Icahn School of Medicine at Mount Sinai	2- Dec- 05	1- Dec -06	12- Jul- 16
US9382590	Methods and compositions for prostate cancer metastasis	FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU)	25- Mar- 11	20- May -15	5- Jul- 16
US9382545	CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity	COLEY PHARMACEUTICAL GMBH	27- Sep- 06	4- Oct -13	5- Jul- 16
US9382288	Derivatives of steroid benzylamines, having an antiparasitic antibacterial, antimycotic and/or antiviral action	Justus-Liebig-Universitat Giessen	6- Oct- 10	6- Oct -11	5- Jul- 16
US9381244	VISTA modulators for diagnosis and treatment of cancer	KING'S COLLEGE LONDON	7- Sep- 12	9- Sep -13	5- Jul- 16
US9381239	VLPS derived from cells that do not express a viral matrix or core protein	Novavax, Inc.	25- May- 07	14- Apr -14	5- Jul- 16
US9381226	Methods and compositions related to inhibition of viral entry	UNIVERSITY OF UTAH RESEARCH FOUNDATION	8- Feb- 07	8- Feb -08	5- Jul- 16
US9381220	Sceletium extract and uses thereof	H. L. Hall & Sons Limited	20- Mar- 09	15- Jul- 14	5- Jul- 16
US9380785	Antiviral resin member	NBC MESHTEC, INC.	6-Jul- 11	6- Jul- 12	5- Jul- 16
US9376486	Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereof	DSO National Laboratories	14- Dec- 10	14- Dec -11	28- Jun- 16
US9376398	Carboxylic acid compounds	Astrazeneca Aktiebolag	18- May- 12	17- May -13	28- Jun- 16
US9375465	Conjugates of GM-CSF and IL-7, compositions and methods related thereto	Children's Healthcare of Atlanta, Inc.	14- Nov- 11	13- Nov -12	28- Jun- 16
US9372156	System for processing contents of a receptacle to detect an optical signal emitted by the contents	GEN-PROBE INCORPORATED	10- Mar- 05	22- Feb -11	21- Jun- 16
US9371563	Nanoreporters and methods of manufacturing and use thereof	NanoString Technologies, Inc.	23- Dec- 05	11- Mar -13	21- Jun- 16
US9370582	Carbohydrate conjugates as delivery agents for oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4- Dec- 07	11- Jul- 14	21- Jun- 16
US9370581	Carbohydrate conjugates as delivery agents for oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4- Dec- 07	11- Jul- 14	21- Jun- 16
US9370570	Polychlorinated biphenyls and squalene-containing adjuvants	Novartis AG	28- Dec- 07	10- Dec -13	21- Jun- 16
US9370531	Method of providing patient specific immune response in amyloidoses and protein aggregation disorders	New York University	31- Aug- 07	1- Sep -08	21- Jun- 16
US9365577	Pyrimidinone compounds as human neutrophil elastase inhibitors	Chiesi Farmaceutici S.p.A.	18- Dec- 12	17- Dec -13	14- Jun- 16
US9365567	Alkoxy substituted imidazoquinolines	3M Innovative Properties Company	3- Oct- 03	30- Sep -14	14- Jun- 16
US9365523	Imidazolyl amide compounds and uses related thereto	Children's Healthcare of Atlanta, Inc.	31- Mar- 11	28- Mar -12	14- Jun- 16
US9365506	Compounds and compositions as TLR2 agonists	NOVARTIS AG	23- Mar- 10	9- Jul- 14	14- Jun- 16
US9364511	Antiviral preparations obtained from a natural cinnamon extract	RAMOT AT TEL-AVIV UNIVERSITY LTD.	24- Dec- 03	22- Jun -06	14- Jun- 16
US9359360	TLR agonists	The Regents of The University of California	22- Aug- 05	20- Nov -12	7- Jun- 16
US9358280	Decreasing potential iatrogenic risks associated with influenza vaccines	Novartis AG	9- Sep- 04	11- Jan -13	7- Jun- 16
US9353133	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	7- Mar -14	31- May -16
US9352048	Carbohydrate conjugates as delivery agents for oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4- Dec- 07	22- Jul- 14	31- May -16
US9347055	Method and kit for preparation of sample for use in nucleic acid amplification	EIKEN KAGAKU KABUSHIKI KAISHA	5- Nov- 07	5- Nov -08	24- May -16
US9346866	Inhibition of tace activity with cyclic peptides	The Regents of the University of California	2- Jun- 11	19- Sep -14	24- May -16
US9346794	Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	23- Aug- 12	29- Dec -15	24- May -16
US9346769	Tetrazolones as inhibitors of fatty acid synthase	Infinity Pharmaceuticals, Inc.	5- May- 10	23- Aug -13	24- May -16
US9346753	Dithiol mucolytic agents	PARION SCIENCES, INC.	23- Aug- 13	13- Aug -14	24- May -16
US9345760	IPNV-ISAV bivalent vaccine using a virus-like particle-based platform and methods of using the same	Advanced Bionutrition Corporation	9- Sep- 11	7- Sep -12	24- May -16
US9340507	Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	23- Aug- 12	2- Sep -15	17- May -16
US9339561	Mutant protease biosensors with enhanced detection characteristics	PROMEGA CORPORATION	11- May- 10	5- May -14	17- May -16
US9339525	Inhibition of biofilm organisms	Novabiotics Limited	31- Mar- 09	31- Mar -10	17- May -16
US9334268	4-amino-imidazoquinoline compounds	HOFFMAN-LA ROCHE INC.	22- Apr- 14	22- Apr -15	10- May -16
US9328110	Substituted imidazo ring systems and methods	3M INNOVATIVE PROPERTIES COMPANY	25- Nov- 03	11- Mar -14	3- May -16
US9328093	Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications	HYBRIGENICS SA	15- Jan- 10	17- Sep -14	3- May -16
US9326972	Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression	Ohio University	16- Mar- 04	9- Feb -12	3- May -16
US9322827	B-cell antigen presenting cell assay	University of Pittsburgh - Of the Commonwealth System of Higher Education	8- Apr- 10	8- Apr -11	26- Apr- 16
US9321999	Compositions for increasing polypeptide stability and activity, and related methods	SOLIS BIODYNE OÜ	19- Nov- 09	19- Nov -10	26- Apr- 16
US9321847	Activatable toxin complexes comprising a cleavable inhibitory peptide	RAMOT at Tel Aviv University Ltd.	20- Sep- 10	22- Aug -11	26- Apr- 16
US9321831	RSV-specific binding molecules and means for producing them	MedImmune Limited	1- Jun- 07	13- Sep -13	26- Apr- 16
US9320784	Peptides shared among lethal cancers and therapeutic compositions comprising said peptides	Not Available	7- Aug- 09	19- Jul- 12	26- Apr- 16
US9320748	Immunologically useful arginine salts	Novartis AG	7- Mar- 12	7- Mar -13	26- Apr- 16
US9315530	Adsorption of immunopotentiators to insoluble metal salts	Novartis AG	1- Sep- 10	1- Sep -11	19- Apr- 16
US9310375	Luminophore-labeled molecules coupled with particles for microarray-based assays	CapitalBio Corporation	27- Oct- 10	27- Oct -10	12- Apr- 16
US9310088	Device and method for reducing spread of microorganisms and airborne health hazardous matter and/or for protection from microorganisms and airborne health hazardous matter	Technical University of Denmark	17- Jul-09	14- Jul- 10	12- Apr- 16
US9309325	Antibodies and methods of use thereof	The Regents of the University of California	7- May- 09	4- May -10	12- Apr- 16
US9303068	D-amino acid derivative-modified peptidoglycan and methods of use thereof	The Regents of the University of California	30- Nov- 12	27- Nov -13	5- Apr- 16
US9303000	Olefin containing nuclear transport modulators and uses thereof	KARYOPHARM THERAPEUTICS INC.	17- Jan- 11	16- Jan -12	5- Apr- 16
US9297010	Short interfering RNA (siRNA) analogues	Roche Innovation Center Copenhagen A/S	21- Mar- 03	11- Feb -14	29- Mar -16
US9295732	Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists	INVIVOGEN	22- Feb- 13	22- Feb -13	29- Mar -16
US9295708	Modified release formulations for oprozomib	Onyx Therapeutics, Inc.	24- Oct- 12	24- Oct -13	29- Mar -16
US9295646	Cationic oil-in-water emulsions	Novartis AG	6-Jul- 10	18- Sep -11	29- Mar -16
US9291628	Direct clone analysis and selection technology	Dublin City University	13- Jul-10	13- Jul- 11	22- Mar -16
US9291597	Detecting targets using mass tags and mass spectrometry	VENTANA MEDICAL SYSTEMS, INC.	2-Jul- 10	1- Jul- 11	22- Mar -16
US9290794	Mutant protease biosensors with enhanced detection characteristics	PROMEGA CORPORATION	11- May- 10	12- Nov -12	22- Mar -16
US9290786	Monoclonal antibody production by EBV transformation of B cells	Institute for Research in Biomedicine	26- Feb- 03	25- Apr -13	22- Mar -16
US9290760	Modified iRNA agents	ALNYLAM PHARMACEUTICALS, INC.	15- Sep- 10	14- Sep -11	22- Mar -16
US9290745	Luciferase biosensor	PROMEGA CORPORATION	10- Oct- 03	14- Feb -14	22- Mar -16
US9290545	Compositions and methods for the treatment of viral infections	Dana-Farber Cancer Institute, Inc.	23- Jan- 08	23- Jul- 10	22- Mar -16
US9290459	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	6- Feb- 13	9- Nov -15	22- Mar -16
US9290457	Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31- Jul-14	27- Jul- 15	22- Mar -16
US9289487	II-key/antigenic epitope hybrid peptide vaccines	Antigen Express, Inc.	14- Sep- 99	11- Jan -05	22- Mar -16
US9284560	Application of highly conserved domain sequences from viral genome as template to design therapeutic sliRNAs	Biocross Institute of Molecular Medicine (Nantong) Co., Ltd.	19- Sep- 11	19- Sep -11	15- Mar -16
US9278128	Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same	The Trustees of the University of Pennsylvania	14- Sep- 09	6- Jan -14	8- Mar -16
US9278126	Influenza vaccines with reduced amounts of squalene	Seqirus UK Limited	10- Feb- 09	10- Feb -10	8- Mar -16
US9272024	Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same	The Trustees of the University of Pennsylvania	12- Dec- 11	11- Dec -12	1- Mar -16
US9271494	Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid antimicrobial compositions	Ecolab USA, Inc.	30- Aug- 07	30- Aug -07	1- Mar -16
US9266844	Suppression of SARS replication by SARS helicase inhibitors	The Curators of the University of Missouri	15- Jun- 12	17- Jun -13	23- Feb -16
US9266843	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	9- May- 12	9- May -13	23- Feb -16
US9265876	Systems and methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto	Hemalux Technologies LLC	22- Oct- 14	22- Oct -14	23- Feb -16
US9260398	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases	PARION SCIENCES, INC.	29- May- 12	9- Dec -14	16- Feb -16
US9255144	Anti-IL-18 antibodies and their uses	MedImmune Limited	20- Dec- 10	20- Dec -11	9- Feb -16
US9255140	Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus	NEW YORK BLOOD CENTER, INC.	15- Jun- 04	23- Mar -09	9- Feb -16
US9254315	Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds	Not Available	28- Apr- 04	3- Feb -10	9- Feb -16
US9254265	Small liposomes for delivery of immunogen encoding RNA	NOVARTIS AG	31- Aug- 10	31- Aug -11	9- Feb -16
US9249427	Recombinant HCMV and RHCMV vectors and uses thereof	Oregon Health & Science University	14- May- 10	14- Nov -12	2- Feb -16
US9249195	Reovirus vaccines and methods of use therefor	Vanderbilt University	7- Apr- 10	4- Apr -11	2- Feb -16
US9248201	Mutant protease biosensors with enhanced detection characteristics	PROMEGA CORPORATION	11- May- 10	5- May -14	2- Feb -16
US9248178	Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens	Not Available	8- Jun- 09	8- Jun -10	2- Feb -16
US9242980	Lipidated immune response modifier compound compositions, formulations, and methods	3M Innovative Properties Company	17- Aug- 10	16- Aug -11	26- Jan- 16
US9238809	Compositions, methods, and kits for isolating and analyzing nucleic acids using an anion exchange material	QIAGEN GAITHERSBURG, INC.	24- Sep- 09	5- Aug -10	19- Jan- 16
US9234175	Creating bioengineered lymph nodes	H. Lee Moffitt Cancer Center and Research Institute, Inc.	17- Nov- 09	16- Nov -10	12- Jan- 16
US9233148	Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza	Not Available	9- Jan- 09	16- Oct -09	12- Jan- 16
US9227977	Phosphoinositide 3-kinase inhibitors	Respivert Ltd.	15- Mar- 13	14- Mar -14	5- Jan- 16
US9222075	Animal protein-free media for cultivation of cells	Baxalta GmbH	29- Oct- 04	2- May -14	29- Dec -15
US9221832	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	22- Jul-11	20- Jul- 12	29- Dec -15
US9221807	Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	21- Feb- 14	12- Feb -15	29- Dec -15
US9220768	Decreasing potential iatrogenic risks associated with influenza vaccines	Novartis AG	9- Sep- 04	14- Oct -11	29- Dec -15
US9217745	Arrayed detector system for measurement of influenza immune response	University of Rochester	2- May- 08	11- Jul- 13	22- Dec -15
US9217157	Recombinant influenza viruses and uses thereof	Icahn School of Medicine at Mount Sinai	27- Jul-09	27- Jul- 10	22- Dec -15
US9216192	Toll-like receptor agonist formulations and their use	VentiRx Pharmaceuticals, Inc.	1- Aug- 08	16- Jul- 12	22- Dec -15
US9213027	Lipoparticles comprising proteins, methods of making, and using the same	Integral Molecular, Inc.	30- Jul-03	1- Nov -13	15- Dec -15
US9212399	Biological specimen collection and transport system and method of use	Longhorn Vaccines and Diagnostics, LLC	1- Oct- 07	7- Jan -14	15- Dec -15
US9212205	Nucleic acid binding compounds and methods of use	University of Rochester	26- Jul-07	28- Jul- 08	15- Dec -15
US9206396	Methods and devices for quantitative viral assays	Wisconsin Alumni Research Foundation	16- Nov- 05	16- Nov -06	8- Dec -15
US9206158	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29- Jul-11	10- Jun -15	8- Dec -15
US9200329	Rapid epidemiologic typing of bacteria	BioFire Diagnostics, LLC	19- May- 08	18- May -09	1- Dec -15
US9200287	Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity	AdiuTide Pharmaceuticals GmbH	18- May- 07	15- May -08	1- Dec -15
US9200280	Methods and compositions for the treatment of cancer or other diseases	CITY OF HOPE	26- Jan- 07	9- Jun -14	1- Dec -15
US9200279	Methods and compositions for the treatment of cancer or other diseases	CITY OF HOPE	26- Jan- 07	14- Jan -14	1- Dec -15
US9200074	Antibodies to IL-1 R1 and methods of making them	MEDIMMUNE LIMITED	7- Nov- 08	16- Apr -14	1- Dec -15
US9199981	Compounds and compositions as C-kit kinase inhibitors	NOVARTIS AG	1- Sep- 11	27- Aug -12	1- Dec -15
US9199897	Methods for preparing squalene	NOVARTIS AG	12- May- 10	12- May -11	1- Dec -15
US9198927	Targeting opposite strand replication intermediates of single- stranded viruses by RNAI	ALNYLAM PHARMACEUTICALS, INC.	24- Sep- 04	1- Mar -10	1- Dec -15
US9193780	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases	Ablynx N.V.	5- Jun- 08	5- Jun -09	24- Nov -15
US9192661	Delivery of self-replicating RNA using biodegradable polymer particles	Novartis AG	6-Jul- 10	7- Jun -11	24- Nov -15
US9187748	Compositions and methods for silencing ebola virus gene expression	Not Available	20- Jul-09	28- Mar -14	17- Nov -15
US9187426	Organic compounds	Novartis AG	27- Jun- 08	25- Jun -09	17- Nov -15
US9186419	Directed evolution and in vitro panning of virus vectors	The University of North Carolina at Chapel Hill	30- Apr- 08	17- Jan -14	17- Nov -15
US9186399	Immune stimulatory oligonucleotide analogs containing modified sugar moieties	AdiutTide Pharmaceuticals GmbH	9- Oct- 07	29- Sep -08	17- Nov -15
US9181303	Treatment of bacterial infections with cyclic antimicrobial peptides	NovaBiotics Limited	22- Dec- 05	20- Jun -14	10- Nov -15
US9181290	Inhibition of biofilm formation by 1,2,3,4,6-penta-O-galloyl-D- glucopyranose	CHANG GUNG UNIVERSITY	17- Jun- 11	19- Sep -11	10- Nov -15
US9175047	Peptidomimetic macrocycles	Aileron Therapeutics, Inc.	14- Jan- 09	14- Jan -10	3- Nov -15
US9174925	Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY	26- Oct- 11	28- Sep -12	3- Nov -15
US9169318	Neutralizing molecules to viral antigens	Sea Lane Biotechnologies, Inc.	28- Mar- 08	18- Jul- 11	27- Oct- 15
US9168318	Oxidative reductive potential water solution and methods of using the same	Oculus Innovative Sciences, Inc.	30- Dec- 03	11- Aug -04	27- Oct- 15
US9168299	Methods for treating juvenile arthritis with ant-bile salt-stimulated lipase (BSSL) antibodies	LIPUM AB	8- Apr- 09	30- Oct -13	27- Oct- 15
US9168269	Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals	THE TRUSTEES OF PRINCETON UNIVERSITY	18- Feb- 10	18- Feb -11	27- Oct- 15
US9163222	Mutations in OAS1 genes	Kineta Two, LLC	4- May- 05	14- Nov -12	20- Oct- 15
US9163065	Depsipeptide and uses thereof	NovoBiotic Pharmaceuticals, LLC	3- Dec- 12	3- Dec -13	20- Oct- 15
US9161976	Immunotherapy comprising TLR9 ligand and CD40 ligand	Trustees of Dartmouth College	30- Dec- 02	22- Oct -12	20- Oct- 15
US9156811	N-myristoyl transferase inhibitors	Univeristy of Dundee	2- Sep- 08	29- Aug -09	13- Oct- 15
US9155309	Virus inactivating sheet	NBC MESHTEC, INC.	2- Oct- 09	4- Oct -10	13- Oct- 15
US9149473	Targeted whole genome amplification method for identification of pathogens	IBIS BIOSCIENCES, INC.	14- Sep- 06	14- Sep -07	6- Oct- 15
US9149445	Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections	THE TRUSTEES OF PRINCETON UNIVERSITY	27- Jul-09	27- Jul- 10	6- Oct- 15
US9145588	Generation of binding molecules	MERUS BIOPHARMACEUTICALS B.V.	26- Sep- 11	26- Sep -12	29- Sep -15
US9145585	Method for using permuted nucleic acid probes	Ventana Medical Systems, Inc.	1- Sep- 06	5- Aug -14	29- Sep -15
US9145410	Pyrazolopyridines and analogs thereof	3M Innovative Properties Company	3- Oct- 03	26- Jan -12	29- Sep -15
US9144575	Anti-viral azide containing compounds	LIFE TECHNOLOGIES CORPORATION	28- Jul-10	28- Jul- 11	29- Sep -15
US9139833	Modified small interfering RNA molecules and methods of use	Arrowhead Research Corporation	26- Jul-02	12- Mar -13	22- Sep -15
US9139647	Diagnosis and treatment of cancer using anti-TM4SF20 antibody	FORERUNNER PHARMA RESEARCH CO., LTD.	25- Dec- 08	25- Dec -09	22- Sep -15
US9139620	Feline morbillivirus and uses thereof	THE GOVERNMENT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA	20- Jan- 12	22- Jan -13	22- Sep -15
US9138472	CD40L vaccines, compositions, and methods related thereto	EMORY UNIVERSITY	28- Sep- 10	28- Sep -11	22- Sep -15
US9134247	Method and apparatus for two-step surface-enhanced raman spectroscopy	REAL-TIME ANALYZERS, INC.	16- Dec- 11	16- Dec -11	15- Sep -15
US9133248	Methods of propagating monkey adenoviral vectors	GenVec, Inc.	9- Nov- 09	9- Nov -10	15- Sep -15
US9132423	Sample-to-answer microfluidic cartridge	Micronics, Inc.	29- Jan- 10	28- Jan -11	15- Sep -15
US9132175	Bacillus based delivery system and methods of use	The Curators of the University of Missouri	18- Apr- 11	18- Apr -11	15- Sep -15
US9128101	Biomarkers for theranostics	Caris Life Sciences Switzerland Holdings GmbH	1- Mar- 10	1- Mar -11	8- Sep -15
US9127256	Method for production of reprogrammed cell using chromosomally unintegrated virus vector	DNAVEC CORPORATION	16- Jul-08	16- Jul- 09	8- Sep -15
US9127251	Means and methods for influencing the stability of antibody producing cells	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM	9- Dec- 05	8- Dec -06	8- Sep -15
US9127028	Substrates for chromogenic detection and methods of use in detection assays and kits	Ventana Medical Systems, Inc.	16- Aug- 10	12- Aug -11	8- Sep -15
US9125952	Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes	Industry Academic Cooperation Foundation, Hallym University	17- Jul-09	13- Aug -14	8- Sep -15
US9115093	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	4- Mar- 13	20- Feb -14	25- Aug -15
US9115065	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses	Kineta, Inc.	6- Dec- 04	26- Feb -13	25- Aug -15
US9109199	Methods to produce bunyavirus replicon particles	STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK	20- Sep- 10	20- Sep -11	18- Aug -15
US9107970	Method and a filter for capturing airborne agents	Not Available	15- Jul-08	13- Jul- 09	18- Aug -15
US9107958	Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom	3M Innovative Properties Company	3- Jun- 11	1- Jun -12	18- Aug -15
US9107906	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC.	28- Oct- 14	8- Jan -15	18- Aug -15
US9107904	Immunostimulatory compositions and methods of use thereof	Massachusetts Institute of Technology	5- Apr- 12	15- Mar -13	18- Aug -15
US9102938	2′ and 5′ modified monomers and oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	31- Mar- 11	31- Mar -11	11- Aug -15
US9102911	High density self-contained biological analysis	BioFire Diagnostics, LLC	15- May- 09	28- Jan -13	11- Aug -15
US9102741	GAS57 mutant antigens and GAS57 antibodies	Novartis AG	12- Sep- 07	13- Oct -14	11- Aug -15
US9102740	Cna-B domain antigens in vaccines against gram positive bacteria	NOVARTIS AG	12- Jan- 09	7- Jun -13	11- Aug -15
US9102633	Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds	Parion Sciences, Inc.	13- Dec- 13	13- Dec -13	11- Aug -15
US9102624	Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	23- Aug- 12	20- Aug -13	11- Aug -15
US9101597	Immunoprotective primary mesenchymal stem cells and methods	Autoimmune Technologies, LLC	14- Mar- 13	14- Mar -13	11- Aug -15
US9101582	Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	31- Jul-08	27- Mar -13	11- Aug -15
US9096585	Antiviral compounds and uses thereof	Icahn School of Medicine at Mount Sinai	28- May- 10	31- May -11	4- Aug -15
US9096543	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	9- May- 12	9- May -13	4- Aug -15
US9090897	Production of IFN-lambda by conventional dendritic cells	Bavarian Nordic A/S	18- Dec- 09	17- Dec -10	28- Jul- 15
US9085641	Peptides regulating the surface expression of the T cell receptor	Max-Delbruck-Centrum Fur Molekulare Medizin	23- Jun- 06	23- Jun -07	21- Jul- 15
US9084808	Modified small interfering RNA molecules and methods of use	Arrowhead Research Corporation	1- Oct- 04	9- May -14	21- Jul- 15
US9084758	Antiviral compositions comprising ethanol extract of Tetracera scandens and use thereof	The Catholic University of Korea Industry-Academic Cooperation Foundation	24- Jul-12	25- Aug -14	21- Jul- 15
US9080209	Non-mass determined base compositions for nucleic acid detection	IBIS BIOSCIENCES, INC.	6- Aug- 09	6- Aug -10	14- Jul- 15
US9080204	Compositions and methods for rapid, real-time detection of influenza a virus (H1N1) Swine 2009	Longhorn Vaccines and Diagnostics, LLC	12- Sep- 06	30- Dec -11	14- Jul- 15
US9079965	Bispecific antibody	Wuhan YZY Biopharma Co., LTD.	21- Nov- 12	13- Mar -14	14- Jul- 15
US9079943	TC-83-derived alphavirus vectors, particles and methods	ALPHAVAX, INC.	18- May- 04	28- Mar -14	14- Jul- 15
US9079865	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29- Jul-11	29- Jul- 12	14- Jul- 15
US9078885	Respiratory disease treatment	Pulmagen Therapeutics (Inflammation) Limited	7- Aug- 08	7- Apr -14	14- Jul- 15
US9078868	Therapeutic agent for accelerating recovery of animal under medical treatment	DAIICHI SANKYO COMPANY, LIMITED	15- Jan- 10	14- Jan -11	14- Jul- 15
US9073869	Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	14- Mar- 13	11- Sep -14	7- Jul- 15
US9072738	Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity	PARION SCIENCES, INC.	27- Jun- 11	27- Jun -12	7- Jul- 15
US9072726	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	20- Jan- 06	21- Dec -09	7- Jul- 15
US9072702	Reverse genetics using non-endogenous pol I promoters	Novartis AG	21- May- 09	21- May -10	7- Jul- 15
US9067873	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses	Kineta Four, LLC	6- Dec- 04	19- Dec -13	30- Jun- 15
US9066964	Use of tylvalosin as antiviral agent	Cambridge University Technical Services	13- Jul-06	13- Jul- 07	30- Jun- 15
US9063150	Method for detection of antigen-specific antibodies in biological samples	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control Prevention	2- Sep- 08	25- Aug -09	23- Jun- 15
US9061001	Combination adjuvant formulation	Dalhousie University	16- Oct- 08	15- Oct -09	23- Jun- 15
US9056900	Compositions and methods for coronavirus inhibition	Autoimmune Technologies, LLC.	4- Nov- 03	8- Aug -13	16- Jun- 15
US9056898	Attenuated RNA virus and applications thereof	Washington University	20- Sep- 07	22- Sep -08	16- Jun- 15
US9056071	Compounds and methods for preventing or treating a viral infection	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)	2- Nov- 07	19- Jun -13	16- Jun- 15
US9051619	Methods and compositions for prostate cancer metastasis	FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU)	25- Mar- 11	23- Mar -12	9- Jun- 15
US9051564	Compositions for and methods of identifying antigens	President and Fellows of Harvard College	21- Feb- 06	21- Feb -07	9- Jun- 15
US9051353	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20- Mar- 09	24- Sep -13	9- Jun- 15
US9050376	Conjugates of synthetic TLR agonists and uses therefor	The Regents of the University of California	7- Feb- 07	19- Jun -14	9- Jun- 15
US9046523	Rapid bioluminescence detection system	THE SECRETARY OF STATE FOR HEALTH	7- Jan- 09	2- Aug -13	2- Jun- 15
US9045855	Anti-viral member	NBC Meshtec, Inc.	26- Dec- 08	28- Dec -09	2- Jun- 15
US9045727	Virus-like particles, methods of preparation, and immunogenic compositions	EMORY UNIVERSITY	17- May- 02	4- Apr -06	2- Jun- 15
US9045472	Imidazoquinoline compounds	ASTRAZENECA AB	16- Dec- 10	16- Dec -11	2- Jun- 15
US9045470	Compounds and compositions as TLR activity modulators	IRM LLC	2- Sep- 09	1- Sep -10	2- Jun- 15
US9044420	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses	IMMUNE DESIGN CORP.	8- Apr- 11	6- Apr -12	2- Jun- 15
US9040310	Antibody-nanoparticle conjugates and methods for making and using such conjugates	Ventana Medical Systems, Inc.	27- Apr- 10	27- Apr -11	26- May -15
US9034646	Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof	ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD.	25- May- 10	26- Nov -12	19- May -15
US9034313	Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same	Inovio Pharmaceuticals, Inc.	8- Feb- 10	8- Feb -11	19- May -15
US9029413	Treatment of viral infections by modulation of host cell metabolic pathways	The Trustees of Princeton University	1- Jun- 07	3- Apr -12	12- May -15
US9029382	3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds	Parion Sciences, Inc.	17- Dec- 12	13- Dec -13	12- May -15
US9029315	Soluble PD-1 variants, fusion constructs, and uses thereof	The University of Hong Kong	11- Nov- 10	11- Nov -11	12- May -15
US9028841	Synergistic bacterial compositions and methods of production and use thereof	Seres Health, Inc.	23- Nov- 12	20- Mar -14	12- May -15
US9028837	Methods and compositions for poxvirus A35R protein	East Carolina University	7- Jun- 12	20- Dec -12	12- May -15
US9028823	Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies	GITR, Inc.	25- Mar- 05	1- Mar -13	12- May -15
US9024001	Alphavirus replicon packaging constructs	Novartis Vaccines and Diagnostics, Inc.	25- May- 04	20- May -05	5- May -15
US9023855	Compounds	Chiesi Farmaceutici S.p.A.	14- Sep- 11	11- Feb -14	5- May -15
US9023839	Compounds and compositions as c-kit kinase inhibitors	IRM LLC	1- Sep- 11	22- Apr -14	5- May -15
US9017699	Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus	New York Blood Center, Inc.	15- Jun- 04	18- Feb -10	28- Apr- 15
US9017696	Adenovirus vectors	Isis Innovation Limited	10- Apr- 07	10- Apr -08	28- Apr- 15
US9012622	Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer	Not Available	31- Dec- 08	31- Dec -09	21- Apr- 15
US9011767	Transportable vacuum assisted decontamination unit and decontamination process	STERIS Inc.	1- Apr- 13	31- Mar -14	21- Apr- 15
US9006264	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	18- Jun- 04	9- Sep -13	14- Apr- 15
US9006194	Compositions and methods for diminishing viral infection and inflammation associated with viral infection	Drexel University	19- Dec- 08	17- Dec -09	14- Apr- 15
US9005974	Means and methods for influencing the stability of cells	Academish Medisch Centrum Bij de Universiteit van Amsterdam	9- Dec- 05	9- Dec -05	14- Apr- 15
US9005665	Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome	Ohio State Innovation Foundation	24- Apr- 12	24- Apr -13	14- Apr- 15
US9005599	Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents	Tissue Regeneration Therapeutics Inc.	21- Apr- 08	20- Apr -09	14- Apr- 15
US8999996	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29- Jul-11	19- Mar -14	7- Apr- 15
US8999975	Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	19- Sep- 11	14- Sep -12	7- Apr- 15
US8999678	Method of increasing the function of an AAV vector	The Trustees of the University of Pennsylvania	7- Apr- 05	7- Apr -06	7- Apr- 15
US8999349	HMGB1-derived peptides enhance immune response to antigens	The Regents of the University of California	27- Jul-10	27- Jul- 11	7- Apr- 15
US8999316	Antiviral compounds	Long Island University	30- May- 07	30- May -08	7- Apr- 15
US8993717	Gadd45beta targeting agents	Imperial Innovations Limited	22- Oct- 09	22- Oct -10	31- Mar -15
US8993581	Methods for treating viral disorders	Trustees of Boston University	24- Sep- 09	11- Jun -13	31- Mar -15
US8993295	Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting	The General Hospital Corporation	20- Jul-06	20- Jul- 07	31- Mar -15
US8992939	Highly efficient influenza matrix (M1) proteins	Novavax, Inc.	11- Jul-03	24- Oct -11	31- Mar -15
US8987249	Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl- cyano-methyl)-amides inhibitors of Cathepsin C	Boehringer Ingelheim International GmbH	14- Mar- 13	12- Mar -14	24- Mar -15
US8987191	Bioactive peptides and methods of using same	Compugen Ltd.	12- Jul-07	21- Jun -13	24- Mar -15
US8986933	Selective detection of human rhinovirus	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control	5- Dec- 08	5- Dec -08	24- Mar -15
US8986926	Compositions comprising oriented, immobilized macromolecules and methods for their preparation	NanoString Technologies, Inc.	23- Dec- 05	22- Dec -06	24- Mar -15
US8986702	Antibodies and processes for preparing the same	Taiga Biotechnologies, Inc.	16- May- 08	18- May -09	24- Mar -15
US8980898	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases	Parion Sciences, Inc.	29- May- 12	29- May -13	17- Mar -15
US8980338	Sceletium extract and uses thereof	H.L. Hall & Sons Limited	20- Mar- 09	16- Mar -10	17- Mar -15
US8980281	High-yield transgenic mammalian expression system for generating virus-like particles	Academia Sinica	5- Sep- 06	12- Feb -10	17- Mar -15
US8975389	Nucleic acid chemical modifications	Alnylam Pharmaceuticals, Inc.	2- Mar- 09	2- Mar -10	10- Mar -15
US8969362	9-substituted 8-oxoadenine compound	AstraZeneca Aktiebolag	26- Mar- 04	21- Oct -13	3- Mar -15
US8969350	Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient	Astrazeneca AB	18- Dec- 08	17- Dec -09	3- Mar -15
US8962580	Chemical modifications of monomers and oligonucleotides with cycloaddition	Alnylam Pharmaceuticals, Inc.	23- Sep- 08	23- Sep -09	24- Feb -15
US8962332	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17- Dec- 01	13- Sep -13	24- Feb -15
US8962330	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17- Dec- 01	31- Oct -07	24- Feb -15
US8961983	Mucosal vaccine using cationic nanogel	National University Corporation Tokyo Medical and Dental University	31- Oct- 08	5- Sep -14	24- Feb -15
US8961477	Delivery of immune response modifier compounds	3M Innovative Properties Company	25- Aug- 03	25- Aug -04	24- Feb -15
US8956863	Agents from cells	The Brigham and Women's Hospital, Inc.	15- Oct- 09	15- Oct -10	17- Feb -15
US8956616	Constructs binding to phosphatidylserine and their use in disease treatment	Board of Regents, The University of Texas System	24- Jan- 05	24- Jan -06	17- Feb -15
US8951768	Mutations in OAS1 genes	Kineta Two, LLC	4- May- 05	11- Jul- 11	10- Feb -15
US8951528	Immune response modifier conjugates	3M Innovative Properties Company	22- Feb- 06	21- Feb -07	10- Feb -15
US8945943	Personal glucose meters for detection and quantification of a broad range of analytes	The Board of Trustees of the University of Illinois	26- May- 10	26- May -11	3- Feb -15
US8945904	Influenza virus reassortment	Novartis AG	21- May- 10	20- May -11	3- Feb -15
US8945610	Condensation products based on bicyclic or polycyclic aromatics or heteroaromatics	BASF SE	14- Nov- 07	11- Nov -08	3- Feb -15
US8940864	Stabilized therapeutic small helical antiviral peptides	New York Blood Center, Inc.	5- Oct- 06	2- Oct -07	27- Jan- 15
US8940501	Methods for ligation and uses thereof	Whitehead Institute for Biomedical Research	30- Jan- 09	1- Feb -10	27- Jan- 15
US8937154	Stabilized therapeutic small helical antiviral peptides	New York Blood Center, Inc.	5- Oct- 06	2- Feb -12	20- Jan- 15
US8933210	Label-free functional nucleic acid sensors for detecting target agents	The Board of Trustees of the University of Illinois	6- Oct- 10	6- Oct -11	13- Jan- 15
US8933019	Antiviral cell-penetrating peptides	New York Blood Center, Inc.	6- May- 08	31- Oct -12	13- Jan- 15
US8916552	Pharmaceutical combinations	Astex Therapeutics Limited	12- Oct- 06	12- Oct -07	23- Dec -14
US8916340	Method for identifying and validating dominant T helper cell epitopes using an HLA-DM-assisted class II binding assay	The John Hopkins University	6- Jan- 06	8- Jan -07	23- Dec -14
US8906872	Antisense antiviral compound and method for treating ssRNA viral infection	Sarepta Therapeutics, Inc.	16- Sep- 04	22- Dec -11	9- Dec -14
US8906863	Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector	The Regents of the University of California	27- Feb- 09	1- Sep -11	9- Dec -14
US8906862	Multiple antigen delivery system using hepatitis E virus-like particle	National Institute of Infectious Disease	27- Feb- 09	29- Aug -11	9- Dec -14
US8901071	Compounds and their use	Novabiotics Limited	31- Mar- 10	30- Mar -11	2- Dec -14
US8900585	Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection	New York Blood Center, Inc.	20- Oct- 10	20- Oct -11	2- Dec -14
US8895629	Circulation of components during homogenization of emulsions	Novartis AG	3- Dec- 09	3- Dec -10	25- Nov -14
US8895577	Compounds and compositions as TLR activity modulators	Not Available	3- Mar- 08	22- Apr -13	25- Nov -14
US8895570	Purine derivatives	AstraZeneca AB	17- Dec- 10	14- Dec -11	25- Nov -14
US8895534	Boron containing small molecules	Anacor Pharmaceuticals, Inc.	20- Jun- 07	30- Jul- 10	25- Nov -14
US8895295	High density self-contained biological analysis	Biofire Diagnostics, LLC	15- Nov- 06	14- Nov -07	25- Nov -14
US8889708	Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	14- Mar- 13	12- Mar -14	18- Nov -14
US8889692	Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses	AstraZeneca AB	27- Jun- 07	14- Sep -12	18- Nov -14
US8889656	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	30- Apr -13	18- Nov -14
US8889398	Composition for inactivating an enveloped virus	Viroblock SA	19- May- 06	18- May -07	18- Nov -14
US8889181	Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes	Industry Academic Cooperation Foundation, Hallym University	17- Jul-09	16- Jun -10	18- Nov -14
US8889118	Anticancer agent containing dendritic cell having RNA virus transferred thereinto	DNA VEC Research Inc.	24- Jun- 04	28- Apr -05	18- Nov -14
US8889117	Modular nanoparticles for adaptable vaccines	Yale University	15- Feb- 07	15- Feb -08	18- Nov -14
US8884020	Indole compounds	Ironwood Pharmaceuticals, Inc.	7- Aug- 06	7- Aug -07	11- Nov -14
US8883790	Pharmaceutical combinations	Astex Therapeutics Limited	12- Oct- 06	12- Oct -07	11- Nov -14
US8883500	Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy	Northeastern University	5- Dec- 08	7- Dec -09	11- Nov -14
US8883481	Reverse genetics methods for virus rescue	Novartis AG	20- Oct- 09	20- Oct -10	11- Nov -14
US8883477	Oligoadenylate synthetase (OAS)	Kineta Two, LLC	23- Nov- 05	14- Jun -13	11- Nov -14
US8882484	Methods and compositions for production of recombinant protein in HBX-expressing mammalian cells	Bayer HealthCare LLC	28- May- 08	27- May -09	11- Nov -14
US8881040	System and method for detecting, collecting, analyzing, and communicating event-related information	Georgetown University	28- Aug- 08	2- Dec -09	4- Nov -14
US8877775	Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl- cyano-methyl)-amides inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	14- Mar- 13	12- Mar -14	4- Nov -14
US8877187	Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases	Avianax, LLC	25- Jul-05	23- Nov -10	4- Nov -14
US8877060	Methods for removing pathogens from a platelet preparation	Biovec Transfusion, LLC	23- Nov- 10	31- Oct -11	4- Nov -14
US8871816	Methods for producing vaccine adjuvants	Novartis AG	3- Dec- 09	3- Dec -10	28- Oct- 14
US8871790	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc.	8- Mar- 11	8- Mar -12	28- Oct- 14
US8871783	Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano- methyl)-amides inhibitors of cathepsin C	Boehringer Ingelheim International GmBh	14- Mar- 13	12- Mar -14	28- Oct- 14
US8871782	Alkoxy substituted imidazoquinolines	3M Innovative Properties Company	3- Oct- 03	1- Oct -04	28- Oct- 14
US8871503	Construct	Isis Innovation Limited	28- Mar- 06	28- Mar -07	28- Oct- 14
US8871487	Compositions, methods and uses for inducing viral growth	Takeda Vaccines, Inc.	5- Dec- 08	4- Dec -09	28- Oct- 14
US8871442	Enhanced deposition of chromogens	Ventana Medical Systems, Inc.	30- Dec- 10	28- Dec -11	28- Oct- 14
US8865865	N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic	Philipps-Universitat Marburg	29- Oct- 08	29- Oct -09	21- Oct- 14
US8865166	Antibodies to IL-17A and uses thereof	MedImmune Limited	23- Jun- 06	22- Jun -07	21- Oct- 14
US8859568	Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy	Astrazeneca AB	6- Dec- 04	3- Nov -10	14- Oct- 14
US8859251	Oligoadenylate synthetase (OAS)	Kineta Two, LLC	23- Nov- 05	1- Jul- 13	14- Oct- 14
US8858958	Adjuvant comprising aluminum, oligonucleotide and polycation	Novartis AG	27- Aug- 09	27- Aug -10	14- Oct- 14
US8858957	GAS57 mutant antigens and GAS57 antibodies	Novartis AG	12- Sep- 07	14- Mar -13	14- Oct- 14
US8854617	Compounds and markers for surface-enhanced Raman scattering	Julius-Maximilians-Universitat Wurzburg	24- Sep- 07	24- Sep -08	7- Oct- 14
US8853382	Expression of antibody or a fragment thereof in lactobacillus	Hera Pharmaceuticals, Inc.	5- Aug- 10	4- Aug -11	7- Oct- 14
US8846710	Method of preferentially inducing the biosynthesis of interferon	3M Innovative Properties Company	23- Feb- 05	22- Feb -06	30- Sep -14
US8846697	Purine analogs	The Regents of the University of California	31- May- 06	23- Apr -07	30- Sep -14
US8846643	Phosphonates with reduced toxicity for treatment of viral infections	The Regents of the University of California	14- Apr- 10	11- Oct -12	30- Sep -14
US8846051	Modulation of replicative fitness by deoptimization of synonymous codons	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	8- Oct- 04	7- Oct -05	30- Sep -14
US8841100	Use of methylsulfonylmethane (MSM) to modulate microbial activity	Biogenic Innovations, LLC	30- Oct- 09	16- Feb -11	23- Sep -14
US8840899	Use of mTOR inhibitors to enhance T cell immune responses	Emory University	5- Aug- 08	5- Aug -09	23- Sep -14
US8840890	Rapid expression cloning of human monoclonal antibodies from memory B cells	University of Maryland, Baltimore	12- Nov- 08	12- Nov -09	23- Sep -14
US8840873	Method of treating second and third degree burns using oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	23- Mar- 05	23- Mar -06	23- Sep -14
US8840774	Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode	Board of Regents of the University of Texas System	3- Jun- 05	28- Oct -13	23- Sep -14
US8835107	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics	Amsterdam Institute of Viral Genomics B.V.	18- Aug- 03	26- Jul- 10	16- Sep -14
US8834445	Methods of treating or preventing peritonitis with oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	20- Jan- 06	30- Mar -12	16- Sep -14
US8828962	SiRNA compositions and methods for potently inhibiting viral infection	Xiangxue Group (Hong Kong) Company Limited	11- Dec- 08	12- Dec -11	9- Sep -14
US8828956	Carbohydrate conjugates as delivery agents for oligonucleotides	Alnylam Pharmaceuticals, Inc.	4- Dec- 07	4- Dec -12	9- Sep -14
US8828940	Method of treating an ischemia-reperfusion injury-related disorder by administering GPCR ligands	Compugen Ltd.	18- Sep- 06	14- Dec -10	9- Sep -14
US8828929	Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereof	Japan as Represented by Director-General of National Institute of Infectious Diseases	28- Nov- 08	27- Nov -09	9- Sep -14
US8828673	Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses	Diagnostic Hybrids Inc	24- Apr- 98	1- Mar -12	9- Sep -14
US8828659	Method for producing nucleic acid probes	Ventana Medical Systems, Inc.	1- Sep- 06	11- Mar -13	9- Sep -14
US8828407	Chimaeric protein	The Pirbright Institute	7-Jul- 09	5- Jul- 10	9- Sep -14
US8828406	Influenza viruses and uses thereof	Icahn School of Medicine at Mount Sinai	30- Jul-09	29- Jul- 10	9- Sep -14
US8822512	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20- Mar- 09	20- Sep -11	2- Sep -14
US8822409	Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith	Phylogica Limited	20- Jun- 07	20- Jun -08	2- Sep -14
US8821897	Viral adjuvants	The University of North Carolina at Chapel Hill	9-Jul- 04	24- Nov -10	2- Sep -14
US8816089	Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity	Masatoshi Hagiwara	26- Dec- 03	19- Nov -12	26- Aug -14
US8816053	Methods for treating viral infection using IL-28 and IL-29 cysteine mutants	ZymoGenetics, Inc.	2- Apr- 04	7- Sep -12	26- Aug -14
US8815837	Respiratory disease treatment	Pulmagen Therapeutics (Inflammation) Limited	7- Aug- 08	29- Jun -12	26- Aug -14
US8815831	Treatment of Acinetobacter with alginate oligomers and antibiotics	Algipharma AS	3- Jun- 09	3- Jun -10	26- Aug -14
US8815611	Surface for label independent detection and method thereof	Corning Incorporated	10- Apr- 08	3- Apr -09	26- Aug -14
US8815249	Ii-key/antigenic epitope hybrid peptide vaccines	Antigen Express, Inc.	4- Sep- 99	26- Jul- 10	26- Aug -14
US8815244	Method for production of antibody using ostrich	Japan Science and Technology Agency	29- Aug- 05	16- Aug -11	26- Aug -14
US8809377	Deubiquitinase inhibitors and methods for use of the same	The Regents of the University of Michigan	24- Sep- 10	23- Sep -11	19- Aug -14
US8808703	Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc	Not Available	23- Mar- 10	23- Mar -11	19- Aug -14
US8808686	Adjuvant-sparing multi-dose influenza vaccination regimen	Novartis AG	15- Jun- 06	19- Sep -11	19- Aug -14
US8802853	Arylalkenyl and arylalkynyl substituted imidazoquinolines	3M Innovative Properties Company	29- Dec- 03	17- Dec -04	12- Aug -14
US8802647	Materials and methods for prevention and treatment of RNA viral diseases	University of South Florida	30- Apr- 02	17- Sep -12	12- Aug -14
US8802106	Peptide compositions and methods for inhibiting herpesvirus infection	The Administrators of the Tulane Educational Fund	30- Oct- 09	29- Oct -10	12- Aug -14
US8796423	Anti-TSG101 antibodies and their uses for treatment of viral infections	Eli Lilly and Company	15- Nov- 06	18- Apr -08	5- Aug -14
US8790655	Conjugates of synthetic TLR agonists and uses therefor	The Regents of The University of California	7- Feb- 07	8- Jan -13	29- Jul- 14
US8785408	Compositions and methods for reducing or protecting against delayed graft function (DGF)	Quark Pharmaceuticals, Inc.	27- Jun- 07	26- Jun -08	22- Jul- 14
US8785375	Cyclic antimicrobial peptides for treating bacterial infections	Novabiotics Ltd.	22- Dec- 05	22- Aug -12	22- Jul- 14
US8784900	Antimicrobial solutions containing dichlorine monoxide and methods of making and using the same	Oculus Innovative Sciences, Inc.	13- Mar- 07	13- Mar -08	22- Jul- 14
US8779132	Pharmaceutical compounds	Astex Therapeutics Limited	12- Oct- 06	12- Oct -07	15- Jul- 14
US8778963	Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	25- Nov- 03	24- Nov -04	15- Jul- 14
US8778846	Composition, device and associated method	General Electric Company	4- Dec- 06	1- Mar -07	15- Jul- 14
US8778845	Composition, device and associated method	Genral Electric Company	15- Dec- 05	1- Mar -07	15- Jul- 14
US8778358	Immunogenic compositions for gram positive bacteria such as Streptococcus agalactiae	Novartis Vaccines and Diagnostics, Inc.	29- Jul-04	18- Oct -10	15- Jul- 14
US8778275	Methods for producing vaccine adjuvants	Novartis AG	3- Dec- 09	3- Dec -10	15- Jul- 14
US8772471	Targeted delivery of siRNA	Immune Disease Institute	26- Jan- 07	25- Jan -08	8- Jul- 14
US8765939	Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers	AstraZeneca AB	22- Nov- 07	16- Aug -12	1- Jul- 14
US8765704	Modified small interfering RNA molecules and methods of use	Novartis AG	28- Feb- 08	14- Dec -11	1- Jul- 14
US8765643	Composition, device and associated method	General Electric Company	4- Dec- 06	1- Mar -07	1- Jul- 14
US8765146	Adenoviral vector-based malaria vaccines	GenVec, Inc.	31- Aug- 05	31- Aug -06	1- Jul- 14
US8765138	Antiviral and antibacterial activity from medicinal mushrooms	Not Available	6- Jan- 04	24- Sep -08	1- Jul- 14
US8765133	Method of producing anti-CD166 antibody in ostrich	Japan Science and Technology Agency	29- Aug- 05	16- Aug -11	1- Jul- 14
US8759307	Oligonucleotide compound and method for treating nidovirus infections	Sarepta Therapeutics, Inc.	24- Dec- 03	25- Apr -08	24- Jun- 14
US8758763	Archaeal polar lipid aggregates for administration to animals	National Research Council of Canada	15- Dec- 06	23- Jan -13	24- Jun- 14
US8758680	Method and device for cleaning air	Not Available	29- Sep- 10	27- Sep -11	24- Jun- 14
US8754071	Compounds and compositions as c-kit kinase inhibitors	Not Available	1- Sep- 11	19- Sep -13	17- Jun- 14
US8754015	Modified phage for displaying post-translationally modified proteins and uses thereof	University of Rochester	21- Nov- 06	20- Nov -07	17- Jun- 14
US8748567	Method for delivery across the blood brain barrier	Children's Medical Center Corporation	22- May- 06	22- May -07	10- Jun- 14
US8748464	Use of SIRT1 activators or inhibitors to modulate an immune response	The J. David Gladstone Institutes	7- Feb- 08	16- Jul- 10	10- Jun- 14
US8748405	Methods and compositions for the treatment of cancer or other diseases	City of Hope	26- Jan- 07	9- Sep -11	10- Jun- 14
US8748156	Animal protein-free media for cultivation of cells	Baxter Healthcare SA	29- Oct- 04	16- Apr -13	10- Jun- 14
US8741813	Composition, device and associated method	General Electric Company	15- Dec- 05	28- Feb -07	3- Jun- 14
US8741653	Single recombination system and methods of use	Emergent Product Development GmbH	22- Dec- 08	16- Dec -09	3- Jun- 14
US8741604	Nucleic acid molecule encoding a specific IL-1R1 antibody	Medimmune Limited	7- Nov- 08	14- Sep -12	3- Jun- 14
US8741564	Quantitative nuclease protection assay (QNPA) and sequencing (QNPS) improvements	HTG Molecular Diagnostics, Inc.	4- May- 11	26- Apr -12	3- Jun- 14
US8741311	Methods and compositions for immunization against virus	Academia Sinica	27- Mar- 09	26- Mar -10	3- Jun- 14
US8735567	Multi-targeted RNAi therapeutics for scarless wound healing of skin	Not Available	6- Nov- 07	6- Nov -08	27- May -14
US8735559	Mutant protease biosensors with enhanced detection characteristics	Promega Corporation	11- May- 10	11- May -11	27- May -14
US8735421	Imidazoquinolinyl sulfonamides	3M Innovative Properties Company	30- Dec- 03	23- Dec -04	27- May -14
US8735410	Quinazoline derivatives as tyrosine kinase inhibitors	AstraZeneca AB	26- Feb- 05	24- Feb -06	27- May -14
US8735348	Casein derived peptides and uses thereof	Peptera Ltd.	1- Mar- 00	5- Sep -12	27- May -14
US8734823	Device including altered microorganisms, and methods and systems of use	The Invention Science Fund I, LLC	14- Dec- 05	28- May -10	27- May -14
US8728793	Amphipathic alpha-helical peptide compositions as antiviral agents	The Board of Trustees of the Leland Stanford Junior University	19- Jul-07	14- Jul- 08	20- May -14
US8722917	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	23- Jan -12	13- May -14
US8722741	Biphenyloxyacetic acid derivatives for the treatment of respiratory disease	AstraZeneca AB	24- Aug- 04	6- Dec -11	13- May -14
US8722725	Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition and usage thereof	Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory	23- Mar- 07	21- Mar -08	13- May -14
US8718948	Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector	Gen-Probe Incorporated	24- Feb- 11	24- Feb -12	6- May -14
US8716464	Compositions and methods for silencing Ebola virus gene expression	Not Available	20- Jul-09	20- Jul- 10	6- May -14
US8716461	Human parvovirus	Blood Systems, Inc.	24- May- 04	24- May -05	6- May -14
US8710224	Heterocyclic compounds as CCR2B antagonists	AstraZeneca AB	24- Dec- 04	13- Sep -13	29- Apr- 14
US8709730	Methods of preventing and treating viral infections by inhibiting the deISGylation activity of OTU domain-containing viral proteins	Icahn School of Medicine at Mount Sinai	5- Apr- 07	7- Apr -08	29- Apr- 14
US8709496	Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract	D2 Bioscience Group Ltd.	6- Jan- 10	23- May -12	29- Apr- 14
US8709447	Compositions and methods for activating innate and allergic immunity	ID Biomedical Corporation of Quebec	22- Oct- 03	26- Apr -12	29- Apr- 14
US8709441	TC-83-derived alphavirus vectors, particles and methods	Alphavax, Inc.	18- May- 04	6- Jul- 10	29- Apr- 14
US8704169	Direct impact ionization (DII) mass spectrometry	The United States of America, as represented by the Secretary, Department of Health and Human Services	11- Oct- 11	11- Oct -11	22- Apr- 14
US8703748	Cleaning composition for treating tissue for transplantation derived from human/animal	CG BIO Co., Ltd.	11- Feb- 09	10- Feb -10	22- Apr- 14
US8703467	Inactivation of a pathogen in a sample by a treatment with formalin and UV light	Baxter Healthcare SA	27- May- 04	26- May -05	22- Apr- 14
US8702958	Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode	Board of Regents of the University of Texas System	3- Jun- 05	31- May -12	22- Apr- 14
US8697873	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines	3M Innovative Properties Company	24- Mar- 04	24- Mar -05	15- Apr- 14
US8697853	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10- Dec- 09	10- Jan -13	15- Apr- 14
US8697659	Analogues of glycolipids useful as immunoadjuvants	Luigi Panza	12- Oct- 07	10- Oct -08	15- Apr- 14
US8697140	Virucidal disinfectant	B. Braun Medical AG	28- Jan- 05	28- May -09	15- Apr- 14
US8697088	VLPs derived from cells that do not express a viral matrix or core protein	Novavax, Inc.	25- May- 07	27- May -08	15- Apr- 14
US8697087	Influenza vaccines including combinations of particulate adjuvants and immunopotentiators	Novartis AG	4- Nov- 05	6- Nov -06	15- Apr- 14
US8691837	Substituted imidazo ring systems and methods	3M Innovative Properties Company	25- Nov- 03	24- Nov -04	8- Apr- 14
US8691826	Compounds	Chiesi Farmaceutici S.p.A.	14- Sep- 11	13- Sep -12	8- Apr- 14
US8691781	Compositions for treating respiratory viral infections and their use	Sirnaomics, Inc.	5- Nov- 04	4- Nov -05	8- Apr- 14
US8691777	Combination therapy	Emory University	27- Jan- 11	25- Jan -12	8- Apr- 14
US8686152	4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)	Janssen Pharmaceutica NV	10- Mar- 10	9- Mar -11	1- Apr- 14
US8682619	Device including altered microorganisms, and methods and systems of use	The Invention Science Fund I, LLC	14- Dec- 05	28- May -10	25- Mar -14
US8679839	Cell line from rousettus as host cell for pathogen amplification	Probiogen AG	4- Mar- 08	4- Mar -09	25- Mar -14
US8678184	Methods for producing vaccine adjuvants	Novartis AG	3- Dec- 09	3- Dec -10	25- Mar -14
US8678002	Devices and methods for decreasing human pathogen transmission	Filligent Limited	26- Jun- 07	25- Jun -08	25- Mar -14
US8673983	Melanins synthesized chemically or via enzyme catalysis	Loyola University Chicago	21- Dec- 07	22- Dec -08	18- Mar -14
US8673932	Oxime substituted imidazo-containing compounds	3M Innovative Properties Company	12- Aug- 03	12- Aug -04	18- Mar -14
US8673907	Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2- butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4- ylpropyl) amino] methyl }phenyl) acetate and their use in therapy	AstraZeneca AB	17- Dec- 07	16- Dec -08	18- Mar -14
US8673904	Epoxide inhibitors of cysteine proteases	The Board of Trustees of the Leland Stanford Junior University	13- Jun- 06	13- Jun -07	18- Mar -14
US8673558	Luciferase biosensor	Promega Corporation	10- Oct- 03	24- Apr -12	18- Mar -14
US8673331	Composition with sterilizing activity against bacteria, fungus and viruses, application thereof and method for preparation thereof	GP&E	18- Nov- 11	18- Nov -11	18- Mar -14
US8669263	Use of TAM receptor inhibitors as antimicrobials	Salk Institute for Biological Studies	9- Nov- 07	8- Mar -13	11- Mar -14
US8669262	3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6- pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra zine-2-carboxamide	Parion Sciences, Inc.	27- Jun- 11	26- Jun -12	11- Mar -14
US8669240	Biological specimen collection and transport system and method of use	Longhorn Vaccines & Diagnostics, LLC	1- Oct- 07	19- Mar -13	11- Mar -14
US8664274	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses	Siga Technologies, Inc.	6- Dec- 04	6- Jul- 11	4- Mar -14
US8664218	Pharmaceutical compounds	Astex Therapeutics Ltd.	11- Apr- 08	30- Jan -13	4- Mar -14
US8664188	siRNA compositions and methods for potently inhibiting viral infection	Xiangxue Group (Hong Kong) Company Limited	11- Dec- 08	11- Dec -09	4- Mar -14
US8663922	Systems and methods for detecting multiple optical signals	Gen-Probe Incorporated	10- Mar- 05	1- Jun -10	4- Mar -14
US8658767	Lipidated polyepitope vaccines	National Health Research Institutes	15- Nov- 10	15- Nov -11	25- Feb -14
US8658697	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses	Siga Technologies, Inc.	6- Dec- 04	26- Oct -10	25- Feb -14
US8658666	Substituted imidazoquinolines and imidazonaphthyridines	3M Innovative Properties Company	11- Feb- 05	10- Feb -06	25- Feb -14
US8658178	Carbon nanotube compositions and methods of use thereof	Yale University	19- Mar- 08	19- Mar -09	25- Feb -14
US8653252	Short interfering RNA (siRNA) analogues	Santaris Pharma A/S	21- Mar- 03	22- Mar -04	18- Feb -14
US8653084	Hydrobenzamide derivatives as inhibitors of Hsp90	Astex Therapeutics Ltd.	12- Oct- 06	12- Oct -07	18- Feb -14
US8653034	Compositions and methods comprising phosphatidylethanolamine- binding peptide derivatives	Board of Regents, The University of Texas System	15- Jul-02	8- May -08	18- Feb -14
US8652836	Defective ribosomal products in blebs (DRibbles) and methods of use to stimulate an immune response	Providence Health System	29- Jul-05	27- Jul- 06	18- Feb -14
US8652782	Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids	Longhorn Vaccines & Diagnostics, LLC	12- Sep- 06	26- Apr -11	18- Feb -14
US8652533	Durable biocides and disinfectants	Mitsui Norin Co., Ltd.	7-Jul- 04	5- Jul- 05	18- Feb -14
US8648076	Cysteine protease inhibitors and their therapeutic applications	Hybrigenics SA	5- Aug- 05	26- Jul- 06	11- Feb -14
US8647676	Antimicrobial composition from copepods	Nofima Ingrediens	28- Oct- 08	28- Oct -09	11- Feb -14
US8642596	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses	Siga Technologies, Inc.	6- Dec- 04	6- Dec -05	4- Feb -14
US8642260	Single quantum-dot based aptameric nanosensors	The Research Foundation of the City University of New York	21- Oct- 08	21- Oct -09	4- Feb -14
US8633322	Alkynyl derivatives useful as DPP-1 inhibitors	Janssen Pharmaceutica NV	29- Oct- 09	28- Oct -10	21- Jan- 14
US8633308	Compounds for preventing or treating viral infections and methods of use thereof	The Governors of The University of Alberta	28- Feb- 07	27- Feb -08	21- Jan- 14
US8632764	Directed evolution and in vivo panning of virus vectors	University of North Carolina at Chapel Hill	30- Apr- 08	29- Apr -09	21- Jan- 14
US8629283	Compounds that modulate negative-sense, single-stranded RNA virus replication and uses thereof	Icahn School of Medicine at Mount Sinai	6- Mar- 08	6- Mar -09	14- Jan- 14
US8629271	Compounds	AstraZeneca AB	6- Feb- 08	2- Apr -12	14- Jan- 14
US8629098	Compositions and methods for adoptive and active immunotherapy	Yale University	15- Jan- 08	14- Jan -09	14- Jan- 14
US8628786	Polychlorinated biphenyls and squalene-containing adjuvants	Novartis AG	28- Dec- 07	2- Dec -11	14- Jan- 14
US8624011	Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same	The Trustees of the University of Pennsylvania	14- Sep- 09	14- Sep -10	7- Jan- 14
US8623419	Technology for preparation of macromolecular microspheres	Ansun Biopharma, Inc.	24- Jan- 06	4- Nov -11	7- Jan- 14
US8623382	Immunogenic compositions for inducing an immune response to HIV	Wyeth LLC	17- Jun- 04	18- Jan -11	7- Jan- 14
US8623364	Antigenic GM-CSF peptides and antibodies to GM-CSF	Morphotek, Inc.	8- Feb- 06	24- Oct -12	7- Jan- 14
US8617838	Fluorescent proteins and related methods and compounds	University of Massachusetts	20- Sep- 04	20- Sep -05	31- Dec -13
US8615368	Method for determining the amount of an analyte in a sample	Gen-Probe Incorporated	10- Mar- 05	10- Mar -06	24- Dec -13
US8609370	Highly active glycoproteins-process conditions and an efficient method for their production	Glycotope GmbH	13- Feb- 04	14- Feb -05	17- Dec -13
US8609101	Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies	Theraclone Sciences, Inc.	23- Apr- 09	23- Apr -10	17- Dec -13
US8604215	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20- Mar- 09	22- Mar -10	10- Dec -13
US8603469	Methods of treating cancer with human monoclonal antibodies against interleukin 8	Genmab A/S	16- Dec- 02	27- Dec -11	10- Dec -13
US8599383	Optical cytometry	The Regents of the University of California	6- May- 09	6- May -09	3- Dec -13
US8598192	Hydroxylamine substituted imidazoquinolines	3M Innovative Properties Company	14- Nov- 03	12- Nov -04	3- Dec -13
US8598134	RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof	South Alabama Medical Science Foundation	22- Oct- 04	23- Jul- 10	3- Dec -13
US8598116	Treatment of influenza virus infection	Educational Fund and Autoimmune Technologies, LLC	4- Nov- 03	29- May -12	3- Dec -13
US8598106	Anti-microbial composition exhibiting residual anti-microbial properties on a surface	Byotrol PLC	17- Sep- 07	5- Jul- 11	3- Dec -13
US8597650	Methods for treating rheumatoid arthritis with anti-bile salt- stimulated lipase (BSSL) antibodies	HERNELL OLLE	8- Apr- 09	6- Apr -10	3- Dec -13
US8592567	Vaccines and immunotherapeutics using codon-optimized IL-15 and methods for using the same	The Trustees of the University of Pennsylvania	13- Jan- 06	3- May -12	26- Nov -13
US8592391	Method for therapeutic, clinical and veterinary use poly-ICLC	SALAZAR ANDRES	1-Jul- 03	17- Oct -08	26- Nov -13
US8586770	Unsaturated steroid compounds	Harbor Therapeutics, Inc.	29- Sep- 04	18- Feb -11	19- Nov -13
US8586364	Cells and methodology to generate non-segmented negative-strand RNA viruses	Institut Pasteur	22- Dec- 06	21- Dec -07	19- Nov -13
US8586363	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10- Dec- 09	10- Dec -10	19- Nov -13
US8581584	Membrane proteins, mechanisms of action and uses thereof	Florida State University Research Foundation	26- May- 10	26- May -11	12- Nov -13
US8580927	Engineered antibody constant domain molecules	The United States of America, as represented by the Secretary, Department of Health and Human Services	31- Jan- 08	30- Jan -09	12- Nov -13
US8580268	CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity	Coley Pharmaceutical GmbH	27- Sep- 06	27- Sep -07	12- Nov -13
US8569283	Compounds and compositions as c-Kit kinase inhibitors	LIU XIAODONG	1- Sep- 11	29- Aug -12	29- Oct- 13
US8562996	RSV-specific binding molecules and means for producing them	MedImmune Limited	1- Jun- 07	30- May -08	22- Oct- 13
US8562943	Quality control methods for oil-in-water emulsions containing squalene	Novartis AG	8- Nov- 06	6- Nov -07	22- Oct- 13
US8560339	System and method to predict the global spread of infectious agents via commercial air travel	Kamran Khan	2- Apr- 07	2- Apr -08	15- Oct- 13
US8557767	Synthetic apolipoprotein E mimicking polypeptides and methods of use	UAB Research Foundation	28- Aug- 07	27- Aug -08	15- Oct- 13
US8557248	Methods and compositions for treating malaria	Cyvax, Inc.	9- Aug- 10	9- Aug -11	15- Oct- 13
US8552051	Use of pharmaceutical compositions containing mesembrenone	H. L. Hall & Sons Limited	20- Mar- 09	16- Mar -10	8- Oct- 13
US8552032	Bicyclic derivatives useful as inhibitors of DPP-1	Janssen Pharmaceutica NV	18- Dec- 09	16- Dec -10	8- Oct- 13
US8551968	Methods for generation of antibodies	National Jewish Health	13- Mar- 07	13- Mar -08	8- Oct- 13
US8551756	Avian influenza chimeric VLPS	Novavax, Inc.	11- Jul-03	19- Jan -10	8- Oct- 13
US8551750	Device including bone cage and method for treatment of disease in a subject	The Invention Science Fund I, LLC	23- Apr- 09	28- Jul- 09	8- Oct- 13
US8551749	Device including bone cage and method for treatment of disease in a subject	The Invention Science Fund I, LLC	23- Apr- 09	23- Apr -09	8- Oct- 13
US8551738	Systems and methods for rapid identification of nucleic acid variants	Ibis Biosciences, Inc.	21- Jul-05	11- Nov -09	8- Oct- 13
US8551469	Treatment of tumors and viral diseases with recombinant interferon alpha	Superlab Far East Limited	28- Feb- 01	6- Oct -08	8- Oct- 13
US8546432	Tetrazolones as inhibitors of fatty acid synthase	Infinity Pharmaceuticals, Inc.	5- May- 10	5- May -11	1- Oct- 13
US8546383	Chiral fused [1,2]imidazo[4,5-c] ring compounds	3M Innovative Properties Company	30- Dec- 04	25- May -12	1- Oct- 13
US8546082	Methods for identification of sepsis-causing bacteria	Ibis Biosciences, Inc.	11- Sep- 03	25- May -07	1- Oct- 13
US8541568	Compositions and methods using siRNA molecules for treatment of gliomas	BIGNER DARELL D	24- May- 08	26- May -09	24- Sep -13
US8541457	Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors	Xenon Pharmaceuticals Inc.	3- Jun- 05	5- Jun -06	24- Sep -13
US8541438	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	18- Jun- 04	21- Dec -10	24- Sep -13
US8541221	Primate T-lymphotropic viruses	Johns Hopkins University	21- Feb- 05	1- Jul- 10	24- Sep -13
US8541003	Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using	Protein Sciences Corporation	20- Jun- 03	21- Jun -04	24- Sep -13
US8529968	Decontaminating composition having simultaneously bactericidal, fungicidal and virocidal properties, methods for obtaining and using said composition	Hightech Bio-Activities Holding GmbH	29- Mar- 04	29- Mar -05	10- Sep -13
US8524715	Phenoxyacetic acid derivatives useful for treating respiratory diseases	Astrazeneca AB	23- Nov- 04	22- Nov -05	3- Sep -13
US8524488	Methods and devices for determining a cell characteristic, and applications employing the same	The Regents of the University of California	10- Sep- 02	9- Mar -05	3- Sep -13
US8524241	Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A	The General Hospital Corporation	20- Jul-07	18- Jul- 08	3- Sep -13
US8519106	Monoclonal human tumor-specific antibody	University of Zurich	13- Mar- 07	13- Mar -08	27- Aug -13
US8507545	Cytotoxic T cell activator comprising EP4 agonist	National University Corporation, Hamamatsu University School of Medicine	8- May- 07	7- May -08	13- Aug -13
US8507544	Bi-aryl amide compounds as CRTh2 receptor modulators	Astrazeneca AB	5-Jul- 07	3- Jul- 08	13- Aug -13
US8507455	Folate conjugates	Alnylam Pharmaceuticals, Inc.	4- Dec- 07	4- Dec -08	13- Aug -13
US8506968	SARS vaccine compositions and methods of making and using them	Eli Lilly and Company	29- Jun- 00	28- Dec -09	13- Aug -13
US8506966	Adjuvanted influenza vaccines for pediatric use	Novartis AG	22- Feb- 08	20- Feb -09	13- Aug -13
US8501746	Organic compounds	Novartis AG	5- Jun- 06	4- Jun -07	6- Aug -13
US8501699	Bicyclic nucleosides and nucleotides as therapeutic agents	Biota Scientific Management Pty Ltd	3-Jul- 08	7- Sep -12	6- Aug -13
US8501461	System for performing multi-formatted assays	Gen-Probe Incorporated	10- Mar- 05	3- Dec -09	6- Aug -13
US8497405	Process for dispersing vaporous hydrogen peroxide	STERIS Inc.	6- Mar- 07	28- Feb -13	30- Jul- 13
US8497112	Method for producing viral vaccines	Baxter Healthcare SA	28- Aug- 07	28- Aug -08	30- Jul- 13
US8494781	Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds	BOGOCH ELENORE S	6- Jun- 03	10- Dec -10	23- Jul- 13
US8492329	Bioactive peptides and methods of using same	Compugen Ltd.	12- Jul-07	11- Jul- 08	23- Jul- 13
US8486959	Dibenzo[f,h]isoquinoline derivatives	National Health Research Institutes	14- Jan- 10	14- Jan -11	16- Jul- 13
US8486678	Pharmaceutical compositions for the treatment of virus infection	Kineta Two, LLC	23- Nov- 05	1- Feb -12	16- Jul- 13
US8486619	Arrayed imaging reflectometry (air) sensor chip comprising influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral immune responses	University of Rochester	2- May- 08	1- May -09	16- Jul- 13
US8486420	Live virus vaccines	Children's Hospital, Inc.	15- Feb- 05	15- Feb -06	16- Jul- 13
US8481547	Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1	Janssen Pharmaceutica NV	18- Dec- 09	16- Dec -10	9- Jul- 13
US8481270	Method for chromogenic detection of two or more target molecules in a single sample	Ventana Medical Systems, Inc.	22- Aug- 08	21- Aug -09	9- Jul- 13
US8481255	Scytovirin domain 1 related polypeptides	The United States of America, as represented by the Secretary, Department of Health and Human Services	25- May- 05	30- Sep -11	9- Jul- 13
US8476292	Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1- dimethylethyl}methanesulfonamide and methods	3M Innovative Properties Company	9- Sep- 05	8- Sep -06	2- Jul- 13
US8476288	Salts 756	AstraZeneca AB	21- May- 09	20- May -10	2- Jul- 13
US8476265	Compounds-801	AstraZeneca AB	30- Jul-10	14- Sep -12	2- Jul- 13
US8470771	Method and medicament for inhibiting the infection of influenza virus	Institute of Microbiology, Chinese Academy of Sciences	14- Nov- 07	18- Dec -07	25- Jun- 13
US8470769	Method of treatment of bacterial infection by administration of poly- lysine	Novabiotics, Ltd.	18- Aug- 04	30- Nov -11	25- Jun- 13
US8470346	Anti-viral pharmaceutical compositions	Mast Therapeutics, Inc.	10- Dec- 03	19- May -11	25- Jun- 13
US8470335	Recombinant SARS-CoV nsp12 and the use of thereof and the method for producing it	Industry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation Foundation	13- Jun- 08	13- Jun -08	25- Jun- 13
US8466284	Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase	Astra Zeneca AB	6- Nov- 07	5- Nov -08	18- Jun- 13
US8466167	Compounds and compositions as TLR activity modulators	IRM LLC	3- Mar- 08	27- Feb -09	18- Jun- 13
US8466124	RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles	Coley Pharmaceutical GmbH	13- Aug- 07	12- Jun -12	18- Jun- 13
US8465751	Cna—B domain antigens in vaccines against gram positive bacteria	Novartis AG	12- Jan- 09	12- Jan -10	18- Jun- 13
US8461125	Compositions and methods to treat asthma	The Children's Hospital of Philadelphia	14- Feb- 08	13- Aug -10	11- Jun- 13
US8460914	Decreasing potential iatrogenic risks associated with vaccines and vaccine antigens	Novartis AG	9- Sep- 04	10- Jan -13	11- Jun- 13
US8460605	Decontaminant dispenser suitable for use as a projectile	STERIS Inc.	6- Mar- 07	20- Feb -08	11- Jun- 13
US8455483	Compounds—801	AstraZeneca AB	31- Jul-09	30- Jul- 10	4- Jun- 13
US8450471	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10- Dec- 09	22- Mar -12	28- May -13
US8450467	Carbohydrate conjugates as delivery agents for oligonucleotides	Alnylam Pharmaceuticals, Inc.	4- Dec- 07	14- Dec -11	28- May -13
US8450350	Triazoles as inhibitors of fatty acid synthase	Infinity Pharmaceuticals, Inc.	5- May- 10	5- May -11	28- May -13
US8450284	Coiled-coil lipopeptide helical bundles and synthetic virus-like particles	Universitaet Zuerich	9- Dec- 06	6- Dec -07	28- May -13
US8450055	Malaria antigen screening method	The United States of America as Represented by the Secretary of the Navy	31- Aug- 05	25- Aug -06	28- May -13
US8445650	Mutant botulinum neurotoxin serotype A polypeptide and uses thereof	Thomas Jefferson University	25- Sep- 07	25- Sep -08	21- May -13
US8445447	B7-DC variants immunogenic compositions and methods of use thereof	The Johns Hopkins University	13- Jul-07	7- Mar -12	21- May -13
US8444961	RNA virus infection inhibitor, method for inhibition of infection by RNA virus, RNA virus infection-inhibiting product, and use as RNA virus infection inhibitor	Sekisui Chemical Co., Ltd.	16- Jun- 09	16- Jun -10	21- May -13
US8440704	Quercetin-containing compositions	Quercegen Pharmaceuticals LLC	17- Jul-06	16- Dec -09	14- May -13
US8440649	Phenanthroindolizidine analogues	National Health Research Institutes	24- Feb- 09	11- Feb -10	14- May -13
US8440642	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	1- Sep -11	14- May -13
US8440432	Tal effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10- Dec- 09	22- Mar -12	14- May -13
US8440431	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10- Dec- 09	22- Mar -12	14- May -13
US8440408	Animal protein-free media for cultivation of cells	Baxter Healthcare S.A.	29- Oct- 04	10- Dec -10	14- May -13
US8436178	Imidazoquinolines with immuno-modulating properties	AstraZeneca AB	8- May- 07	6- May -08	7- May -13
US8436024	2-pyridone compounds	Astrazeneca AB	2- Oct- 09	1- Oct -10	7- May -13
US8431160	Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions	Novartis AG	24- Feb- 06	24- Feb -07	30- Apr- 13
US8431134	Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	31- Jul-08	31- Jul- 09	30- Apr- 13
US8426565	Dendritic cell marker and uses thereof	Walter and Eliza Hall Institute of Medical Research	30- Aug- 07	29- Aug -08	23- Apr- 13
US8420798	Method for producing nucleic acid probes	Ventana Medical Systems, Inc.	1- Sep- 06	31- Aug -07	16- Apr- 13
US8420784	Interleukin 10 receptor, (IL-10R) antibodies	Kyowa Hakko Kirin Co., Ltd.	27- May- 08	27- May -09	16- Apr- 13
US8420096	Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signaling	Vanderbilt University	4- Mar- 04	4- Mar -05	16- Apr- 13
US8420094	Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A	The General Hospital Corporation	20- Jul-07	18- Jul- 08	16- Apr- 13
US8415394	Biphenyloxyacetic acid derivatives for the treatment of respiratory disease	Astrazeneca AB	6- Oct- 05	21- Dec -11	9- Apr- 13
US8415361	Use of TAM receptor inhibitors as antimicrobials	The Salk Institute for Biological Studies	9- Nov- 07	7- Nov -08	9- Apr- 13
US8415330	Biological specimen collection and transport system and method of use	Longhorn Vaccines & Diagnostics, LLC	1- Oct- 07	1- Oct -12	9- Apr- 13
US8415309	Bicyclic nucleosides and nucleotides as therapeutic agents	Biota Scientific Managment Pty Ltd	1-Jul- 09	11- Jan -12	9- Apr- 13
US8415118	Porcine DC-SIGN, ICAM-3 and LSECtin and uses thereof	Virginia Tech Intellectual Properties, Inc.	29- Oct- 07	29- Oct -08	9- Apr- 13
US8415102	Methods and computer systems for identifying target-specific sequences for use in nanoreporters	NanoString Technologies, Inc.	10- Apr- 07	10- Apr -08	9- Apr- 13
US8410149	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses	Siga Technologies Inc.	6- Dec- 04	28- Oct -10	2- Apr- 13
US8410114	2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial	AstraZeneca AB	8- May- 06	6- Jan -12	2- Apr- 13
US8409589	Mutant forms of streptolysin O	Novartis AG	21- Dec- 07	14- Sep -11	2- Apr- 13
US8399651	Nucleic acids encoding GAS57 mutant antigens	Novartis AG	12- Sep- 07	10- Sep -12	19- Mar -13
US8398992	Methods and compositions for polytopic vaccination	Polytopos LLC	29- Apr- 05	22- Dec -11	19- Mar -13
US8394986	Phenoxiacetic acid derivatives	AstraZeneca AB	21- Aug- 03	26- Jul- 11	12- Mar -13
US8394945	Compositions for use in identification of bacteria	Ibis Biosciences, Inc.	11- Sep- 03	7- Mar -07	12- Mar -13
US8394386	Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations	The Trustees of the University of Pennsylvania	28- Apr- 04	27- Apr -05	12- Mar -13
US7829712	Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase	Xenon Pharmaceuticals Inc.	20- Sep- 04	20- Sep -05	9- Nov -10
US7829707	Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy	AstraZeneca AB	6- Dec- 04	5- Dec -05	9- Nov -10
US7829302	Method for detecting the specificity of activated lymphocyte	HU JUN	8- Dec- 03	7- Dec -04	9- Nov -10
US7820210	Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers	Inhalation, Inc.	3- Apr- 00	18- Mar -08	26- Oct- 10
US7812135	GITR-binding antibodies	TOLERRX, Inc.	25- Mar- 05	27- Mar -06	12- Oct- 10
US7803918	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics	Amsterdam Institute of Viral Genomics B.V.	18- Aug- 03	18- Aug -04	28- Sep -10
US7803796	Homopiperazine compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot structure of SARS coronavirus	Sungkyunkwan University Foundation For Corporate Collaboration	22- Dec- 06	20- Dec -07	28- Sep -10
US7803765	Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom	Phylogica Limited	20- Feb- 04	20- Feb -04	28- Sep -10
US7799800	Lipid-modified immune response modifiers	3M Innovative Properties Company	30- Oct- 03	12- Aug -04	21- Sep -10
US7794998	Primate T-lymphotropic viruses	Johns Hopkins University	21- Feb- 05	24- Feb -07	14- Sep -10
US7794659	Signal measuring system having a movable signal measuring device	Gen-Probe Incorporated	10- Mar- 05	10- Mar -06	14- Sep -10
US7790878	RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof	Alnylam Pharmaceuticals, Inc.	22- Oct- 04	25- Jun -09	7- Sep -10
US7790449	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor	The Trustees of the University of Pennsylvania	17- Dec- 01	6- Sep -07	7- Sep -10
US7790159	Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	7- Sep -10
US7786290	Double-stranded ribonucleic acid with increased effectiveness in an organism	Alnylam Pharmaceuticals, Inc.	13- Jun- 03	14- Jun -04	31- Aug -10
US7785775	Human virus causing severe acute respiratory syndrome (SARS) and uses thereof	Versitech Limited	24- Mar- 03	8- Jun -07	31- Aug -10
US7785612	Polyamino acid for use as adjuvant	Masanori Baba	20- Apr- 05	19- Apr -06	31- Aug -10
US7781226	Particle on membrane assay system	The Board of Regents of the University of Texas System	27- Feb- 04	22- Dec -04	24- Aug -10
US7781203	Supports for assaying analytes and methods of making and using thereof	Corning Incorporated	29- Dec- 05	7- Jun -06	24- Aug -10
US7777036	Heterocyclic derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	20- Sep- 04	20- Sep -05	17- Aug -10
US7777022	Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof	Rosetta Genomics, Ltd.	26- Nov- 02	26- May -04	17- Aug -10
US7776521	Coronavirus isolated from humans	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	25- Apr- 03	14- May -07	17- Aug -10
US7767817	Water soluble boronic acid fluorescent reporter compounds and methods of use thereof	FANG HAO	5- Sep- 03	7- Sep -04	3- Aug -10
US7767677	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors	Xenon Pharmaceuticals Inc.	20- Sep- 04	20- Sep -05	3- Aug -10
US7767658	Vaccine composition	Aventis Pasteur SA	17- Nov- 03	9- Jan -08	3- Aug -10
US7767657	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	16- Aug -06	3- Aug -10
US7767210	RNA virus vaccines and methods	The Board of Regents of the University of Oklahoma	14- Dec- 05	14- Dec -06	3- Aug -10
US7763618	Pyridyl derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	29- Jul-03	29- Jul- 04	27- Jul- 10
US7758868	Modified polymerases and attenuated viruses and methods of use thereof	The Penn State Research Foundation	22- Dec- 06	24- Dec -07	20- Jul- 10
US7754711	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30- Jul-03	9- Feb -05	13- Jul- 10
US7750123	Antibodies against SARS-CoV and methods of use thereof	Dana Farber Cancer Institute, Inc.	25- Nov- 03	24- Nov -04	6- Jul- 10
US7749445	Method and apparatus for analyzing bioprocess fluids	BioScale, Inc.	2- May- 05	19- Dec -06	6- Jul- 10
US7745486	Quercetin-containing compositions	Quercegen Pharma LLC	17- Jul-06	16- Jul- 07	29- Jun- 10
US7745442	Methods of reducing risk of infection from pathogens	Parion Sciences, Inc.	20- Aug- 03	18- Aug -04	29- Jun- 10
US7745147	Methods and uses of antibodies in the purification of interferon	ViraNative AB	12- Feb- 05	13- Feb -06	29- Jun- 10
US7745119	System for detecting polynucleotides	Investigen, Inc.	20- May- 03	21- Nov -05	29- Jun- 10
US7745118	Comparative genomic resequencing	Roche Nimblegen, Inc.	8- Apr- 04	8- Apr -05	29- Jun- 10
US7741450	Antibodies to GM-CSF	Morphotek Inc.	8- Feb- 06	8- Feb -07	22- Jun- 10
US7741360	Bi-aryl or aryl-heteroaryl substituted indoles	AstraZeneca AB	26- May- 06	25- May -07	22- Jun- 10
US7740858	SARS-CoV-specific B-cell epitope and applications thereof	National Taiwan University	21- Sep- 04	21- Sep -04	22- Jun- 10
US7737135	Biphenyloxyacetic acid derivatives for the treatment of respiratory disease	AstraZeneca AB	24- Aug- 04	22- Aug -05	15- Jun- 10
US7736850	Strain of SARS-associated coronavirus and applications thereof	Centre National de la Recherche Scientifique	2- Dec- 03	2- Dec -04	15- Jun- 10
US7732177	Oligoadenylate Synthetase (OAS)	Illumigen Biosciences, Inc.	23- Nov- 05	17- Nov -06	8- Jun- 10
US7731978	Mutant forms of streptolysin O	Novartis AG	21- Dec- 07	19- Dec -08	8- Jun- 10
US7728110	Antibodies to SARS coronavirus	Amgen, Inc.	19- May- 06	21- May -07	1- Jun- 10
US7725565	System and method for detecting, collecting, analyzing, and communicating event related information	Georgetown University	25- Feb- 08	19- Nov -08	25- May -10
US7723570	Edible vaccines expressed in soybeans	SoyMeds, Inc.	12- Oct- 04	12- Oct -05	25- May -10
US7723041	Assay for SARS coronavirus by amplification and detection of the replicase sequence	Becton, Dickinson and Company	12- Sep- 03	3- Feb -09	25- May -10
US7722886	Compositions and methods for treatment of severe acute respiratory syndrome (SARS)	Wyeth	20- May- 04	20- May -04	25- May -10
US7714109	Combinations and kits for cancer treatment using selected antibodies to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	11- May -10
US7713515	Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis	R.E.D. Laboratories N.V.	27- May- 03	26- May -04	11- May -10
US7709521	Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases	AstraZeneca AB	18- Aug- 03	16- Aug -04	4- May -10
US7709511	Benzothiazolone derivatives	AstraZeneca AB	9- Aug- 05	3- Aug -06	4- May -10
US7709188	Multi-allelic detection of SARS-associated coronavirus	Birch Biomedical Research LLC	22- Aug- 03	13- Aug -04	4- May -10
US7700782	Compounds 569	AstraZeneca AB	19- Dec- 07	19- Dec -07	20- Apr- 10
US7700728	Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors	Schering Corporation	24- Mar- 05	24- Mar -06	20- Apr- 10
US7700727	Compositions and kits for detecting pathogen infection	Biokit, S.A.	23- Dec- 03	27- Apr -05	20- Apr- 10
US7700273	Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV) CCR5 coreceptor	The United States of America as represented by the Department of Health and Human Services	9- Apr- 04	11- Apr -05	20- Apr- 10
US7700120	Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus	New York Blood Center	15- Jun- 04	15- Jun -05	20- Apr- 10
US7696406	Expression of a recombinant transgene	Board of Trustees Operating Michigan State University	3-Jul- 03	2- Jul- 04	13- Apr- 10
US7696330	Binding molecules against SARS-coronavirus and uses thereof	Crucell Holland B.V.	22- Jul-03	20- Jan -06	13- Apr- 10
US7691877	Pharmaceuticals	Pfizer Inc.	17- Feb- 06	16- Feb -07	6- Apr- 10
US7691646	Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereof	Daikin Industries, Ltd.	28- Mar- 03	21- Nov -08	6- Apr- 10
US7691599	Mammalian genes involved in viral infection and tumor suppression	Zirus, Inc.	2- May- 02	2- May -03	6- Apr- 10
US7691390	Viral protein	CHANG MING-FU	2- Mar- 04	19- Sep -07	6- Apr- 10
US7687535	Substituted 3-sulfur indoles	AstraZeneca AB	27- May- 03	25- May -04	30- Mar -10
US7687475	RNA interference in respiratory epithelial cells	University of Iowa Research Foundation	9-Jul- 04	16- Oct -07	30- Mar -10
US7682688	Microporous materials, methods, and articles for localizing and quantifying analytes	University of Utah Research Foundation	26- Nov- 02	20- Nov -03	23- Mar -10
US7678774	Treating severe acute respiratory syndrome	Hemispherx Biopharma	16- May- 03	26- Jan -07	16- Mar -10
US7678386	Liposomes coated with selected antibodies that bind to aminophospholipids	Board of Regents the University of Texas	15- Jul-02	15- Aug -03	16- Mar -10
US7674795	Fluorene derivatives, composition containing said derivatives and the use thereof	Aventis Pharma SA	19- May- 05	14- Nov -07	9- Mar -10
US7670807	RNA-dependent DNA polymerase from Geobacillus stearothermophilus	East Tennessee State Univ. Research Foundation	10- Mar- 04	10- Mar -04	2- Mar -10
US7670565	Building decontamination with vaporous hydrogen peroxide	Steris Inc	31- Jan- 03	3- Mar -08	2- Mar -10
US7666996	Casein derived peptides and uses thereof	Peptera Pharmaceuticals Ltd	1- Mar- 00	1- Mar -04	23- Feb -10
US7666592	Methods for concurrent identification and quantification of an unknown bioagent	Ibis Biosciences, Inc.	18- Feb- 04	17- Feb -05	23- Feb -10
US7662860	3D-structure model of SARS coronavirus 3CL protease and anti- SARS drugs	Shanghai Institute of Materia Medica, Chinese Academy of Sciences	4- Jun- 03	2- Dec -05	16- Feb -10
US7648997	Hydroxylamine substituted imidazoquinolines	Coley Pharmaceutical Group, Inc.	12- Aug- 03	12- Aug -04	19- Jan- 10
US7648844	Method and apparatus for detection of analyte using an acoustic device	BioScale, Inc.	2- May- 05	2- May -06	19- Jan- 10
US7645881	Methods for treating hepatitis C	PTC Therapeutics, Inc.	22- Jul-04	14- Jul- 05	12- Jan- 10
US7642350	Purine derivatives	Pfizer Limited	4- May- 05	3- May -06	5- Jan- 10
US7636637	Variable length probe selection	Roche NimbleGen, Inc.	18- Jun- 04	20- Jun -05	22- Dec -09
US7635557	Enzymatic diagnostic test for SARS and other viral diseases	MND Diagnostic Ltd.	23- Jun- 03	23- Jun -04	22- Dec -09
US7635485	Method of accelerated vaccination against Ebola viruses	The United States of America as represented by the Department of Health and Human Services	1- Aug- 03	17- Jan -06	22- Dec -09
US7632638	Methods and apparatus for detecting viruses using an acoustic device	BioScale, Inc.	2- May- 05	2- May -06	15- Dec -09
US7629443	Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus	New York Blood Center, Inc.	2- Jun- 04	8- Feb -06	8- Dec -09
US7629385	Sphingolipid-derived pharmaceutical compositions	Jado Technologies GmbH	29- Jun- 04	29- Jun -05	8- Dec -09
US7629137	Methods and apparatus for detecting bacteria using an acoustic device	BioScale, Inc.	2- May- 05	2- May -06	8- Dec -09
US7629114	Method of collecting nasopharyngeal cells and secretions for diagnosis of viral upper respiratory infections and screening for nasopharyngeal cancer	World Sense Technology Limited	26- Aug- 03	20- Aug -04	8- Dec -09
US7625563	Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	1- Dec -09
US7625492	Charge-based water filtration systems	The University of Wyoming Research Corporation	28- Jan- 03	28- Jan -04	1- Dec -09
US7625428	Bioagent air filtration systems	The University of Wyoming Research Corporation	28- Jan- 03	28- Jan -04	1- Dec -09
US7623997	Computer-implemented biological sequence identifier system and method	The United States of America as represented by the Secretary of the Navy	2-Jul- 04	6- Jun -06	24- Nov -09
US7622559	Human monoclonal antibodies against interleukin 8 (IL-8)	Genmab A/S	16- Dec- 02	27- Jun -07	24- Nov -09
US7622125	Polycistronic HIV vector constructs	Novartis Vaccines and Diagnostics, Inc.	5- May- 04	5- May -05	24- Nov -09
US7622118	Cancer treatment methods using selected antibodies to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	24- Nov -09
US7622112	Anti-SARS monoclonal antibodies	Not Available	5- Dec- 03	6- Dec -04	24- Nov -09
US7619067	Evolved interferon-alpha polypeptides	Maxygen, Inc.	18- May- 05	17- May -06	17- Nov -09
US7618802	Compositions of coronaviruses with a recombination-resistant genome	The University of North Carolina at Chapel Hill	21- Jul-03	19- Jan -06	17- Nov -09
US7618788	Proteome epitope tags and methods of use thereof in protein modification analysis	Millipore Corporation	10- May- 02	5- Feb -04	17- Nov -09
US7618635	Super-antigen fusion proteins and the use thereof	Healthbanks Biotech Co., Ltd.	21- Jul-04	19- Jul- 05	17- Nov -09
US7615381	Method and apparatus for detecting estradiol and metabolites thereof using an acoustic device	BioScale, Inc.	2- May- 05	2- May -06	10- Nov -09
US7615223	Selected immunoconjugates for binding to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	10- Nov -09
US7611908	Method and apparatus for therapeutic drug monitoring using an acoustic device	BioScale, Inc.	2- May- 05	2- May -06	3- Nov -09
US7611704	Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	3- Nov -09
US7605161	Pyridyl derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30- Jul-03	29- Jul- 04	20- Oct- 09
US7605135	Baicalin as a treatment for SARS infection	The University of Hong Kong	10- Nov- 03	8- Nov -04	20- Oct- 09
US7604960	Transient protein expression methods	Crucell Holland B.V.	15- Apr- 99	1- Jun -07	20- Oct- 09
US7604801	Methods for detecting parvovirus infections	The Research Foundation of State University of New York	5- May- 03	16- Oct -08	20- Oct- 09
US7598382	Aryl substituted imidazoquinolines	Coley Pharmaceutical Group, Inc.	20- Dec- 02	13- Jan -06	6- Oct- 09
US7598094	Methods and apparatus for detecting cardiac injury markers using an acoustic device	BioScale, Inc.	2- May- 05	2- May -06	6- Oct- 09
US7598072	Assay to detect viral uncoating	Wisconsin Alumni Research Foundation	9- Dec- 03	8- Dec -04	6- Oct- 09
US7597936	Method of producing a pigmented composite microporous material	University of Utah Research Foundation	26- Nov- 02	26- May -04	6- Oct- 09
US7595381	Method for detecting SARS coronavirus	Eiken Kagaku Kabushiki Kaisha	27- Jun- 03	10- Jun -08	29- Sep -09
US7595163	Method for detecting SARS coronavirus	Eiken Kagaku Kabushiki Kaisha	27- Jun- 03	10- Jun -08	29- Sep -09
US7592343	Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors	Xenon Pharmaceuticals Inc.	20- Sep- 04	20- Sep -05	22- Sep -09
US7592322	RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof	Alnylam Pharmaceuticals, Inc.	22- Oct- 04	14- Jun -05	22- Sep -09
US7592008	Membrane scaffold proteins	The Board of Trustees of the University of Illinois, a body corporate and politic of the State of Illinois	20- Nov- 00	11- Jan -05	22- Sep -09
US7589092	Prodrugs of heteroaryl compounds	Koronis Pharmaceuticals, Incorporated	20- Jun- 03	27- Dec -06	15- Sep -09
US7585647	Nucleic acid encoding recombinant interferon	WEI GUANGWEN	28- Aug- 03	26- Aug -04	8- Sep -09
US7582740	Methods and kits for detecting SARS-associated coronavirus	The Trustees of Columbia University In the City of New York	17- Apr- 03	23- Jan -04	1- Sep -09
US7582621	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16- Feb- 05	16- Feb -06	1- Sep -09
US7579396	Polymer composite	Eastman Kodak Company	31- Jan- 07	31- Jan -07	25- Aug -09
US7579359	1-alkoxy 1H-imidazo ring systems and methods	3M Innovative Properties Company	2- Sep- 04	1- Sep -05	25- Aug -09
US7572621	Detection, characterization and treatment of viral infection and methods thereof	Canadian Blood Services	9- Apr- 03	11- Oct -05	11- Aug -09
US7572448	Combined cancer treatment methods using selected antibodies to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	11- Aug -09
US7572442	Selected antibody compositions for binding to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Jul- 03	11- Aug -09
US7569536	Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity	Masatoshi Hagiwara	26- Dec- 03	24- Dec -04	4- Aug -09
US7569384	Albumin fusion proteins	Human Genome Sciences, Inc.	9- Feb- 04	8- Aug -06	4- Aug -09
US7550140	Antibody to the human OX40 receptor	Crucell Holland B.V.	13- Jun- 02	13- Jun -03	23- Jun- 09
US7547698	Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)	Xenon Pharmaceuticals Inc.	20- Sep- 04	20- Sep -05	16- Jun- 09
US7547516	Method for reducing the presence of amplification inhibitors in a reaction receptacle	Gen-Probe Incorporated	10- Mar- 05	10- Mar -06	16- Jun- 09
US7547512	High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)	The University of Hong Kong	24- Mar- 03	24- Mar -04	16- Jun- 09
US7544697	Pyrazolopyridines and analogs thereof	Coley Pharmaceutical Group, Inc.	3- Oct- 03	1- Apr -05	9- Jun- 09
US7541436	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19- May- 04	4- May -07	2- Jun- 09
US7541163	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19- May- 04	14- Aug -07	2- Jun- 09
US7531630	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19- May- 04	13- Sep -06	12- May -09
US7531324	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19- May- 04	13- Sep -06	12- May -09
US7521424	Albumin fusion proteins	Human Genome Sciences, Inc.	22- Jan- 03	7- Jul- 05	21- Apr- 09
US7521185	Assay for SARS coronavirus by amplification and detection of the replicase sequence	Becton, Dickinson and Company	12- Sep- 03	13- Sep -04	21- Apr- 09
US7514436	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30- Jul-03	29- Jul- 04	7- Apr- 09
US7511124	Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	31- Mar -09
US7504384	Use of lipid conjugates in the treatment of infection	Yissum Research Development Company of the Hebrew University of Jerusalem	10- Jan- 00	8- Sep -05	17- Mar -09
US7504382	Protease inhibitors for coronaviruses and SARS-CoV and the use thereof	Cytovia, Inc.	6- May- 03	6- May -04	17- Mar -09
US7504205	Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP- dependent kinase and a target for SARS therapy	The Burnham Institute	17- May- 04	17- May -05	17- Mar -09
US7504097	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18- Nov- 02	30- Oct -06	17- Mar -09
US7498409	Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists	Schering Corporation	24- Mar- 05	23- Mar -06	3- Mar -09
US7498152	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18- Nov- 02	30- Oct -06	3- Mar -09
US7495011	Anti-coronavirus drug	aRigen Pharmaceuticals, Inc.	15- Jul-03	14- Jul- 04	24- Feb -09
US7491793	Influenza virus inhibiting peptides	The Administrators of the Tulane Educational Fund	4- Nov- 03	3- Nov -04	17- Feb -09
US7491706	Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof	Changchun Huapu Biotechnology Co., Ltd.	25- Jul-03	26- Jul- 04	17- Feb -09
US7491508	Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses	The Trustees of the University of Pennsylvania	20- Jun- 03	15- Jun -04	17- Feb -09
US7491489	Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof	The University of Hong Knog	22- Nov- 04	28- Oct -05	17- Feb -09
US7491397	Receptor binding polypeptides	National Health Research Institutes	9- Jan- 04	10- Jan -05	17- Feb -09
US7488801	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18- Nov- 02	30- Oct -06	10- Feb -09
US7488589	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18- Nov- 02	30- Oct -06	10- Feb -09
US7488473	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18- Nov- 02	30- Oct -06	10- Feb -09
US7485432	Selective modulation of TLR-mediated biological activity	3M Innovative Properties Company	27- Feb- 03	27- Feb -04	3- Feb -09
US7482334	Therapeutic treatment methods	Hollis-Eden Pharmaceuticals, Inc.	28- Aug- 02	12- Feb -07	27- Jan- 09
US7482149	Inhibition of SARS coronavirus infection with clinically approved antiviral drugs	Genome Institute of Singapore	9- Jun- 03	9- Jun -04	27- Jan- 09
US7479484	Peptides and peptidomimetics having immune-modulating, anti- inflammatory, and anti-viral activity	Takeda Pharmaceutical Company Limited	25- Jun- 03	25- Jun -04	20- Jan- 09
US7470666	Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome	Guangdong Techpool Biochem. Pharma. Co., Ltd.	26- May- 03	25- May -04	30- Dec -08
US7470548	Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereof	Daikin Industries, Ltd.	28- Mar- 03	26- Mar -04	30- Dec -08
US7468418	Compositions for enhancing transport of molecules into cells	AVI BioPharma., Inc.	29- Apr- 03	29- Apr -04	23- Dec -08
US7465836	Hydrolytically-resistant boron-containing therapeutics and methods of use	Anacor Pharmaceuticals, Inc.	16- Jun- 03	15- Jun -04	16- Dec -08
US7462615	Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications	Hybrigenics SA	8- Dec- 05	8- Dec -05	9- Dec -08
US7460960	Proteome epitope tags and methods of use thereof in protein modification analysis	Epitome Biosystems, Inc.	10- May- 02	13- Nov -03	2- Dec -08
US7456180	Piperazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30- Jul-03	29- Jul- 04	25- Nov -08
US7455833	Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	25- Nov -08
US7452542	Live attenuated coronavirus vaccines	Vanderbilt University	21- May- 04	23- May -05	18- Nov -08
US7445889	Methods for detecting parvovirus infections	The Research Foundation of State University of New York	5- May- 03	5- May -04	4- Nov -08
US7442761	Replikin peptides and uses thereof	BOGOCH ELENORE S	6- Jun- 03	4- Jun -04	28- Oct- 08
US7442508	Methods for detection and production of influenza viruses	Diagnostic Hybrids, Inc.	24- Apr- 98	28- Apr -06	28- Oct- 08
US7439349	Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof	Not Available	3-Jul- 02	1- Jul- 03	21- Oct- 08
US7439052	Method of making modified immunodeficiency virus particles	Lipid Sciences	29- Jun- 00	10- Apr -06	21- Oct- 08
US7435588	Systems for detection and production of respiratory, herpes and enteric viruses	Diagnostic Hybrids, Inc.	20- Sep- 05	28- Apr -06	14- Oct- 08
US7435538	High throughput screening method of drug for physiologically active protein	CellFree Sciences Co., Ltd.	8- Sep- 03	8- Sep -04	14- Oct- 08
US7432045	Method of inhibiting influenza infection with antiviral peptides	Wisconsin Alumni Research Foundation	1- Dec- 03	1- Dec -04	7- Oct- 08
US7429656	Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference	The University of Hong Kong	19- May- 03	14- Jun -06	30- Sep -08
US7427479	Methods and kits for identifying target nucleotides in mixed populations	Applera Corporation	30- Apr- 04	29- Apr -05	23- Sep -08
US7424370	Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential	Council of Scientific and Industrial Research	20- Jul-04	7- Feb -05	9- Sep -08
US7407663	Modified immunodeficiency virus particles	Lipid Sciences, Inc.	29- Jun- 00	20- Jun -03	5- Aug -08
US7407662	Modified viral particles with immunogenic properties and reduced lipid content	Lipid Sciences, Inc.	29- Jun- 00	21- Jun -04	5- Aug -08
US7405207	Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof	Epigenesis Pharmaceuticals, Inc.	17- Jun- 02	17- Jun -03	29- Jul- 08
US7405046	Compositions and methods for treatment of rhinovirus	The Quigley Corporation	6- Aug- 01	27- Oct -06	29- Jul- 08
US7399588	Method for detecting SARS coronavirus	Eiken Kagaku Kabushiki Kaisha	27- Jun- 03	15- Jun -04	15- Jul- 08
US7396914	SARS nucleic acids, proteins, antibodies, and uses thereof	University of Massachusetts	4- Aug- 03	4- Aug -04	8- Jul- 08
US7393856	Anti-viral uses of borinic acid complexes	Anacor Pharmaceuticals, Inc.	14- Jun- 04	14- Jun -05	1- Jul- 08
US7393638	Assay system and methods for detecting SARS-CV	AsiaGEN Corporation	1-Jul- 03	1- Jul- 03	1- Jul- 08
US7387271	Immunostimulatory combinations	3M Innovative Properties Company	30- Dec- 02	30- Dec -03	17- Jun- 08
US7384909	Anti-viral treatment methods using phosphatidylethanolamine- binding peptides linked to anti-viral agents	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	10- Jun- 08
US7378386	Anti-viral treatment methods using phosphatidylethanolamine- binding peptide derivatives	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	27- May -08
US7375210	PCR primer set for detecting severe acute respiratory syndrome (SARS)-Coronavirus, method and kit for detecting SARS- Coronavirus using the same	Samsung Electronics Co., Ltd.	12- Dec- 03	24- Nov -04	20- May -08
US7375202	Human virus causing severe acute respiratory syndrome (SARS) and uses thereof	The University of Hong Kong	24- Mar- 03	24- Mar -04	20- May -08
US7375180	Methods and compositions related to IRM compounds and Toll-like receptor 8	3M Innovative Properties Company	13- Feb- 03	12- Feb -04	20- May -08
US7374883	Method and kit for the detection of a novel coronoavirus associated with the severe acute respiratory syndrome (SARS)	QIAGEN Diagnostics GmbH	30- Apr- 03	30- Apr -04	20- May -08
US7371850	Method and composition for reducing expression of ROCK-II	Myriad Genetics, Inc.	20- Aug- 03	20- Aug -04	13- May -08
US7371837	Human virus causing respiratory tract infection and uses thereof	The University of Hong Kong	21- Jul-04	16- May -05	13- May -08
US7371525	Compositions and methods for diagnosing and treating severe acute respiratory syndrome (SARS)	The Chinese University of Hong Kong	29- Jul-03	28- Jul- 04	13- May -08
US7361747	Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus	The University of Hong Kong	22- May- 03	24- May -04	22- Apr- 08
US7361304	Building decontamination with vaporous hydrogen peroxide	Steris Inc.	31- Jan- 03	29- Jan -04	22- Apr- 08
US7358068	Antiviral oligonucleotides	Replicor, Inc.	13- Sep- 02	12- Sep -03	15- Apr- 08
US7354908	Materials and methods for prevention and treatment of RNA viral diseases	University of South Florida	30- Apr- 02	30- Apr -03	8- Apr- 08
US7354551	Room decontamination with hydrogen peroxide vapor	Steris Inc	8-Jul- 04	8- Jul- 04	8- Apr- 08
US7344740	Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers	Inhalation, Inc.	3- Apr- 00	27- Nov -04	18- Mar -08
US7344720	Vaccine composition	Sanofi Pasteur SA	17- Nov- 03	15- Nov -04	18- Mar -08
US7339051	Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)	Isis Pharmaceuticals, Inc.	28- Apr- 03	26- Apr -04	4- Mar -08
US7335658	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30- Jul-03	29- Jul- 04	26- Feb -08
US7332475	Preventive or therapeutic composition for viral infectious disease	Kyowa Hakko Kogyo Co., Ltd.	22- Jul-03	22- Jul- 04	19- Feb -08
US7332294	CXCL10-based diagnosis and treatment of respiratory illnesses	University Health Network	17- Aug- 04	17- Aug -04	19- Feb -08
US7320857	Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof	Chinese National Human Genome Center at Shanghai	9-Jul- 04	9- Jul- 04	22- Jan- 08
US7318918	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19- May- 04	18- May -05	15- Jan- 08
US7314613	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18- Nov- 02	19- May -04	1- Jan- 08
US7312036	Compositions for use in identification of viral hemorrhagic fever viruses	ISIS Pharmaceuticals, Inc.	22- Mar- 04	21- Mar -05	25- Dec -07
US7297786	RNA interference in respiratory epitheial cells	University of Iowa Research Foundation	9-Jul- 04	11- Jul- 05	20- Nov -07
US7291498	Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses	The Trustees of the University of Pennsylvania	20- Jun- 03	20- Jun -03	6- Nov -07
US7282568	Human monoclonal antibodies against interleukin 8 (IL-8)	Genmab A/S	16- Dec- 02	16- Dec -03	16- Oct- 07
US7282199	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17- Dec- 01	25- Apr -03	16- Oct- 07
US7267942	Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)	The University of Hong Kong	24- Mar- 03	24- Mar -04	11- Sep -07
US7261867	Production of silver sulfate grains using organo-sulfate or organo- sulfonate additives	Eastman Kodak Company	7- Apr- 06	7- Apr -06	28- Aug -07
US7247303	Selected antibody CDRs for binding to aminophospholipids	Board of Regents, The University of Texas System	15- Jul-02	15- Aug -03	24- Jul- 07
US7244732	Prodrugs of heteroaryl compounds	Koronis Pharmaceuticals, Incorporated	20- Jun- 03	31- Mar -04	17- Jul- 07
US7223787	Prenylation inhibitors reduce host cell permissiveness to viral replication	Board of Regents, The University of Texas System	21- Oct- 03	21- Oct -03	29- May -07
US7220852	Coronavirus isolated from humans	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	25- Apr- 03	12- Apr -04	22- May -07
US7183300	Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof	AGARWAL ATUL	11- Nov- 04	10- Nov -05	27- Feb -07
US7166435	Compositions and methods for reducing the transmissivity of illnesses	The Quigley Corporation	6- Aug- 01	14- Dec -04	23- Jan- 07
US7163947	1-Amino 1H-imidazoquinolines	3M Innovative Properties Company	7- Mar- 03	3- Sep -04	16- Jan- 07
US7151163	Antiviral agents for the treatment, control and prevention of infections by coronaviruses	Sequoia Pharmaceuticals, Inc.	28- Apr- 03	28- Apr -04	19- Dec -06
US7151091	Compositions and methods for preventing infection	La Jolla Biosciences LLC	20- Sep- 02	22- Sep -03	19- Dec -06
US7148248	Method of treating or inhibiting the development of brain inflammation and sepsis	NOZAKI MASAKO	29- Nov- 02	26- Nov -03	12- Dec -06
US7129223	Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference	The University of HongKong	19- May- 03	19- May -04	31- Oct- 06
US7129042	Compositions and methods for detecting severe acute respiratory syndrome coronavirus	Diagnostic Hybrids, Inc.	3- Nov- 03	3- Nov -03	31- Oct- 06
US7115563	Composition and its therapeutic use	Insignion Holding Limited	29- May- 02	29- May -03	3- Oct- 06
US7091214	Aryl substituted Imidazoquinolines	3M Innovative Properties Co.	20- Dec- 02	18- Dec -03	15- Aug -06
US7048953	Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)	Inhalation, Inc.	3- Apr- 00	2- May -03	23- May -06
US7023593	Apparatus for forming nano-grating device	Industrial Technology Research Institute	28- Nov- 03	17- Mar -04	4- Apr- 06
US6946291	Mixed cell diagnostic systems	Diagnostic Hybrids, Inc.	24- Apr- 98	30- Mar -04	20- Sep -05
US20200176 079	METHODS AND DEVICES FOR NUCLEIC ACID-BASED REAL-TIME DETERMINATION OF DISEASE STATES	Not Available	19- Jul-17	18- Jul- 18	4- Jun- 20
US20200173 925	MICROSCOPIC BODY ENCLOSING METHOD, MICROSCOPIC BODY DETECTION METHOD, AND MICROSCOPIC BODY DETECTION DEVICE	JAPAN SCIENCE AND TECHNOLOGY AGENCY	29- Mar- 17	28- Mar -18	4- Jun- 20
US20200172 883	COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS	Not Available	19- Nov- 09	13- Sep -19	4- Jun- 20
US20200172 879	DHFR TUNABLE PROTEIN REGULATION	Not Available	3- Mar- 17	2- Sep -19	4- Jun- 20
US20200172 600	RSV F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME	GLAXOSMITHKLINE BIOLOGICALS, SA	15- Jul-09	16- Aug -17	4- Jun- 20
US20200172 513	DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS	Hoffmann-La Roche Inc.	12- Jun- 16	5- Feb -20	4- Jun- 20
US20200172 480	CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS	HANGZHOU DAC BIOTECH CO., LTD.	12- Jul-12	5- Feb -20	4- Jun- 20
US20200171 085	Method of Treating Respiratory Tract Infection	Not Available	19- May- 17	18- May -18	4- Jun- 20
US20200171 060	FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST FILOVIRUSES AND FLAVIVIRUSES	Not Available	31- Jul-17	26- Jan -18	4- Jun- 20
US20200166 505	METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETS	The U.S.A., as represented by the Secretary, Department of Health and Human Services	1- Sep- 15	30- Jan -20	28- May -20
US20200165 632	ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION	Spark Therapeutics, Inc.	7- Jun- 17	6- Jun -18	28- May -20
US20200165 630	COMPOSITIONS FOR THE TREATMENT OF DISEASE	Not Available	29- Apr- 16	28- Apr -17	28- May -20
US20200165 613	VIRUS LIKE PARTICLE	The University of Leeds	1- Jun- 17	31- May -18	28- May -20
US20200165 594	CRISPR SYSTEM BASED ANTIVIRAL THERAPY	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	7-Jul- 17	6- Jul- 18	28- May -20
US20200165 585	NEW CHIMERIC ENZYMES AND THEIR APPLICATIONS	Not Available	27- Jul-17	27- Jul- 18	28- May -20
US20200165 357	CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF	Not Available	2- Dec- 05	21- Oct -19	28- May -20
US20200164 334	MICROSPOTTING DEVICE	Not Available	18- Apr- 12	11- Oct -19	28- May -20
US20200164 067	Methods and Compositions for Inhibiting Akt3	Not Available	15- Jan- 16	5- Feb -20	28- May -20
US20200164 058	TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS	King Abdulaziz University	27- Nov- 18	27- Nov -18	28- May -20
US20200164 020	PUM 1 PROTEIN AS TARGET FOR VIRUS INHIBITION	Not Available	12- Apr- 17	12- Apr -17	28- May -20
US20200163 878	LIPID NANOPARTICLE MRNA VACCINES	Not Available	26- Oct- 16	26- Oct -17	28- May -20
US20200157 600	METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION	Not Available	19- Nov- 18	19- Nov -18	21- May -20
US20200157 222	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Not Available	29- Mar- 18	29- Mar -19	21- May -20
US20200157 221	ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES	Not Available	30- Jun- 16	28- Jan -20	21- May -20
US20200155 704	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30- Sep- 03	30- Jan -20	21- May -20
US20200155 699	MODIFIED VIRUS-LIKE PARTICLES OF CMV	Not Available	22- Oct- 14	26- Nov -19	21- May -20
US20200155 667	VACCINE COMPOSITIONS	Not Available	27- Jul-17	24- Jan -20	21- May -20
US20200155 664	INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE	Not Available	10- Feb- 09	26- Jun -19	21- May -20
US20200155 662	COMBINATION IMMUNOTHERAPIES COMPRISING IL-15 SUPERAGONISTS	Not Available	26- May- 17	25- May -18	21- May -20
US20200155 660	COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERY	Not Available	23- Sep- 15	22- Nov -19	21- May -20
US20200155 646	EV576 For Use in the Treatment of Viral Infections of the Respiratory Tract	Volution Immuno Pharmaceuticals SA	8- Jan- 10	7- Jun -19	21- May -20
US20200149 062	ENGINEERED TSC2	Not Available	14- Jul-17	13- Jul- 18	14- May -20
US20200149 048	Transbiotic Regulation of Bacterial Gene Expression	Not Available	22- May- 17	22- May -18	14- May -20
US20200148 749	ANTIBODIES AND PROCESSES FOR PREPARING THE SAME	Not Available	16- May- 08	10- Oct -19	14- May -20
US20200147 203	VACCINATION OF IMMUNOCOMPROMISED SUBJECTS	Not Available	26- Sep- 14	10- Jan -20	14- May -20
US20200147 193	COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY INVOLVING HER ANTIGENS	Not Available	2- Jun- 17	2- Jun -18	14- May -20
US20200147 171	COMPOSITIONS OF CRACC FUSIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE AGAINST CANCERS, INFECTIONS DISEASES AND DISORDERS	Not Available	18- Sep- 18	18- Sep -19	14- May -20
US20200140 547	MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE	Not Available	26- May- 17	25- May -18	7- May -20
US20200140 493	Engineering Virus-like Nanocarriers for Biomolecule Delivery	Not Available	26- Oct- 18	25- Oct -19	7- May -20
US20200140 398	HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS	AZIENDA OSPEDALIERA UNIVERSITARIA SENESE	13- Feb- 15	6- Jan -20	7- May -20
US20200138 937	Genetically Attenuated Nucleic Acid Vaccine	Not Available	2- Jun- 17	1- Jun -18	7- May -20
US20200138 936	Phenotypically Wild-Type and Genetically Attenuated Viruses	Not Available	2- Jun- 17	1- Jun -18	7- May -20
US20200138 818	METHODS OF TREATING PAIN AND/OR INFLAMMATORY DISORDERS USING LAPATINIB	Not Available	7- Nov- 18	6- Nov -19	7- May -20
US20200138 780	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C	Not Available	14- Mar- 13	19- Dec -19	7- May -20
US20200131 518	CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE	Not Available	14- Mar- 17	14- Mar -18	30- Apr- 20
US20200129 487	CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND	TAIHO PHARMACEUTICAL CO., LTD.	30- Jun- 17	29- Jun -18	30- Apr- 20
US20200127 954	RNA TARGETING METHODS AND COMPOSITIONS	Salk Institute for Biological Studies	22- Aug- 17	31- Dec -18	23- Apr- 20
US20200124 599	ACCURATE, RAPID AND CONVENIENT SINGLE-STEP DISEASE DIAGNOSTIC METHOD USING SELF-AMPLIFICATION PRINCIPLE OF DETECTION SIGNAL	CELLEMEDY CO., LTD	13- Apr- 17	13- Apr -18	23- Apr- 20
US20200123 233	AMINO ACID SEQUENCES  DIRECTED AGAINST  ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES	Ablynx N.V.	5- Jun- 08	1- Aug -19	23- Apr- 20
US20200123 205	Inhibition Of TCR Signaling With Peptide Variants	Not Available	22- Oct- 18	18- Dec -19	23- Apr- 20
US20200123 203	COMPOSITIONS COMPRISING CURONS AND USES THEREOF	FLAGSHIP PIONEERING INNOVATIONS V, INC.	13- Jun- 17	13- Jun -18	23- Apr- 20
US20200115 448	CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF	Not Available	26- Apr- 17	22- Oct -19	16- Apr- 20
US20200115 434	ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF	Not Available	23- Oct- 15	29- Oct -19	16- Apr- 20
US20200113 996	CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES	Not Available	23- Jun- 17	21- Jun -18	16- Apr- 20
US20200113 967	PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS	Not Available	26- May- 17	26- May -17	16- Apr- 20
US20200113 831	LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul- 11	16- Dec -19	16- Apr- 20
US20200113 830	PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA	GLAXOSMITHKLINE BIOLOGICALS S.A.	31- Aug- 11	16- Dec -19	16- Apr- 20
US20200109 403	IN VIVO DELIVERY OF OLIGONUCLEOTIDES	Not Available	12- Dec- 11	18- Dec -19	9- Apr- 20
US20200108 136	METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES	Not Available	6- Apr- 07	22- Nov -19	9- Apr- 20
US20200102 558	TRANSKINGDOM PLATFORM FOR THERAPEUTIC NUCLEIC ACID DELIVERY	Not Available	3- Apr- 17	3- Oct -19	2- Apr- 20
US20200102 550	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Not Available	10- Dec- 09	28- Aug -19	2- Apr- 20
US20200102 544	POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND METHODS OF MAKING AND USING THE SAME	Not Available	30- Dec- 13	11- Sep -19	2- Apr- 20
US20200102 362	TUMOR NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN COMPLEX WITH IMPROVED BINDING AND BIOACTIVITY	Not Available	6- Apr- 17	5- Apr -18	2- Apr- 20
US20200102 292	SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF	Not Available	3-Jul- 13	10- Jul- 19	2- Apr- 20
US20200101 158	ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF	Not Available	1- Oct- 15	22- Oct -19	2- Apr- 20
US20200101 153	MVA-BN AND AD26.ZEBOV OR AD26.FILO PRIME-BOOST REGIMEN	Not Available	6- Apr- 17	6- Apr -18	2- Apr- 20
US20200101 142	PDE5 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY	Not Available	12- Jun- 17	12- Jun -18	2- Apr- 20
US20200101 119	METHODS OF TREATMENT OF INFECTIONS USING BACTERIA	Not Available	27- Sep- 18	26- Sep -19	2- Apr- 20
US20200101 087	PHARMACEUTICAL COMPOSITIONS AND METHODS	Not Available	3- Aug- 15	21- Nov -19	2- Apr- 20
US20200100 480	TRAIT SELECTION IN AVIANS	Not Available	31- May- 17	31- May -18	2- Apr- 20
US20200095 324	ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF	Not Available	30- Mar- 17	30- Mar -18	26- Mar -20
US20200093 919	MODIFIED PEDV SPIKE PROTEIN	Not Available	20- Sep- 18	18- Sep -19	26- Mar -20
US20200093 909	PLASMODIUM SPOROZOITE NPDP PEPTIDES AS VACCINE AND TARGET NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TO	Not Available	19- Apr- 17	19- Apr -18	26- Mar -20
US20200093 855	ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDE	Not Available	11- Sep- 17	3- Jun -19	26- Mar -20
US20200093 841	Broad Spectrum Antiviral and Methods of Use	Not Available	17- Apr- 06	30- Apr -19	26- Mar -20
US20200087 655	PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES	Not Available	14- Jul-15	22- Nov -19	19- Mar -20
US20200087 646	OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION CASSETTES AND THEIR USE	Not Available	31- May- 17	31- May -18	19- Mar -20
US20200087 630	INFLUENZA VIRUS AND TYPE 1 DIABETES	Istituto Zooprofilattico Sperimentale delle Venezie	10- Oct- 12	25- Jul- 19	19- Mar -20
US20200087 359	GRIFFITHSIN MUTANTS	The United States of America,as represented by the Secretary,Department of Health and Human Services	10- Feb- 15	27- Nov -19	19- Mar -20
US20200087 313	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	29- Jul-11	25- Apr -19	19- Mar -20
US20200087 298	Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups	Not Available	1- Mar- 17	27- Feb -18	19- Mar -20
US20200087 280	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5- Feb- 15	25- Nov -19	19- Mar -20
US20200086 324	DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION	Not Available	30- Jun- 16	27- Dec -18	19- Mar -20
US20200085 984	APPARATUS, METHOD AND SYSTEM FOR SELECTIVELY AFFECTING AND/OR KILLING A VIRUS	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	7- Mar- 11	25- Nov -19	19- Mar -20
US20200085 947	VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER	Not Available	7- Sep- 12	14- May -19	19- Mar -20
US20200085 943	PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN	CureVac AG	31- Jan- 12	29- Aug -19	19- Mar -20
US20200085 872	IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS	Not Available	19- Apr- 17	19- Apr -18	19- Mar -20
US20200085 852	EPIDERMAL MRNA VACCINE	Not Available	5- Aug- 15	5- Aug -16	19- Mar -20
US20200085 756	NANOPARTICLE VACCINE ADJUVANT AND METHODS OF USE THEREOF	Not Available	14- Sep- 18	12- Jul- 19	19- Mar -20
US20200080 141	METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS	Not Available	11- Dec- 13	19- Nov -19	12- Mar -20
US20200080 111	Methods for Autocatalytic Genome Editing and Neutralizing Autocatalytic Genome Editing and Compositions Thereof	Not Available	18- Sep- 15	19- Sep -16	12- Mar -20
US20200079 820	DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE	Hangzhou DAC Biotech Co., Ltd.	20- Apr- 16	20- Apr -16	12- Mar -20
US20200079 781	Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases	Not Available	5- Sep- 18	1- Aug -19	12- Mar -20
US20200078 335	COMPOSITIONS AND METHODS TO REDUCE PATHOGENESIS	Not Available	1- May- 17	1- May -18	12- Mar -20
US20200072 836	MEDIA ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES (MENSA) AND USES THEREOF	Not Available	5- May- 14	2- Apr -19	5- Mar -20
US20200071 723	RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROL	Not Available	30- Aug- 18	29- Aug -19	5- Mar -20
US20200071 421	BISPECIFIC ANTIBODY	Not Available	20- Nov- 13	8- Apr -19	5- Mar -20
US20200069 814	CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE	Hangzhou DAC Biotech Co., Ltd.	6- Apr- 17	6- Apr -17	5- Mar -20
US20200062 764	ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING AND USING SAME	Not Available	17- Nov- 16	17- Nov -17	27- Feb -20
US20200061 187	METHODS FOR PREPARING SQUALENE	Not Available	12- May- 10	4- Nov -19	27- Feb -20
US20200061 185	PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE	The Scripps Research Institute	25- Oct- 16	25- Oct -17	27- Feb -20
US20200060 981	CATIONIC NANOPARTICLES FOR ENHANCING INFECTIOUS CAPACITY OF LIVE VIRUSES	Not Available	9- Dec- 16	11- Dec -17	27- Feb -20
US20200056 221	METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA	Not Available	8- Nov- 13	25- Oct -19	20- Feb -20
US20200056 159	NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR	Not Available	28- Feb- 17	27- Feb -18	20- Feb -20
US20200055 927	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8- Sep- 16	25- Oct -19	20- Feb -20
US20200055 926	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8- Sep- 16	25- Oct -19	20- Feb -20
US20200054 731	IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	7- Jan- 14	15- Jul- 19	20- Feb -20
US20200054 660	DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY	St. Jude Children's Research Hospital	9- Dec- 16	7- Dec -17	20- Feb -20
US20200054 259	HIGH DENSITY ANALOG MULTIPEXING	EnLiSense, LLC	17- Aug- 18	16- Aug -19	20- Feb -20
US20200048 722	METHODS FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION AND IDENTIFICATION OF BACTERIAL, VIRAL, AND PROTOZOAN NUCLEIC ACIDS	Not Available	8- May- 15	24- Aug -19	13- Feb -20
US20200048 649	VIRUS-LIKE PARTICLES AND USES THEREOF	Not Available	13- Mar- 17	13- Mar -18	13- Feb -20
US20200048 636	IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul- 10	18- Oct -19	13- Feb -20
US20200046 865	DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION	Not Available	29- Dec- 17	22- Aug -19	13- Feb -20
US20200046 826	METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS	Academia Sinica	27- Mar- 09	4- Jun -19	13- Feb -20
US20200046 692	SPECIFIC AKT3 INHIBITOR AND USES THEREOF	Not Available	15- Jan- 16	2- Oct -19	13- Feb -20
US20200040 408	HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION	Not Available	8- Feb- 16	6- May -19	6- Feb -20
US20200040 042	CHIMERIC MOLECULES AND USES THEREOF	Not Available	30- Mar- 17	29- Mar -18	6- Feb -20
US20200038 871	DEVICES, PROCESSES, AND SYSTEMS FOR DETERMINATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, COPY NUMBER, OR METHYLATION CHANGES USING COMBINED NUCLEASE, LIGASE, POLYMERASE, AND SEQUENCING REACTIONS	Not Available	29- Mar- 17	29- Mar -18	6- Feb -20
US20200038 373	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	9- May- 12	16- May -19	6- Feb -20
US20200033 343	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES	Not Available	6- Oct- 08	14- Oct -19	30- Jan- 20
US20200032 255	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES	Not Available	26- Jan- 07	6- Mar -19	30- Jan- 20
US20200031 871	NOVEL DEPSIPEPTIDES AND USES THEREOF	Not Available	4- Apr- 17	30- Mar -18	30- Jan- 20
US20200031 819	COMPOSITIONS AND METHODS FOR INHIBITING KINASES	Not Available	23- Apr- 15	26- Jun -19	30- Jan- 20
US20200030 441	Lipidated Immune Response Modifier Compound Compositions, Formulations, and Methods	Not Available	17- Aug- 10	8- Jul- 19	30- Jan- 20
US20200030 432	ZOONOTIC DISEASE RNA VACCINES	ModernaTX, Inc.	17- Mar- 17	16- Mar -18	30- Jan- 20
US20200030 422	COMBINATION OF VACCINATION AND OX40 AGONISTS	CureVac AG	9- Sep- 16	15- Apr -19	30- Jan- 20
US20200024 616	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN PANCREATIC TROPISM	Not Available	30- Mar- 18	29- Mar -19	23- Jan- 20
US20200024 310	NOVEL DEPSIPEPTIDE AND USES THEREOF	Not Available	3- Dec- 12	1- Aug -19	23- Jan- 20
US20200020 420	Method for Establishing Machine Learning Model for Predicting Toxicity of siRNA to Certain Type of Cells and Application Thereof	Not Available	8- Dec- 16	7- Dec -17	16- Jan- 20
US20200017 926	CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS THEREOF	Not Available	7- Nov- 13	28- Aug -19	16- Jan- 20
US20200017 832	COMPOSITIONS FOR REPROGRAMMING CELLS INTO DENDRITIC CELLS OR ANTIGEN PRESENTING CELLS, METHODS AND USES THEREOF	Not Available	5- Apr- 17	5- Apr -18	16- Jan- 20
US20200017 588	MODULAR TETRAVALENT BISPECIFIC ANTIBODY PLATFORM	Not Available	14- Oct- 16	16- Oct -17	16- Jan- 20
US20200017 554	SELF-ASSEMBLING PROTEIN NANOPARTICLES WITH BUILT-IN SIX- HELIX BUNDLE PROTEINS	Not Available	23- Mar- 17	22- Mar -18	16- Jan- 20
US20200017 514	ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION	Not Available	12- Jul-18	12- Jul- 18	16- Jan- 20
US20200017 455	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS	Not Available	24- Jan- 14	19- Mar -19	16- Jan- 20
US20200016 589	LOADING VIALS	Not Available	10- Nov- 11	24- Sep -19	16- Jan- 20
US20200016 286	Production of Immune-Response-Stimulating Aerosols By Non- Thermal Plasma Treatment Of Airborne Pathogens	Not Available	13- Jul-18	12- Jul- 19	16- Jan- 20
US20200016 280	Compositions For Enhancing Transport Of Molecules Into Cells	Not Available	29- Apr- 03	9- Apr -19	16- Jan- 20
US20200016 161	METHODS FOR TREATING VIRAL DISORDERS	TRUSTEES OF BOSTON UNIVERSITY	24- Sep- 09	22- Jul- 19	16- Jan- 20
US20200010 883	METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS	Not Available	9- Oct- 15	7- Jun -19	9- Jan- 20
US20200010 519	NUCLEASE FUSIONS FOR ENHANCING GENOME EDITING BY HOMOLOGY-DIRECTED TRANSGENE INTEGRATION	Not Available	10- Mar- 17	9- Mar -18	9- Jan- 20
US20200009 244	NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL COMPONENTS	Not Available	13- Jun- 18	13- Jun -19	9- Jan- 20
US20200002 674	ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE	Not Available	18- Nov- 13	16- Sep -19	2- Jan- 20
US20200000 931	SYNTHETIC NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS	Not Available	15- Jul-16	10- Apr -19	2- Jan- 20
US20190391 150	COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES	Not Available	1- May- 15	10- Sep -19	26- Dec -19
US20190390 249	BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM	Longhorn Vaccines and Diagnostics, LLC	1- Oct- 07	19- Jun -17	26- Dec -19
US20190390 229	GENE EDITING REAGENTS WITH REDUCED TOXICITY	Not Available	21- Apr- 16	20- Apr -17	26- Dec -19
US20190390 179	SYNTHETIC REVERSE TRANSCRIPTASES AND USES THEREOF	Not Available	12- Apr- 16	12- Apr -17	26- Dec -19
US20190390 176	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN SKELETAL MUSCLE TROPISM	Not Available	2- Dec- 15	3- Jul- 19	26- Dec -19
US20190389 816	ANTIVIRAL COMPOUNDS AND METHODS	Biotron Limited	26- Jun- 03	29- Aug -19	26- Dec -19
US20190388 473	METHODS AND COMPOSITIONS FOR IMMUNOMODULATION	Not Available	1- Apr- 14	30- Aug -19	26- Dec -19
US20190382 799	VIRAL METHODS OF MAKING GENETICALLY MODIFIED CELLS	Not Available	27- Oct- 16	19- Apr -19	19- Dec -19
US20190382 433	GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY	THE UNIVERSITY OF NOTTINGHAM	4- Apr- 14	25- Jul- 19	19- Dec -19
US20190381 180	HYBRID CARRIERS FOR NUCLEIC ACID CARGO	Not Available	9- Jun- 16	9- Jun -17	19- Dec -19
US20190381 162	PAN FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF MAKING	Not Available	28- Mar- 16	27- Mar -17	19- Dec -19
US20190381 155	COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY	CureVac AG	22- Feb- 13	29- Aug -19	19- Dec -19
US20190380 995	PREVENTION AND TREATMENT OF VIRAL INFECTIONS	Not Available	2- Jun- 16	3- Jul- 19	19- Dec -19
US20190380 891	MOBILE CLINICS	Baylor College of Medicine	12- Nov- 14	28- Aug -19	19- Dec -19
US20190376 151	MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND USE THEREOF FOR DETECTING NUCLEIC ACIDS